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Abstract 
 
 
Understanding the pathways to oesophageal and stomach cancer diagnosis:  
a multi-methods approach 
 
Elka Suzanne Humphrys                  March 2018 
 
Increasing symptom awareness, encouraging help-seeking, and facilitating timely referral are 
key for improving cancer outcomes, particularly for cancers such as oesophageal and gastric 
(stomach), where five-year survival is less than 20%. In this research, I used multiple methods 
to explore factors that influence timely diagnosis of these cancers from a patient's perspective, 
with a particular focus on health literacy (accessing, understanding and using health 
information, and navigating healthcare systems).  
 
I started by exploring current knowledge in this field before conducting a systematic review 
investigating health literacy in the timely diagnosis of symptomatic cancer. Literature was 
searched from January 1990–May 2017 using six bibliographic databases. I screened 2304 
titles/abstracts, assessed 26 full-text papers and included three, although they were 
methodologically weak, therefore limiting the conclusions.  
 
To examine pathways to diagnosis for oesophageal and gastric cancer, I conducted a 
questionnaire study of newly diagnosed patients across two hospitals in the East and North 
East of England. 127 participants were recruited (39.6% recruitment rate), aged 44–96 
(median 71); 102 male (80%). Most had oesophageal cancer (n=102, 80%); 64 (50%) of the 
total cohort were late-stage at diagnosis. Common pre-diagnostic symptoms varied between 
cancers (oesophageal: difficulty swallowing (n=66, 65%), painful swallowing (n=55, 54%); 
gastric: fatigue/tiredness (n=20, 80%), weight loss (n=13, 52%)). The questionnaire included 
two domains (engagement, understanding) of the Health Literacy Questionnaire with 
participants demonstrating high health literacy (mean 4.18 and 4.28, score 1-5). The median 
time from noticing the trigger symptom (prompting help-seeking) to diagnosis was 81 days 
(IQR 45-137.5, n=107). 
 
Twenty-six participants were purposively sampled, from questionnaire respondents, for face-
to-face interviews (aged 55-88, 18 male, 15 with oesophageal cancer). I undertook thematic 
analysis to explore participant accounts of their pathways to diagnosis, identifying that the 
symptom nature was important for appraisal, while health literacy ability influenced the health 
system interval. Descriptions of ‘heartburn’, ‘reflux’ and ‘indigestion’ differed between 
4 
participants, suggesting these terms may introduce uncertainty in relation to symptom 
experience. 
 
This is the first study to explore the role of health literacy in the timely diagnosis of symptomatic 
cancer, and pathways to diagnosis for oesophageal and gastric cancers, from a patient’s 
perspective. Findings provide important insights for the development of targeted awareness 
campaigns and strategies enhancing GP symptom exploration. 
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Chapter 1: Introduction 
 
 
“I am positive but not irrational. I’m not out of options. No one has the foggiest idea what will 
happen. The statistics may not look great, but none of them say there is no hope at all.”1 
 
Steve Hewlett, 08 Aug 1958 – 20 Feb 2017 
 
Steve Hewlett, quoted above, was a British journalist diagnosed with oesophageal cancer in 
2016, who documented his cancer journey in a series of radio broadcasts and newspaper 
articles until his death in February 2017. His short survival following diagnosis is typical of this 
cancer, as less than 50% of people diagnosed with oesophageal cancer survive for more than 
one year, and less than 20% survive five years or more2. The survival statistics for gastric 
(stomach) cancer are comparable3. These cancers are often referred to together as 
oesophago-gastric cancers, based on the similar symptoms associated with each.  
 
Less than 35% of oesophageal and gastric cancer patients were managed with curative intent 
in England and Wales over a two year period to March 20134 due to most patients having 
advanced stage disease at diagnosis. Diagnosis at later disease stage, generally classed as 
stage III or IV cancer, is a major contributory factor to the poor survival outcomes observed 
across many cancers in the UK in comparison to Europe5. To address this, a focus for research 
over the last ten years has been on exploring ways to diagnose patients at an earlier stage (I 
or II), thereby improving outcomes for cancer patients. Since then, definitions, models and 
guidelines have been proposed to assist with the design and conduct of studies in this field, 
with researchers exploring factors influencing the pathways to cancer diagnosis using various 
methods, from large scale database studies through to smaller scale survey and interview 
studies. While research has expanded across many cancers, in comparison there has been 
limited research relating to timely diagnosis of oesophageal and gastric cancer, particularly 
based on the patient’s perspective.  
 
My motivation for focusing on oesophageal and gastric cancers in my thesis came from an 
interest in exploring rarer cancers and promoting timely diagnosis to improve outcomes. While 
these cancers account for 4.4% of all cancers diagnosed in the UK in 2015, they are 
responsible for 7.6% of cancer related deaths annually2,3. Based on these figures there is a 
need to identify ways of moving towards earlier disease stage at diagnosis, and therefore 
treatment options with curative intent.  
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1.1. Aim and objectives 
The aim of my research was to understand the pathways to diagnosis of oesophageal and 
gastric cancer from a patient's perspective, and to explore the factors that influence the 
pathway, with a particular focus on health literacy. Specific objectives were: 
 To explore current research investigating the factors that influence the pathways to 
diagnosis for oesophageal and gastric cancer; 
 To systematically identify and review literature exploring the role of health literacy in 
timely diagnosis of symptomatic cancer; 
 To identify and appraise health literacy instruments and to evaluate those available for 
research, designed to be self-administered and used to assess the multi-dimensional 
concept of health literacy; 
 To conduct a study exploring the perspective of newly diagnosed patients on the 
pathways to diagnosis for oesophageal and gastric cancer.   
 
Based on the study objectives, I summarise my overall research design in Figure 1.1, also 
illustrating the relationships between each stage. This includes two literature reviews to explore 
current knowledge of oesophageal and gastric cancer and health literacy instruments available 
for research, leading to the development of a systematic review and multi-methods study.  
 
1.2. Patient and public involvement 
My research was supported by two patient representatives, one with previous experience of 
working on research studies in the Primary Care Unit, and the other involved with promoting 
timely diagnosis, following his experience with oesophageal cancer. Both contributed to the 
design and development of the multi-methods study and the associated documents, and also 
participated in the analysis of the interview study data.  
 
1.3. Thesis structure 
I begin by outlining the background to my work in Chapter 2; exploring oesophageal and gastric 
cancer, considering timely diagnosis research and introducing health literacy, before 
describing my systematic review in Chapter 3. In Chapter 4 I focus on my review of health 
literacy instruments, followed in Chapter 5 by the development of the questionnaire, for use in 
my study with newly diagnosed patients. In the final chapters (6 and 7) I discuss the design, 
conduct and results of the questionnaire and interview strands of the multi-methods study. I 
conclude the thesis (Chapter 8) with an integrated discussion of my work, outlining strengths 
and limitations, comparing findings with existing literature and considering implications of the 
research.   
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 Figure 1.1. Research design and relationships 
 
OG = oesophago-gastric 
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Chapter 2: Background 
 
 
This chapter provides the background to the thesis, outlining the literature and knowledge that 
motivated my research in this field. I start with a brief overview of gastrointestinal disorders 
before exploring oesophageal and gastric cancer, focusing on: incidence, symptoms 
associated with the cancers, risk factors and staging information, along with survival and 
mortality rates. Following this I describe timely diagnosis research, including the use of 
conceptual frameworks and knowledge around factors influencing the pathways to diagnosis 
for oesophageal and gastric cancer. In the final part of this chapter, I outline research relating 
to health literacy; its definition, concept, measurement and how it may influence health 
outcomes.  
 
2.1. Gastrointestinal tract 
The gastrointestinal (GI) tract is anatomically divided into the upper and lower tract. The upper 
GI tract is comprised of the oral cavity, pharynx, oesophagus, stomach and the duodenum (the 
beginning of the small intestine), while the lower GI tract is comprised of the small intestine 
(excluding the duodenum) and the large intestine including the rectum and anus (Figure 2.1). 
 
Figure 2.1. The gastrointestinal tract  
 
Reproduced with permission from Shakespeare et al., 20176 
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2.1.1. Gastrointestinal disorders  
The GI tract can be affected by various conditions and diseases including: 
 Infections causing conditions such as gastroenteritis and appendicitis; 
 Inflammatory bowel disease such as Crohn’s disease (autoimmune disease) and 
ulcerative colitis; 
 Motility disorders such as gastro-oesophageal reflux disease (GORD), constipation and 
diarrhoea; 
 Functional disorders, the most common being irritable bowel syndrome; 
 Barrett’s oesophagus, caused by changes to the cells lining the oesophagus; 
 Cancers such as mouth, oesophagus, stomach and colorectal. 
  
The focus of my thesis is oesophageal and gastric cancer; however, in the following sections 
I briefly consider GORD and Barrett’s oesophagus, the latter as a known risk factor for 
oesophageal cancer. Research relating to these conditions provides insights into the 
experience, understanding and management of heartburn, which is considered an early 
indicator of oesophago-gastric cancer, as I describe later in this chapter.   
 
2.2. Gastro-oesophageal reflux disease 
GORD (known as GERD in the USA) is a condition caused by a weakening of the muscle at 
the gastro-oesophageal junction, where contents of the stomach enters the oesophagus 
resulting in symptoms such as a burning sensation behind the breastbone or an acid taste in 
the mouth7. These symptoms are very common, with surveys indicating that approximately 20-
40% of the population experience them at some point within a 6-12 month period7. GORD is 
diagnosed when the symptoms are frequent or severe enough to impact on daily life or sleep 
quality8-11. Studies estimate that around 10-20% of North American and European populations 
have GORD8,11-13, with risk factors including older age, being overweight or obese and having 
a history of smoking9. However, estimating the prevalence can be difficult, as it is known that 
many patients do not consult their general practitioner (GP). Instead, patients manage their 
symptoms through diet, lifestyle changes, and over-the-counter (OTC) medications11-13, only 
consulting their GP when symptoms worsen or when they feel they can no longer control their 
symptoms10,12,13. 
 
Having sought help, patients often use a range of language to describe their symptoms, which 
may not match the medical terminology for the symptom experienced. This can lead to a 
mismatch between patient and GP assessment of symptom severity11-13. In a study by 
Spechler et al., 2002, set in one medical centre in the USA, the authors interviewed 129 
patients with GORD and identified that only 44 (34.1%) patients understood the term 
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heartburn, classified by the researchers as the patient describing a burning, acid or a warm 
feeling in the upper abdominal or breastbone area, or both14. Similarly, in a secondary analysis 
of data from four clinical trials comparing drug treatments for patients aged 18-80 with a main 
symptom of heartburn, symptom agreement between patients and clinicians was poor at study 
baseline, with clinicians underestimating symptoms of heartburn, regurgitation and upper 
abdominal (epigastric) pain in up to 34%, 46% and 55% of patients respectively15,16. 
 
2.2.1. Diagnosis 
To address these communication issues, the Gastro-(o)esophageal Reflux Disease 
Questionnaire (GerdQ)11 was developed for GPs to administer in primary care, with the 
purpose of assisting the diagnosis by facilitating patient reporting of symptoms (Appendix 1). 
The GerdQ was based on three previous questionnaires: the GERD Impact Scale, the Reflux 
Disease Questionnaire17 and the Gastrointestinal Symptom Rating Scale18. It includes four 
symptom questions, one lifestyle question relating to sleep, and one question on OTC 
medication. The lifestyle and medication questions along with two of the symptom questions 
(heartburn and regurgitation) are positive predictors for GORD, while the other symptom 
questions (abdominal pain and nausea) are negative predictors.  
 
2.2.2. Treatment 
Treatment can include lifestyle adjustments such as dietary changes, weight loss and/or 
smoking cessation, or medication; either OTC or prescribed, such as proton pump inhibitors 
(PPIs) or H2-receptor antagonists (H2RAs), both of which reduce the amount of acid in the 
stomach19. 
 
2.2.3. Risk factors for other conditions 
GORD is a risk factor for the development of other conditions including oesophagitis 
(inflammation and damage to the lining of the oesophagus), and oesophageal strictures 
(scarring and narrowing of the oesophagus). Importantly, it increases the risk for developing 
Barrett’s oesophagus (changes in the cellular lining of the oesophagus), which is a risk factor 
for oesophageal cancer (adenocarcinoma)9,14,20,21. Recent studies using large routinely 
collected datasets from UK general practice have also identified a small increased risk of 
oesophageal adenocarcinoma in patients diagnosed with GORD independently of Barrett’s 
oesophagus22,23.  
 
2.3. Barrett’s oesophagus 
Barrett’s oesophagus is a condition where the squamous epithelial cells usually lining the lower 
portion of the oesophagus are replaced by columnar epithelial cells14,24,25 and which is visible, 
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on endoscopic examination, at least 1cm above the gastro-oesophageal junction26. Barrett’s 
oesophagus is more common in North American and European populations, with the incidence 
estimated at approximately 2% of the population, increasing to 10% in those with acid reflux 
or GORD14,24,25. Recent studies have identified a significant association between GORD and 
Barrett’s oesophagus27,28. Obesity, and particularly abdominal fat, have also been identified as 
risk factors25,29-31, along with male gender, older age, White ethnic group and diet24,25,28,30. 
Some people do not have symptoms, and therefore have the condition identified during other 
tests. However, for those with symptoms, the British Society of Gastroenterology guidelines 
recommend endoscopic screening to check for Barrett’s oesophagus, where the patient has 
chronic GORD and at least three risk factors, or fewer if there is a family history of Barrett’s 
oesophagus26. 
 
The current gold standard for diagnosing Barrett’s oesophagus is an endoscopy with 
histological confirmation, although new diagnostic techniques are being evaluated for use in 
primary care, including the Cytosponge™, a non-endoscopic procedure comprising a 
swallowed sponge and immunohistochemical biomarkers32. 
 
Following a diagnosis of Barrett’s oesophagus, current guidelines recommend endoscopic 
monitoring of the condition with biopsies to histologically assess any cellular changes. 
Depending on the extent of the condition, monitoring can range from every three months to 
every few years33.  
   
2.3.1. Risk of oesophageal adenocarcinoma 
Barrett’s oesophagus is a known risk factor for oesophageal adenocarcinoma, with studies 
estimating that patients with Barrett’s oesophagus are up to ten times more likely to develop 
oesophageal adenocarcinoma than the general population9,14,24,25,34. Studies have also shown 
that the risk increases in patients with high grade dysplasia (severely abnormal cells) 
compared to low grade, and where the cellular changes affect a longer section of the 
oesophagus (long-segment Barrett’s oesophagus)35,36. There is some evidence to suggest that 
monitoring Barrett’s oesophagus (as described above) is associated with earlier diagnosis of 
oesophageal cancer and therefore improved survival26. 
 
2.4. Oesophageal cancer 
Oesophageal cancer is the eighth most common cancer worldwide, with almost 456,000 cases 
diagnosed in 201237. It is more prevalent in less developed countries, while in the UK it is the 
14th most common cancer, with almost 9000 new cases diagnosed in 201438. It usually occurs 
in the middle (thoracic) or lower/distal (abdominal) regions of the oesophagus rather than the 
26 
upper (cervical) section and is predominately either oesophageal adenocarcinoma or 
squamous cell carcinoma, although there are rarer subtypes such as stromal tumours39. 
Oesophageal adenocarcinoma develops from glandular cells usually found in the distal part of 
the oesophagus34. It is the most common type of oesophageal cancer in North American and 
European populations and the incidence has increased dramatically over the past 40 years, 
predominantly affecting White males25,40. Squamous cell carcinoma develops from the 
epithelial cell lining of the oesophagus and is more prevalent in Asia and Africa, and in lower 
socioeconomic groups25,39. 
 
2.4.1. Symptoms 
According to the 2015 National Institute for Health and Care Excellence (NICE) referral 
guidelines for suspected cancer, the symptoms of oesophageal and gastric cancer are the 
same except for the addition of ‘upper abdominal mass’ for gastric cancer (Appendix 2)41. As 
mentioned, these cancers are often described in combination as ‘oesophago-gastric’ or 
‘gastro-oesophageal’ cancer. Table 2.1 outlines the symptoms for both cancers, separated 
where possible, with the table arranged in two parts: 1) symptoms described in the 2015 NICE 
referral guidelines, 2) other symptoms identified from peer-reviewed and patient literature. 
 
The symptoms of oesophageal cancer can be very similar to other gastrointestinal disorders, 
which account for approximately 10% of consultations with GPs in the UK12. In 2009-10, 22.6% 
of oesophageal cancer patients had three or more primary care consultations before referral42. 
Research has identified that 31% of oesophageal cancer patients had a non-cancer diagnosis 
after onset of symptoms and prior to the cancer diagnosis43. A study by Rubin et al., 2015, 
using data from the English National Audit of Cancer Diagnosis in Primary Care, found that 
64% of patients diagnosed with oesophageal cancer had symptoms at presentation that should 
prompt an urgent referral44. However, 37% of these patients were investigated in primary care 
prior to referral.  
 
Difficulty swallowing (dysphagia) is the most common symptom associated with oesophageal 
cancer45-53. However, it is often associated with advanced stage disease54,55, occurring when 
the tumour is restricting the passage of food and liquid from the oral cavity to the stomach56,57. 
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Over the last few years, policy approaches with symptom awareness initiatives, such as the 
Be Clear on Cancer campaigns, have aimed to improve community recognition of potential 
cancer symptoms. Between April and July 2012 a Be Clear on oesophago-gastric cancer pilot 
campaign was conducted across seven areas in England. This lead to a 26% increase in two-
week wait referrals from GPs in those areas for suspected upper GI cancers (a statistically 
significant increase), and a 20% increase in oesophageal cancer diagnosis (although this was 
not statistically significant)97. A regional pilot followed in the North of England from February to 
March 2014. A survey of 300 adults aged 50 and over indicated an increased awareness of 
oesophago-gastric cancer symptoms following the campaign, with 31% of people mentioning 
heartburn and 24% recalling difficulty in swallowing food (the main campaign messages)97. 
The campaign also showed a 52% increase in two-week wait referrals compared to 17% in the 
control areas, and a significant increase in the number of cancers diagnosed, following urgent 
referral, in people aged 60-6997. Following the two pilot campaigns, a National campaign was 
conducted from the 26th January to the 22nd February 2015. The key message, promoted in 
leaflets and on television, encouraged people to seek help if they were experiencing “heartburn 
most days for three weeks or more”, with a secondary radio-based campaign related to 
difficulty swallowing (food sticking)69 (Appendix 3). Additional symptoms were included in the 
campaign information leaflet. 
 
2.4.2. Risk factors 
As described in Sections 2.2 and 2.3, GORD and Barrett’s oesophagus are both risk factors 
for developing oesophageal adenocarcinoma. In Table 2.2 I outline other sociodemographic 
and lifestyle risk factors. 
 
2.4.3. Staging 
Oesophageal cancers are staged according to numerical staging (I-IV) or the Tumour, Node, 
Metastasis (TNM) system, describing the size of the tumour, lymph node involvement and 
whether the cancer has spread (Table 2.3)98. 
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Table 2.2. Risk factors for oesophageal cancer 
Risk factor Description 
Gender 
 
 Ninth most common cancer in males, 14th most common in females in the UK38 
 Male:female ratio of 2.1:1 in the UK and 2.4:1 worldwide in 201237,38 
o Over 6000 cases in males, almost 3000 cases in females in the UK in 2014 
o 323,008 cases in males, 132,776 cases in females across the world in 2012
Age 
 
 In the UK, 96% of oesophageal cancers are diagnosed in people aged 50 or over, 
with over 50% diagnosed in those aged 70 or older38  
 However, studies have explored stage at diagnosis and survival in younger 
patients compared to older patients and found: 
o Patients <40 years old were more likely to be diagnosed with stage IV 
disease and have a shorter median survival40,99 
o Patients <50 years old were more likely to have dysphagia for over 6 months 
prior to diagnosis and be diagnosed with advanced disease50,83 
Ethnic group 
 
 In England, 2002-2009, oesophageal cancer was more prevalent in White ethnic 
groups than Asian or Black groups; age-standardised rates (per 100,000)100: 
o Male: White 13.9 to 14.4 vs Asian 3.6 to 6.1 and Black 6.0 to 10.2 
o Female: White 5.5 to 5.7 vs Asian 2.5 to 4.5 and Black 2.1 to 4.5 
 Recent study found a male:female ratio of 2:1 for White ethnic groups in 
Birmingham, UK, compared to Asian (1:1) and Black (8:1) ethnic groups67 
Smoking 
 
 It has been estimated that 66% of oesophageal cancer cases in the UK in 2010 
were attributable to smoking101 
 Meta- and pooled analyses identified the risk of developing SCC is up to 5.6 times 
higher among smokers than never-smokers102-104, and up to 2.8 times higher for 
adenocarcinoma103,105,106 
 Smoking is associated with an almost three-fold increase in the risk of developing 
oesophageal SCC when combined with alcohol use104 
Alcohol 
 
 An estimated 21% of oesophageal cancer diagnoses were attributable to alcohol 
consumption in the UK in 2010101 
 Meta-analysis showed that the risk of SCC increased significantly in line with daily 
alcohol consumption103; not identified with adenocarcinoma103,105 
Obesity 
 
 Estimated that 22% of oesophageal adenocarcinoma diagnoses in the UK in 
2010 were attributable to being overweight or obese, with men at greater risk 
than women (27% vs 11%)101,107. Association not established for SCC107.  
 Meta-analyses found that higher BMI is a risk factor for adenocarcinoma with or 
without reflux (i.e. GORD or Barrett’s oesophagus)108,109 
 Significant association between higher abdominal fat levels and adenocarcinoma 
risk, although could not assess the mediating effect of BMI or GORD109 
Diet 
 
 Oesophageal SCC associated with high consumption of red or processed meat, 
up to 57% increase in risk compared with lower intake110 
 Estimated that 46% of oesophageal cancer cases were attributable to a low 
consumption of fruit and vegetables in the UK in 2010101  
 Studies have shown that eating fruit and vegetables can lower the risk of 
oesophageal adenocarcinoma and SCC by up to 47%111,112 
SCC = squamous cell carcinoma; BMI = body mass index; GORD = gastro-oesophageal reflux disease 
 
Table 2.3. Staging for oesophageal cancer 
Stage TNM Description 
I T1/2 N0 M0 Cancer contained within the oesophagus 
II T1/2 N1 M0 
T3 N0 M0 
Cancer has grown outside of the oesophagus and possibly spread to 
a couple of nearby lymph nodes 
III T1/2 N2/3 M0 
T3 N1-3 M0 
T4 N0-3 M0 
Cancer has grown in to nearby tissues and involves multiple lymph 
nodes close to the oesophagus 
 
IV M1 with any T or N Cancer has spread to other parts of the body 
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2.4.4. Survival and mortality 
Advanced stage disease at diagnosis is a contributory factor to the poor survival outcomes 
observed for oesophageal cancers, with 42% one year survival and 15% five-year survival 
(2010-2011)113. There were around 400,000 deaths worldwide in 2012 from oesophageal 
cancer, and almost 8000 deaths in the UK in 2014 making it the sixth most common cause of 
cancer related death in the UK and the world37,114. The highest mortality rates are seen in Asia 
and Africa, reflecting the increased incidence of the disease in these regions, with men at 
higher risk than women37. This is also seen in the UK with over 5000 deaths in males in 2014 
compared to less than 3000 in females, making it the fourth most common cause of cancer 
related deaths in males, and the sixth in females114. 
 
2.5. Gastric cancer 
In 2012 more than 950,000 new cases of gastric cancer were diagnosed worldwide, making it 
the fifth most common cancer. In the UK it is the 16th most common cancer, with 6,682 new 
cases diagnosed in 2014115. The highest incidence of the disease is seen in east Asia, with 
over 400,000 new diagnoses in China in 2012, accounting for 43% of worldwide cases37.  
 
Almost 90% of gastric cancers are adenocarcinomas, which develop from glandular cells and 
occur in the upper (cardia) or lower (non-cardia) sections of the stomach116. Rarer forms of 
gastric cancer include lymphomas, gastrointestinal stromal tumours, and carcinoid tumours, 
which arise from lymphoid tissue, smooth muscle or neuroendocrine cells respectively116. 
 
2.5.1. Symptoms 
As discussed in Section 2.4, oesophageal and gastric cancer are often described together, as 
presenting symptoms are broadly similar. Studies that assess the cancers together have found 
that dysphagia is reported by over 50% of the patients73-75. However, studies that focus on 
gastric cancer alone have reported lower prevalence. Irving et al., 2002 recruited 90 patients 
(65 oesophageal, 25 gastric) from a cancer unit in England from 1st November 1999 to 30th 
December 2001 and found the most common symptom at presentation was dysphagia, 
experienced by 58 (64%) patients47. When the oesophageal and gastric patients were 
analysed separately, the symptom experience was different, with 77% of oesophageal cancer 
patients experiencing dysphagia compared to only 32% of gastric patients. Similar results have 
been found in other studies, with dysphagia reported by less than a third of patients51,62-64,84,85. 
These findings suggest that whilst dysphagia can be associated with gastric cancer, it may not 
necessarily be the most common symptom. Further research is required to fully understand 
the significance of this symptom for gastric compared to oesophageal cancer patients. 
Between 2009 and 2010, 32.1% of gastric cancer patients had three or more consultations 
37 
before referral, in comparison to 22.6% of oesophageal cancer patients (as previously 
stated)42. It is possible that this difference may be attributable to the subtle variations in 
symptoms between these cancers. The symptoms of gastric cancer have been outlined in 
Table 2.1 in combination with oesophageal cancer, or separately where possible. 
 
2.5.2. Risk factors 
In Table 2.4 I have outlined the sociodemographic, lifestyle and other risk factors associated 
with gastric cancer.  
 
Table 2.4. Risk factors for gastric cancer 
Risk factor Description 
Gender 
 
 13th most common cancer type for males and 15th for females in the UK117 
 Male:female ratio of 1.9:1 in the UK and 2:1 worldwide in 201237,117 
o Over 4000 cases in males, over 2000 cases in females in the UK in 2014 
o 631,293 cases in males, 320,301 cases in females across the world in 2012
 Recent studies found similar results: retrospective review of 157 cases in 
Morocco (2.1:1) and 23 cases in Nigeria (2.3:1)58,91 
Age 
 
 In the UK (2012-2014), around 51% of gastric cancers were diagnosed in patients 
aged ≥75, with less than 10% in those aged under 55117 
 Gastric cancer is rare in younger age groups, yet two studies based in the USA 
and Mexico found that patients aged <40 experienced later diagnosis and 
advanced stage disease at diagnosis (stage III or IV) leading to poor survival94,118
Ethnic group 
 
 Worldwide gastric cancer incidence is highest in Black ethnic groups116 
 In England, 2002-2009, gastric cancer was more prevalent in Black ethnic groups 
than White or Asian groups; age-standardised rates (per 100,000)100: 
o Male: White 14.1 to 14.7 vs Asian 5.2 to 8.5 and Black 16.1 to 25.6 
o Female: White 5.5 to 5.8 vs Asian 2.7 to 5.0 and Black 6.5 to 11.9 
Smoking 
 
 It has been estimated that 22% of gastric cancers diagnosed in the UK in 2010 
were attributable to smoking101  
 Meta-analyses: risk of gastric cancer in males was approximately 60% higher in 
smokers compared to never smokers, and up to 20% higher in females119-121 
Alcohol 
 
 Mild to moderate alcohol consumption has not been identified as a risk factor   
 However, there is some evidence to suggest that drinking more than six units per 
day can increase the risk of gastric cancer, although these estimates could be 
confounded by other factors such as diet and smoking122,123 
Obesity 
 
 Recent meta-analyses have associated being overweight (BMI 25-29.9 kg/m2) 
with a 21-22% higher risk of gastric cardia cancer than those with a normal 
weight, and being obese (BMI ≥30 kg/m2) with a 61-82% increased risk124,125 
 Association not identified for non-cardia gastric cancer 
Diet 
 
 High consumption of pickled foods or salt associated with an increased risk of 
gastric cancer, with varied evidence surrounding processed meat products101,126 
 The opposite has been found for fruit and vegetables, where a higher 
consumption is associated with up to a 50% reduction in risk101,127-129 
 Study exploring cancer incidence in vegetarians and non-vegetarians (average 
follow-up 14.9 years), found lower risk of gastric cancer in vegetarians130 
Helicobacter 
Pylori  
 
 Helicobacter Pylori is a bacterium found in the stomach, and has been identified 
as a risk factor for gastric cancer131 
 An analysis of 12 case-control studies identified that the risk of developing non-
cardia gastric cancer was up to 2.6 times higher in people with a positive 
Helicobacter Pylori test within 10 years of their diagnosis, and almost six times 
higher in those with a positive test 10 years or more prior to diagnosis132 
BMI = body mass index 
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2.5.3. Staging 
As with oesophageal cancers, gastric cancer is staged according to numerical staging (I-IV) or 
the TNM system (Table 2.5)133. 
 
Table 2.5. Staging for gastric cancer 
Stage TNM Description 
I T1/2 N0 M0 
T1 N1 M0 
Cancer is within the stomach lining and may involve up to two nearby 
lymph nodes, or it is within the stomach wall without lymph node 
involvement 
II T1/2 N2 M0 
T2/3 N1 M0 
T3/4 N0 M0 
Cancer is within the stomach lining or wall with multiple nearby lymph 
nodes involved, or it has grown to the outer layers of the stomach 
with no lymph node involvement 
III T1-4 N3 M0 
T3/4 N2 M0 
T4 N1 M0 
Cancer has grown to the outer layers of the stomach or in to nearby 
tissues and also involves multiple nearby lymph nodes 
IV M1 with any T or N Cancer has spread to other parts of the body 
 
2.5.4. Survival and mortality 
In the UK survival outcomes for gastric cancer are poor, with 42% one year survival and 19% 
five-year survival (2010-2011)115. In 2012 there were over 720,000 deaths worldwide from 
gastric cancer, making it the third most common cause of cancer related death worldwide37. In 
the UK it is the 12th most common cause of cancer related deaths, with almost 4,600 deaths 
in 2014115. Eastern Asia has the highest mortality rates, reflecting the increased incidence of 
the disease in this region, with 24 deaths in males per 100,000 of the population and 9.8 per 
100,000 in females37. In 2014 in the UK there were almost 3000 deaths in males and under 
2000 in females, making gastric cancer the eighth most common cause of cancer related death 
in males, and the 13th in females115. 
 
2.6. Timely diagnosis 
As described above, oesophageal and gastric cancer were diagnosed in over 15,000 people 
in the UK in 2014. With the poor one- and five-year survival rates, it is essential to find ways 
to diagnose these cancers at an earlier stage to enable patients to have access to potentially 
curative treatment. In this section, I discuss the evidence supporting timely diagnosis of cancer 
(decreasing the time between a patient first noticing a potential cancer symptom and the 
diagnosis134), including the use of conceptual frameworks and current knowledge in relation to 
oesophageal and gastric cancer. 
 
2.6.1. Conceptual frameworks 
In the UK, promoting timely diagnosis has been a policy priority in improving outcomes for 
cancer patients since the launch of the National Awareness and Early Diagnosis Initiative  
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(NAEDI) in 2008135. In my thesis I will be exploring the timely diagnosis of oesophageal and 
gastric cancer, so it is important to understand the patient pathways to diagnosis and potential 
influences. A number of models have provided conceptual frameworks to describe the 
pathway, which I discuss below. 
 
Three-stage Delay Model 
The patient pathway was explored by Safer et al., 1979, to understand how delays may affect 
the period from first noticing a symptom through to entering healthcare and starting 
treatment136. In the Three-stage Delay Model (Figure 2.2), the authors proposed that the period 
should be split into three sequential stages to account for the decisions and processes 
happening along the pathway, and to identify where delays may occur:  
 Appraisal delay – from noticing a symptom to appraising it as a potential illness; 
 Illness delay – from determining a potential illness to the decision to seek help; 
 Utilisation delay – from deciding to seek help to the point that the patient enters the 
healthcare system and starts treatment or uses healthcare services.  
 
The model focuses on patient ‘delay’ leading to healthcare service use, with the patient’s 
decisions in each stage potentially lengthening the time from first noticing a symptom to 
seeking help. 
 
Figure 2.2. Three-stage Delay Model136 
 
 
General Model of Total Patient Delay 
The General Model of Total Patient Delay, published by Andersen et al. in 1995, updated and 
expanded the Three-stage Delay Model, to a five-stage model to further understand the period 
from deciding to seek help to receiving treatment (Figure 2.3)137. The model retained the first 
two stages of the Safer et al. model:  
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 Appraisal delay – from detection of an unexplained sign or symptom to inferring illness; 
 Illness delay – inferring illness to deciding to seek help.  
 
The third stage, utilisation delay, was split into three stages:  
 Behavioural delay – from deciding to seek help to making the appointment; 
 Scheduling delay – from making an appointment to first consultation; 
 Treatment delay – first consultation to treatment.  
 
While the General Model of Total Patient Delay recognises that the period from deciding to 
seek help to receiving treatment is more complex than Safer et al. proposed, the model still 
focuses entirely on patient mediated delay along the pathway. 
 
Figure 2.3. General Model of Total Patient Delay137 
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Categorisation of Delay model 
In 2008 the Categorisation of Delay model was proposed (Figure 2.4)138,139, which differed from 
the previous two models in that it focused primarily on delays occurring once the patient had 
entered the healthcare system. In the model, three main time periods were defined, attributing 
delay at the patient, healthcare provider and system level: 1) Patient delay – first symptom to 
first contact with the GP, 2) GP delay – first contact with the GP to initiation of investigations, 
3) System delay – initiation of investigations to initiation of treatment. The GP and System 
delay were further categorised into delays in primary health care and those in secondary health 
care. 
 
Figure 2.4. Categorisation of Delay model138,139 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Model of Pathways to Treatment 
The Model of Pathways to Treatment (MoPT)140,141 (Figure 2.5) was published in 2012 following 
a systematic review exploring the application and use of the General Model of Total Patient 
Delay in cancer diagnosis research. Compared to previous models, the MoPT acknowledges 
that processes along any diagnostic pathway are not usually linear. The model also describes 
the pathway based on intervals, rather than periods of ‘delay’, with key time points (events) 
defining the start and end of each interval: 
 Appraisal interval – detection of bodily change to deciding to consult a healthcare 
provider; 
 Help-seeking interval – decision to consult a healthcare provider to first presentation in 
primary care; 
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 Diagnostic interval – first presentation in primary care to referral to secondary care, and 
first presentation in secondary care (as a referral from primary care or directly as an 
emergency) to diagnosis; 
 Pre-treatment interval – diagnosis to initiation of treatment. 
 
Within the intervals, patients and/or healthcare providers evaluate symptom information and 
respond accordingly; from assessing, managing and investigating symptoms, to referral, 
diagnosis and planning of treatment. These processes are influenced by patient, healthcare 
system and disease factors, such as socio-demographics, healthcare policies and tumour 
location, which in turn can impact the timing of events and interval durations, therefore affecting 
timely diagnosis and initiation of treatment.   
 
Figure 2.5. Model of Pathways to Treatment140,141 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCP = healthcare provider 
 
The Aarhus Statement 
Referring to intervals rather than using the term ‘delay’ in time to diagnosis research was one 
of the recommendations made by the Aarhus Statement, a methodological consensus 
statement published in 2012142. The authors suggested that ‘delay’ infers unnecessarily 
postponing help-seeking or the diagnosis, which does not accurately reflect the actions of 
patients or healthcare providers. The Aarhus Statement highlighted lack of consistency in the 
definition and measurement of intervals and the methods used in early diagnosis research. 
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The consensus group suggested that research on early cancer diagnosis could be improved 
by using a conceptual framework to underpin studies, with key recommendations highlighting 
the importance of describing methodological approaches and defining time points in a 
consistent way across research. As such, they proposed the following142: 
 Date of first symptom 
“The time point when first bodily changes and/or symptoms are noticed.” Researchers 
should clarify the date based on whether this time point refers to the first bodily change 
noticed, first symptom noticed, perceiving a reason to seek help (trigger symptom) or 
noticing the first alarm (high-risk) symptom.  
 
 Date of first presentation 
“The time point at which, given the presenting signs, symptoms, history and other risk 
factors, it would be at least possible for the clinician seeing the patient to have started 
investigation or referral for possible important pathology, including cancer.”  
 
 Date of diagnosis 
Should be clearly defined in relation to how it was measured, along with the context of 
the health system and diagnostic journey. 
 
Based on the recommendations, a checklist was developed to assist researchers in the design 
and conduct of studies and to ensure that future research is transparent and comparable 
(Figure 2.6). 
 
The use of conceptual frameworks 
By defining intervals along the pathways to diagnosis, rather than contextualising the pathway 
in terms of delay, it is possible to identify how patient, healthcare and disease factors influence 
timely diagnosis, either increasing or decreasing the interval lengths. The importance of factors 
within each interval, such as symptom experience and socio-demographics5,143-145, can also be 
determined, leading to the development of strategies to mitigate these factors. An example of 
a strategy to shorten the appraisal and help-seeking intervals is the use of the Be Clear on 
Cancer campaigns that aim to raise public awareness of symptoms and encourage earlier 
presentation.  
 
In exploring influences on the diagnostic interval, research over the last few years has utilised 
large clinical datasets and population based surveys, to explore symptoms, presentation and 
consultations patterns prior to diagnosis that may influence timely diagnosis. Lyratzopoulos et 
al., 2012, explored pre-referral consultations using the 2010 National Cancer Patient 
Experience Survey in England, analysing data from 41,299 patients diagnosed with 24 different  
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Figure 2.6. The Aarhus Checklist142 
Item Y/N 
   
DEFINITIONS OF TIME POINTS AND INTERVALS 
1. For studies requiring the measurement of an interval, are the beginning and end points 
of this interval clearly defined? 
 
2. For all time points and intervals described, are there precise, transparent and 
repeatable definitions, and is the complexity of time points such as the date of first 
symptom and date of first presentation addressed? 
 
For studies that require an estimate of the date of first symptom: 
3. Do the researchers refer to a theoretical framework underpinning definition of this time 
point? 
 
4. Is there a discussion of the different biases influencing measurement of this time 
point? 
 
For studies that require measurement of a date of first presentation to healthcare: 
5. Do the researchers discuss the complexity of the date of first presentation?  
For studies that require measurement of a date of referral: 
6. Do the researchers discuss the nature of the referral and provide adequate detail – for 
example, whether it was for investigation or consultation by a colleague in secondary 
care? 
 
For studies that require measurement of the date of diagnosis: 
7. Do the researchers use an existing hierarchical rationale for the date of diagnosis 
measurement? 
 
MEASUREMENT 
8. Is the healthcare context in which the study is based fully described?  
9. Do the questions on time points and/or intervals clearly derive from stated definitions?  
10. Do researchers acknowledge the need for theoretical validation and make reference 
to the theoretical framework(s) underpinning measurement and analysis of the time 
points? 
 
For studies using questionnaires and/or interviews with patients and/or health-care providers: 
11. Has a validated instrument been used?  
12. Have the researchers included a copy of their instrument?  
13. Is there some discussion of how reliability and validity (trustworthiness) has been 
established? 
 
14. Do researchers acknowledge the need for theoretical validation and make reference 
to the theoretical framework(s) underpinning measurement and analysis of the time 
points? 
 
15. Is there discussion of the different biases influencing measurement of the time points, 
such as how and when the question is asked and who is being asked? 
 
16. Is the timing of the interview in relation to the date of diagnosis provided?  
17. Is there any triangulation of self-reported data with other data sources such as case 
notes? 
 
18. Is data analysis described in full including how and why data are categorised, how 
missing and incomplete data are managed, and how outliers at both ends of the 
spectrum are accounted for? 
 
For studies using primary case-note audit and database analysis: 
19. Case-note analysis: is there a clear and precise description of how case-note data 
were used to ascertain time points with an acknowledgment of limitations of such 
data? 
 
20. For database analysis: is there a thorough description of the database chosen 
including sampling coverage and completeness of information? 
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cancers to identify an increased likelihood of three or more consultations for certain cancer 
types (including gastric), younger patients, ethnic minorities and women146. Din et al., 2015, 
used the Clinical Practice Research Datalink (CPRD), a large database of primary care 
records, to analyse diagnostic intervals for 18,618 patients diagnosed with 15 cancer types 
from 2007 to 2010147. They identified that in 10 cancer types, including oesophageal and 
gastric, the diagnostic interval was longer for patients presenting with symptoms not 
specifically described in the NICE guidelines for suspected cancer (oesophageal, mean 67.0 
days, p<0.001; gastric, mean 24.1 days, p=0.02). This type of research has helped to identify 
groups of patients potentially at risk of later diagnosis and has led to the development of cancer 
risk prediction models and new diagnostic tools for use in primary care65,79,148, which may help 
to promote timely diagnosis, although these tools are still in the early stages of testing. 
 
2.6.2. Timely diagnosis of oesophageal and gastric cancer 
As mentioned, advanced stage disease at diagnosis is common for oesophageal and gastric 
cancer, therefore timely diagnosis is a priority to improve outcomes. A systematic review 
published by Macdonald et al. in 2006 explored the factors that influence the timely diagnosis 
of upper gastrointestinal cancer (oesophageal, gastric, pancreas and small intestine)149. 
Twenty-five studies were identified, published from 1970 to November 2003, with 20 involving 
oesophageal or gastric cancer patients. The authors reported on various factors that 
lengthened the appraisal and help-seeking intervals (patient interval), and the diagnostic 
interval. These included patient non-recognition of symptom seriousness and practitioner use 
of inappropriate tests or ‘misdiagnosis’: either an alternative diagnosis at initial presentation or 
negative investigations.  
 
As it has been over ten years since the previous review, I conducted an updated literature 
review, firstly obtaining the full text of the 20 oesophageal and gastric papers evaluated by 
Macdonald et al. Following this, I searched recent literature (01 December 2003 to 31 
December 2015) using six bibliographic databases that covered multiple disciplines; 
MEDLINE, Embase, Scopus, PsycINFO, Cumulative Index to Nursing and Allied Health 
Literature (CINAHL) and Applied Social Sciences Index and Abstracts (ASSIA). The search 
identified a further 24 studies exploring factors that influence the total time to diagnosis, or 
intervals along the pathway, producing a total of 44 articles; 43 quantitative, 1 qualitative (Table 
2.6). Having reviewed the full text of the 44 studies, I identified six key factors most frequently 
discussed in relation to their influence on the timely diagnosis of oesophageal and gastric 
cancer: age, gender, symptom recognition, medication use, cancer type and diagnosis (Table 
2.6). I have described these factors below. 
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Age 
13 studies explored the influence of age, with nine demonstrating that younger age increased 
time to diagnosis. This was based on increasing the patient interval (PI)50,61,83,99, diagnostic 
interval64,74,147,163 or both94. The studies were all retrospective with patients in the UK (4), USA 
(4) and Singapore (1). Methods included: medical record review (n=44-374)50,61,74,83,94,99, CPRD 
database (n=5524-18,618)147,163 and a patient survey (n=83)64. 
 
Three of the medical record based studies explored oesophageal or gastric cancer diagnosis 
in patients aged 50 or younger compared to those over 5050,61,83. Two of these studies found 
that younger patients were more likely to experience dysphagia for six months or more 
compared to older patients (25-32% vs 3-7%)50,83, with all studies concluding that the PI was 
longer in younger patients. One of the CPRD studies explored dysphagia in relation to gastro-
oesophageal cancer and found that younger patients had a slightly longer time to diagnosis 
(p=0.065)163, while Mehta et al., 2010, identified that patients under 55 years old, from 17 
hospitals in the UK, had fewer urgent referrals from GPs74. The survey conducted with 83 
gastric cancer patients, found that younger patients (aged 40-59) experienced a longer 
diagnostic interval than older patients (median 16 weeks). However, in contrast, patients in 
their 80s were more likely to experience a longer PI, waiting on average six weeks before 
consultation (IQR 4-15 weeks)64. A further two studies also found that older age increased the 
PI156 or time to diagnosis166 and another two found no impact44,62. These studies were all 
retrospective, based in the UK (4) and Spain (1), using patient surveys (n=83–183)62,64,156, 
audit data (n=5036)44 or a large database (n=749,645)166. 
 
Gender 
Evidence was inconclusive regarding the impact of gender on time to diagnosis. One survey 
of 183 patients (65.6% male) in a Spanish hospital found that males were 2.8 times more likely 
to have a longer PI for OG cancer156. However, two other studies using patient surveys in the 
UK and Spain (n=83 and 217) found no association between gender and the PI64,158. For gastric 
cancer patients, three studies found the diagnostic interval was significantly longer for 
females93,147,153. Two were retrospective studies (patient survey, n=50; CPRD data, n=18,618) 
conducted in Sweden and the UK93,147, and one was a prospective trial in Norway (n=1165)153. 
The CPRD study assessed 15 cancers including 1842 oesophageal cancers and 2021 gastric 
cancers diagnosed in England and Wales from 2007-2010.  The authors found that on average, 
the diagnostic interval was 14.3 (CI 1.1 to 27.6) days longer for females than males147.  
 
Another large database study (n=749,645) in the UK, found that females had a greater risk of 
emergency presentation for gastric cancer compared to males166. However, other studies using 
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patient surveys, medical record review and audit data (n=83–5036) in the UK (2) and Spain 
(1) have shown no difference in the diagnostic interval based on gender44,64,158. 
 
Symptom recognition 
Seven studies using patient surveys, medical record review, descriptive and qualitative 
interview approaches identified that where patients did not recognise the seriousness of their 
symptoms, the appraisal and help-seeking intervals were lengthened59,64,77,81,85,151,156. These 
studies included between 13 and 536 patients and were based in the UK, Ireland, Spain, 
Greece, Sweden, Japan and Uganda. Symptoms that patients considered vague or non-
specific such as weight loss, minor swallowing difficulties and heartburn, were often initially 
dismissed, with patients consulting if symptoms persisted, increased in severity, or became 
visible or worrying64,81,156.  
 
Two studies based in the UK and Spain, using patient surveys and medical record review 
(n=150 and 217), found that pain prompted presentation62,158. However, a prospective 
descriptive study in Uganda (n=35) and a patient survey study in the USA (n=563) found the 
opposite59,150. A further study reviewed medical records of 44 patients with early gastric cancer 
in Singapore and also found that a PI of six months or more was associated with pain at 
presentation61.  
 
A review of medical records (n=92) across four hospitals in Italy found a difference in total time 
to diagnosis (TTD) between gastric cancer patients presenting with or without alarm symptoms 
(TTD 16.8 ± 13.9 weeks vs 29.3 ± 39.9 weeks) although the result was not significant63. 
However, the recent study by Din et al. using CPRD data, did find a significant increase in the 
length of the diagnostic interval for patients presenting without alarm symptoms compared to 
those with alarm symptoms: oesophageal (67.0 days; p<0.001) and gastric (24.1 days; 
p=0.02)147. 
 
Medication use 
The 11 studies that explored medication use all found that it increased the time to diagnosis. 
Tata et al., 2013, conducted a retrospective review of medical records for 112 patients 
diagnosed with oesophageal and gastric cancer in Malaysia and found that self-medication 
was an important factor in lengthening the PI164. Panter et al., 2004, found that oesophageal 
cancer patients (n=198) diagnosed at South Tees NHS Trust, UK, between 1991 and 2001 
used anti-secretory medication prior to help-seeking more than gastric cancer patients 
(n=487)159. In a database case control study in the Netherlands (n=65 cases, 260 controls) 
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patients diagnosed with oesophageal cancer were more likely to be taking medication in the 
six months prior to diagnosis compared to controls (50% vs 10%)161.  
 
Nine studies in the UK (5), Ireland (1), Nigeria (1), Malaysia (1) and Germany (1) using patient 
surveys and/or medical record review methods (n=23–685) found that the diagnostic interval 
was lengthened where patients were treated with medication51,59,64,73,77,90,91,159,164. This included 
antacids, PPIs or H2RAs, with Berrill et al., 2012, associating the use of medication with 
multiple primary care consultations prior to referral73. A UK based medical record review found 
that 17 (20%) patients, all using medication, were not diagnosed at the initial endoscopy. This 
lead to an average increase in time to diagnosis of 13 months (range 2-36)157. 
 
Cancer type 
As with the literature around gender, the effect of cancer type on time to diagnosis is 
inconclusive. Three studies in Spain (1) and the UK (2) used a patient survey (n=183), medical 
record review (n=747) and audit data (n=10,297) to compare the PI between those diagnosed 
with oesophageal and gastric cancer156,159,165. The studies found that patients with 
oesophageal cancer had a longer PI, with the survey by Porta et al., 1996, reporting a median 
PI of 28.5 days compared to 21.0 days for gastric patients156. Keeble et al., 2014, used data 
from the National Audit of Cancer Diagnosis in Primary Care (2009–2010) and found that only 
38.8% of patients with oesophageal cancer consulted within 14 days of symptom onset 
compared to 55.6% of gastric patients165. In comparison Hackett et al., 1973150, and MacAdam, 
197962, found that the PI was lengthened for gastric cancer patients in the USA (n=563) and 
UK (n=150). However, MacAdam did not include oesophageal cases in their study, instead 
comparing gastric to other gastrointestinal cancers.  
 
A retrospective analysis of GP records in Devon, UK, between 1986-1990 identified 1465 
patients diagnosed with six common types of cancer and found that the referral interval was 
longer for oesophageal cancer patients than gastric cancer patients (median 84 vs 66 days)154. 
A second study, based on a survey of 115 patients between 1994-1995 at one surgical unit in 
the UK, found an association between longer time to diagnosis and advanced tumour stage 
for oesophageal cancer, which was not found for gastric cancer90. However, a recent study 
using data from 41,299 people taking part in the National Cancer Patient Experience Survey 
in England, UK, identified that gastric cancer patients were more likely to have three or more 
consultations prior to referral (36% of gastric patients vs 24.9% oesophageal)146. Other studies 
based on a patient survey and/or medical record review (Malaysia, n=112; Germany, n=126) 
and a National primary care audit (UK n=5036) found both the referral interval and total time 
to diagnosis for gastric cancer patients was up to twice as long as oesophageal patients44,51,164.  
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Diagnosis 
Fourteen studies discussed the diagnostic interval, with one study showing a significant 
decrease in time from presentation to referral and referral to endoscopy following the 
introduction of the two-week wait referral guidelines (90 patients in one hospital in the UK)47. 
However, the other 13 studies including a total of 8,598 patients (range 13–5036) from across 
the world, identified factors increasing the time to diagnosis. These included inappropriate tests 
or investigations in primary care lengthening the time from presentation to referral44,52,64,75,77,164, 
alternative diagnosis at initial presentation75,77,81,85,94,152 or negative investigations in secondary 
care61,93,155. The latter studies found that a negative barium meal or gastroscopy/biopsy was a 
major factor for increasing the time to diagnosis.   
 
2.7. Health literacy 
It is possible that health literacy may mediate the influence of some or all of the factors 
influencing the time to diagnosis of oesophageal and gastric cancer. In 1974, Simonds 
proposed that minimum health literacy standards should be a requirement in schools in the 
USA and that health education should be viewed as a social policy issue integrating the “health 
care system, the educational system, and the mass communication system”167. However, it 
was not until the 1990s, when the first widely used instruments to measure health literacy were 
published, that research in the field started to expand, initially in North America and more 
recently across Europe168,169. Certain groups known to be at risk of low health literacy, such as 
those with low education170-175, low socio-economic status171,172,174, ethnic minority groups173 
and older aged adults172-174,176, are also known to have difficulties accessing cancer services177-
179. Health literacy could therefore be an important patient factor influencing timely diagnosis. 
In this section I will discuss the following: how the definition and concept of health literacy has 
evolved from an initial focus on comprehension and numeracy skills to a multi-dimensional 
construct, how health literacy is measured, and finally, current research exploring its 
importance for health outcomes.  
 
2.7.1. Definitions 
In 2012 a systematic review by Sorensen et al. identified 17 definitions of health literacy 
published between 1998 and 2009168 (Table 2.7). The most widely cited definitions are those 
proposed by the World Health Organisation (1998)180, the American Medical Association 
(1999)181 and the Institute of Medicine (2004)182. The systematic review highlighted the lack of 
consensus around a universally accepted definition; hence, the authors proposed a new 
definition, based on the key elements of the previous definitions: 
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“Health literacy is linked to literacy and entails people’s knowledge, motivation and 
competences to access, understand, appraise, and apply health information in 
order to make judgments and take decisions in everyday life concerning 
healthcare, disease prevention and health promotion to maintain or improve quality 
of life during the life course.”168 
 
However, this has not been widely accepted, as original definitions are still widely cited and 
new definitions continue to be published, such as that by Public Health England, in their 2015 
report on ‘Improving health literacy to reduce health inequalities’: 
 
“Having the skills (language, literacy and numeracy), knowledge, understanding 
and confidence to access, understand, evaluate, use and navigate health and 
social care systems can empower people to be active partners in their own health 
and social care, and in the care of their children, families and communities.”183  
 
The lack of clarity around the definition of health literacy may reflect the evolution of health 
literacy from two distinct areas, clinical care and public health184. These areas, along with 
conceptual models, are discussed below. 
 
2.7.2. Conceptual models 
As discussed by Nutbeam in 2008, the concept of health literacy originated from a clinical care 
setting based around ‘clinical risk’, and from a public health perspective which viewed health 
literacy as a ‘personal asset’184 (Figure 2.7).  
 
In the ‘clinical risk’ model, the focus is on the relationship between literacy and health, with 
general literacy informing an individual’s health literacy ability. This concept is reflected in the 
health literacy definition proposed by the Institute of Medicine182 (Table 2.7). In this respect, 
health literacy can be measured using instruments designed to assess literacy, comprehension 
and numeracy skills. The aim of these instruments is to identify those at risk and to improve 
the management of these patients in clinical settings. 
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Figure 2.7. Health literacy ‘clinical risk’ and ‘personal asset’ models 
 
 
 
A. ‘Clinical risk’ model 
 
B. ‘Personal asset’ model 
Models reproduced from Nutbeam, 2008184 
 
In the ‘personal asset’ model, used in public health approaches, health literacy is not derived 
from an individual’s literacy and numeracy skills, and is instead a distinct ability, built on the 
foundation of these skills. However, it is also influenced and developed through health 
education and communication, as suggested by Simonds in 1974167. The health literacy 
definition proposed by the World Health Organisation180 (Table 2.7) reflects this ‘asset’ based 
concept of health literacy. It builds on the tiered structure of functional, interactive and critical 
literacy skills described by Nutbeam in 2000185 and prior to that, Freebody and Luke in 1990201 
(Figure 2.8):  
 Functional health literacy – the basic literacy skills needed for everyday living. This 
forms the core of the structure, with each subsequent layer increasing in complexity;  
 Interactive health literacy – requires the integration of cognitive, social and literacy skills 
to understand and apply information;  
 Critical health literacy – uses advanced skills for analysing information and making 
decisions about healthcare.  
With this focus, health literacy is a set of skills enabling people to take control of their health 
through understanding and influencing personal, social, and environmental determinants and 
by engaging in health decision making.  
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Figure 2.8. Functional, interactive and critical health literacy model 
 
 
 
 
 
 
 
 
 
 
Based on Freebody and Luke, 1990201, and Nutbeam, 2000185  
 
In their systematic review of health literacy definitions, Sorensen et al. also identified and 
evaluated 12 conceptual models. However, they found that most models presented health 
literacy as a static element rather than an evolving process influenced by accessing and 
evaluating information and navigating through healthcare systems168. They therefore created 
a new conceptual model (Figure 2.9). The model incorporated the main elements of existing 
models, such as the influence of personal and social factors, along with the core aspects of 
current definitions (the ability to access, understand, appraise and apply health information), 
and extended the model to illustrate health literacy as a process. This included the integration 
between individual and population health literacy, and how the core aspects of health literacy 
are applied across the domains of health care, disease prevention and health promotion. 
 
Figure 2.9. Integrated model of health literacy 
 
Model proposed by Sorensen et al., 2012168 
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Although there is no widely used conceptual model for health literacy, the models discussed 
above illustrate how health literacy has developed from a narrow focus on literacy skills to a 
multi-dimensional construct. This is reflected in the development of measurement instruments, 
as discussed below. 
 
2.7.3. Measurement instruments 
Along with the multiple health literacy definitions and various conceptual models, there are also 
many instruments available for measuring health literacy. The first widely used instrument was 
published in 1991, the Rapid Estimate of Adult Literacy in Medicine (REALM)202 assessing 
pronounciation of a list of 125 medical words. A shortened version, the REALM-SF, with 66 
words derived from the original instrument was published in 1993203. However, with the focus 
of the REALM-SF purely on reading comprehension, Parker et al. published the Test of 
Functional Health Literacy in Adults (TOFHLA) in 1995 to assess numeracy skills in addition 
to reading comprehension204. Both the REALM-SF and the TOFHLA continue to be widely 
used in health literacy research today. However, with more recent definitions of health literacy 
and the emergence of more complex conceptual models, researchers have started to develop 
alternative instruments based on health literacy as a multi-dimensional concept. I discuss 
health literacy measurement instruments in more detail in Chapter 4. 
 
2.7.4. Health outcomes 
Health literacy has been described by Public Health England as the “bridge between people 
and health settings”183. With shared decision making and the prominence of patient centred 
healthcare today, it is essential for patients to feel confident in taking responsibility for their 
health. However, in England up to 61% of adults aged 16-65 years have difficulty 
understanding health information, particularly where numeracy skills are required183. Low 
health literacy has been associated with poor health outcomes including: increased possibility 
of hospitalisation205-208, use of emergency care205, poor medication management205,206, lower 
knowledge relating to chronic disease206,209, increased mortality in the elderly205,210,211 and 
difficulty when communicating with healthcare providers212-214. In cancer research, low health 
literacy has been associated with limited cancer risk knowledge215, poor knowledge and uptake 
of cancer screening205,206,216-218, difficulty in making treatment decisions following 
diagnosis219,220 and reduced quality of life in cancer patients221,222. Health literacy could have 
an important influence on timely diagnosis, through the appraisal of symptom information in 
the PI and/or difficulties in communication leading to GP misinterpretation or under-estimation 
of symptoms, which can lengthen the diagnostic interval149. I describe health literacy and timely 
diagnosis in further detail in Chapter 3.  
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2.8. Summary 
Oesophageal and gastric cancers accounted for almost 8% of cancer deaths in the UK in 
2014114,115 and have been ranked in the bottom five for survival compared to other cancers in 
England and Wales223. Reducing the time to diagnosis is a priority for diagnosing these cancers 
at an earlier stage and improving outcomes. My literature review identified important factors 
affecting timely diagnosis, such as younger age, recognising the seriousness of symptoms, 
use of PPI (or similar) medication and investigations or an alternative diagnosis in primary 
care. However, only one study used qualitative methods, to explore patient’s experiences of 
living with oesophageal cancer81. Further qualitative studies are needed to understand the 
patient’s perspective on the pathways to diagnosis for these cancers. In addition, exploring 
health literacy would provide new insights in relation to timely diagnosis of oesophageal and 
gastric cancer. In the following chapter I discuss the systematic review I conducted to explore 
the influence of health literacy in the timely diagnosis of symptomatic cancer.  
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Chapter 3: Systematic Review 
 
 
In Chapter 2 I discussed how health literacy has been associated with poor health outcomes 
across various populations and diseases. Research in the field of cancer has focused on the 
relationship between health literacy and screening216,217, treatment decisions219,220 and quality 
of life221,222. However, the evidence base on the relationship between health literacy and the 
diagnosis of symptomatic patients is less well developed. Patient, healthcare and disease 
factors are known to influence the pathways to diagnosis for many cancers, and I hypothesise 
that health literacy also has an important role. Reflecting on the definition by Public Health 
England183, the likely mechanisms through which health literacy may influence timely diagnosis 
include an individual’s ability to: 
 Access and understand information in relation to bodily changes or symptoms; 
 Evaluate and use the information in relation to their own situation; 
 Navigate the healthcare system by seeking help and accessing the specialist care 
required. 
 
Although oesophageal and gastric cancer are the focus of my PhD, in the background literature 
review I did not identify any research specific to health literacy and timely diagnosis in these 
cancers. I therefore decided to conduct a systematic review in relation to all cancer types, to 
understand how health literacy has been incorporated in to early diagnosis research, and to 
explore its influence on the pathways to diagnosis.   
 
3.1. Aim 
The aim of this systematic review was to identify research that explored the influence of health 
literacy on the timely diagnosis of symptomatic cancer. 
 
3.2. Methods 
I conducted a systematic review to identify articles published worldwide from January 1990 to 
May 2017, exploring health literacy in the timely diagnosis of any cancer. In this section I 
describe the methods, including development of the search strategy and inclusion/exclusion 
criteria, along with the processes for study selection, data extraction and quality assessment. 
Reporting of the review follows the guidelines proposed by the PRISMA Statement: Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses224.  
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3.2.1. Search strategy 
Peer-reviewed literature published from 1990 onwards was searched using six bibliographic 
databases; MEDLINE, Embase, Scopus, PsycINFO, CINAHL and ASSIA. These databases 
incorporate research from multiple disciplines including medical/health, social science, nursing 
and psychology. I considered other commonly used databases such as Web of Science, British 
Nursing Index and the Cochrane Library. However, the content covered by Web of Science 
and British Nursing Index is similar to Scopus and CINAHL respectively, and the Cochrane 
Library focuses on systematic reviews, which I chose not to include in this review. The search 
was limited to 1990 onwards as health literacy is a relatively new field, particularly in cancer 
research, with the number of studies expanding following the publication in 1991 of the 
REALM202. Grey literature was not explored in this review as relevant research was not 
identified during a prior scoping exercise of thesis titles, relevant conferences and a recent 
Public Health England report on health literacy183.  
 
I developed the search strategy in MEDLINE (Table 3.1) based on search terms identified from 
previous reviews exploring time to diagnosis or health literacy149,205,225,226, and with the help of 
a Medical Librarian and my primary supervisor (Dr Fiona Walter, FW).  
 
Table 3.1. Search strategy for MEDLINE/Embase  
Search Query 
1 “Cancer*”.mp 
2 “Tumour*”.mp 
3 “Tumor*”.mp 
4 “Malignan*”.mp 
5 “Neoplasm*”.mp 
6 exp Neoplasm/ 
7 Or/1-6 
8 exp Health Literacy/ 
9 “Health Literacy”.mp 
10 “Health Literate”.mp 
11 “Health Literacies”.mp  
12 “Literacy”.mp 
13 “Literate”.mp 
14 “Literacies”.mp  
15 “Cancer literacy”.mp  
16 “Cancer literate”.mp 
17 “Numeracy”.mp 
18 “Numerate”.mp 
19 Or/8-18 
20 7 AND 19 
21 “Systematic review”.ti 
22 20 NOT 21 
23 Limit 22 to yr="1990 -Current" 
Current = May 2017 
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It was important to identify research that specifically aimed to evaluate health literacy (or 
literacy/numeracy in relation to health) in the pathways to diagnosis of any cancer, yet to avoid 
excluding relevant articles. I therefore developed a high sensitivity, low precision search using 
a broad search strategy and incorporating a combination of subject headings and free text, 
which I adapted for each database (Appendix 5). While this type of strategy increases the 
likelihood of identifying all relevant studies, it also leads to the inclusion of a high proportion of 
additional citations to screen, therefore increasing the possibility of researcher error. I identified 
additional articles from the reference lists of included articles, other studies published by 
included authors, and running a forward citation search in Scopus to identify publications citing 
the included articles (described in Section 3.3). 
 
The initial search was conducted in October 2016 and updated in May 2017 to identify any 
additional articles published prior to the start of the analysis. Articles identified from each 
database were imported in to EndNote X7 (reference manager software) and duplicates were 
removed.  
 
3.2.2. Inclusion and exclusion criteria 
As the systematic review aimed to evaluate health literacy in the timely diagnosis of 
symptomatic cancer, I reflected on the MoPT140,141 as a conceptual framework for defining the 
intervals along the pathway: appraisal, help-seeking and diagnostic. However the Aarhus 
Statement demonstrated that there was little consistency across the literature in the definition 
and measurement of intervals and key time points142. I therefore developed the inclusion 
criteria to account for these inconsistencies and to ensure that all relevant studies were 
included in the review. 
 
Inclusion criteria  
The review included studies published in any language in a peer-reviewed journal from 1990 
onwards where the article met the following inclusion criteria: 
 Adult patients (aged 18 years and older) with a primary diagnosis of any cancer;  
 Exploring the time to diagnosis of symptomatic cancer, either assessed by the total 
pathway, or by one or more intervals as defined in the MoPT140,141; 
 Evaluating health literacy (or literacy/numeracy related to health yet not termed as 
‘health literacy’); 
 Relating health literacy to the time to diagnosis. 
 
This broad description of health literacy was chosen as earlier studies originally focused on 
literacy and numeracy skills in a healthcare setting with early measurement tools reflecting 
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this, such as the REALM202 and TOFHLA204. I therefore did not want to limit the inclusion criteria 
to ‘health literacy’ and unintentionally exclude studies that studied literacy or numeracy in 
relation to health. In adopting this approach I acknowledged that the low precision of the 
search, using wide search terms, could identify a large number of studies requiring manual 
exclusion where they referred to a more general definition of literacy i.e. the ability to read or 
write. Whilst general literacy skills are important in how people interact with healthcare, it was 
not the focus of this review. In addition to the broad definition of health literacy, I also did not 
limit studies to those using a validated health literacy measurement tool, as I wanted to explore 
how researchers were defining and evaluating health literacy in early diagnosis research.  
 
Exclusion criteria 
Systematic reviews, reviews, editorial and letters were excluded, along with studies that: 
 Focused on recurrent cancers, cancer incidence, survival and mortality, risk factors, 
genetics, screening and prevention, or assessing the validity of referral decisions; 
 Reported on time to diagnosis without the association with health literacy, or vice versa. 
 
3.2.3. Study selection 
I screened all titles and abstracts against the inclusion/exclusion criteria to identify articles for 
full text review. Two of my supervisors (FW and Dr Jenni Burt, JB) assessed a random sample 
of the excluded titles/abstracts (10% of the total) and agreed with the exclusions. 
 
Following the review of all titles and abstracts, the full text article was obtained for all studies 
identified as potential inclusions. I reviewed each full text article, as did FW and JB, and we 
discussed each article to identify those for inclusion in the systematic review. Included studies 
were subject to data extraction and quality assessment as described below.  
 
3.2.4. Data extraction 
Data were extracted from each of the included studies to collate study details and 
characteristics. This included: study type, recruitment setting, data collection details, 
participant characteristics, patient pathway/interval data as defined within the study, health 
literacy data including the definition and health literacy instrument used (if any), and the 
findings in relation to time to diagnosis. I developed an electronic data extraction form for use 
in the review (Appendix 6), and the forms for all included studies were reviewed by FW and JB 
to confirm completeness of data.      
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3.2.5. Quality assessment 
During data extraction I also conducted a quality assessment for each of the studies. Quality 
assessment tools considered for this purpose were: the Critical Appraisal Skills Programme 
(CASP)227, STrengthening the Reporting of OBservational studies in Epidemiology 
(STROBE)228 checklist, Scottish Intercollegiate Guidelines Network (SIGN)229 checklist, 
Joanna Briggs Institute (JBI) Critical Appraisal Tools230, the Dixon-Woods et al. criteria231 and 
the scoring system as used in Macdonald et al., 2006149. I chose the JBI tools as they allowed 
a concise assessment of the validity of the results for the full range of studies expected in the 
review, whereas the other checklists and scoring systems had not been designed for all study 
types. The aim of the quality assessment was to determine the validity of the results based on 
the design, methods, analysis and conclusions of each study, and to assess the relative 
contribution of each study to the review. Limitations were acknowledged; however, studies 
were not excluded based on the quality assessment alone. The JBI ‘Qualitative Research’ and 
‘Analytical Cross Sectional Studies’ checklists were used in the review (Appendix 7). 
 
3.2.6. Protocol registration 
Prior to starting the review, the protocol was registered with PROSPERO (CRD42016048917), 
an international prospective register of systematic reviews.   
 
3.3. Results 
The original bibliographic database search in October 2016 identified 4924 citations, with a 
further 264 citations identified from the updated search in May 2017. Of the total 5188 citations 
identified, 2884 were duplicates (Figure 3.1). I screened 2304 titles and abstracts against the 
inclusion and exclusion criteria to identify 26 full text articles, of which three were suitable for 
inclusion in the review.  
 
Studies were mainly excluded based on either not being related to the time to diagnosis or not 
assessing health literacy. The reference lists of the three included studies and all other 
publications by the authors were reviewed, and a forward citation search for each article was 
conducted using Scopus to screen for additional relevant studies: none were identified. Table 
3.2 gives details of the 26 full text articles screened for inclusion. 
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Figure 3.1. Systematic review process 
 
Based on the PRISMA Statement guidelines224 
 
3.3.1. Included studies 
The three studies identified for the review were set in Japan, the USA and Egypt, and included 
patients diagnosed with gastrointestinal (colon, rectum, pancreas), cervical or breast cancer 
(Table 3.3). Two studies used qualitative methods, while the third reported a survey. The 
number of participants ranged from 10 to 37 and the overall sample was predominately female 
(92%). The studies set in the USA and Egypt were published in English while the study set in 
Japan was published in Japanese and was therefore professionally translated.  
 
Table 3.4 summarises the definition(s) used by the authors to describe the intervals along the 
pathways to diagnosis and the corresponding interval according to the MoPT140,141, while Table 
3.5 summarises the health literacy definition and assessment used in each study. Only one 
study used a validated instrument to measure health literacy, the short-form of the REALM 
(REALM-SF)203, while the other studies used alternative approaches that I explore in more 
detail later in this chapter. The completed data extraction form for each study has been 
included in Appendix 6.  
 
Due to the heterogeneity of studies I used a descriptive approach for the data analysis, 
combining the results of the studies where possible. 
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3.3.2. Study quality 
I assessed the quality of all included studies using the JBI Qualitative Research or Analytical 
Cross Sectional Study Checklist230 (see Appendix 7 for the completed checklists). The quality 
of each study varied considerably, as represented in Table 3.6. 
 
Nakagami & Akashi and McEwan et al. had clear aims that correlated with the methodology, 
results and conclusions of the studies. The study by Tecu & Potter initially stated the aim was 
to explore cervical cancer screening practices in patients diagnosed with late stage cervical 
cancer, yet data collection and analysis primarily explored symptom experience, knowledge of 
cervical cancer, and help-seeking behaviours influencing time to diagnosis. The aim as stated 
in the discussion, and which accurately reflected the results and methodology used, was “to 
explore literacy as a factor contributing to delay in cervical cancer diagnosis and treatment in 
a group of low-income women with late stage incurable disease”256. As the study was not 
primarily related to cancer screening, the systematic review exclusion criteria did not apply and 
it was therefore eligible for inclusion.  
 
Two of the studies (Nakagami & Akashi, Tecu & Potter) identified the recruitment setting as 
secondary care, yet did not give further details as to the location of the hospital or gynaecology 
tumour clinic. The study by McEwan et al. did not specify the setting in the paper; however, 
the participants had been recruited from a prior survey based study, which identified 
recruitment from Cancer Treatment Centres in various locations across Egypt258. This study 
described reasons for non-participation, while the other studies did not. None of the studies 
adequately described their sampling strategy or the characteristics of non-responders/those 
declining participation and only Nakagami & Akashi gave dates of recruitment. Nakagami & 
Akashi also gave a detailed description of their inclusion criteria, as did Tecu & Potter, although 
the latter study did not address ‘income’ within their criteria, yet stated in their discussion that 
the study aimed to focus on ‘low-income women’. McEwan et al. recruited their participants 
from the prior quantitative study based on the time interval within which delay was experienced 
(Table 3.4), although they did not provide any additional details regarding selection of 
participants. The exclusion criteria were not discussed in any of the studies. The overall quality 
of study design was poor as key aspects were either not adequately described, or not 
addressed at all.  
 
When describing the characteristics of the participants, Nakagami & Akashi only gave basic 
details of their participants (low quality) such as gender and approximate age range (early 40’s 
to late 70’s). The other two studies provided more accurate details of gender, age ranges and 
additional information such as employment, education level and marital status (high quality).  
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Data collection methods reflected the methodology used in each study, although my 
assessment of quality rated all of the studies as either adequate or poor because none of the 
studies defined the date of diagnosis, or reported the specific time period between diagnosis 
and data collection. This was an important issue raised by the Aarhus Statement142 and I have 
explored this in more detail in my discussion of time to diagnosis later in this chapter. In 
addition, Tecu & Potter’s survey study also did not provide sufficient detail in relation to the 
content of the Cervical Cancer Knowledge and Health Practices Survey used in the study, or 
how it was adapted from the colorectal instrument on which it was based.  
 
All studies analysed their data according to the health literacy definition or conceptual 
framework proposed, yet the overall analysis was either adequate or poor. In the qualitative 
studies, Nakagami & Akashi included very few quotations and instead used their own words 
to summarise what participants said. In contrast, McEwan et al. included many quotes yet it 
was unclear whether these reflected the voices of most participants or just a few, as the 
identification label used against the quotes was not sufficiently detailed to distinguish the 
participants. It was therefore unclear from both studies whether the data that was presented 
accurately reflected the data within the study. The latter study considered the influence of the 
researcher in data collection and analysis, whereas Nakagami & Akashi only considered the 
researcher in the pre-interview observation stage. Tecu & Potter provided a descriptive 
analysis of their data and examined the REALM-SF score in relation to the PI, yet did not 
evaluate time to treatment or the influence of other factors on these intervals. The conclusions 
from the studies could therefore only be described as adequate or poor based on the 
methodology and data presented, with the overall quality of the studies rated as poor (Tecu & 
Potter) or poor to adequate (Nakagami & Akashi, McEwan et al.). I have discussed the analysis 
and conclusions of the data in more detail in the rest of this chapter. 
 
3.3.3. Main findings 
I begin this section by describing how the studies define and measure both the time to 
diagnosis and health literacy before discussing the study results and conclusions in relation to 
the influence of health literacy on timely diagnosis.  
 
Time to diagnosis 
The included studies explored the time to diagnosis of symptomatic cancer patients either 
based on evaluating the total patient pathway, or intervals along the pathway. However, as 
previously mentioned, the Aarhus Statement142 found little consistency in the definition and 
measurement of the patient pathway, and this is reflected in the three papers included in my 
systematic review. Two of the studies251,256 were published prior to, or very close to, the 
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publication of the Aarhus Statement (2012), while the third was published two years later250.  
All studies explored the time period from symptom onset and went on to describe various 
intervals (Table 3.4). Nakagami & Akashi, 2010251, focused on the total time to diagnosis, from 
symptom detection to diagnosis, Tecu & Potter, 2012256, investigated symptom onset to first 
presentation and to treatment, while McEwan et al., 2014250, evaluated three intervals: 
symptom discovery to initial medical consultation, initial consultation to diagnosis, and 
diagnosis to treatment. Tecu & Potter clearly defined symptom onset as “when they [patients] 
first noticed the symptom or symptoms that they now believed resulted from cancer”, whereas 
Nakagami & Akashi did not provide a definition. McEwan et al. identified the time point as 
“symptom discovery” yet did not clarify what was meant by this. For example this could relate 
to the first bodily change or symptom noticed by the participant, or the first symptom that 
prompted consultation. ‘First presentation’ or ‘initial medical consultation’ were clearly defined 
(first consultation with a doctor) as was receipt of/initiation of first treatment. However, none of 
the studies defined the date of diagnosis. This left it unclear as to whether the diagnosis was 
the histological or cytological confirmation of the malignancy, date of admission to hospital, 
first consultation as an outpatient, or another definition of the time point264. 
 
The study by Tecu & Potter was the only one to provide details on the length of the intervals, 
with the average PI as 5.26 months (standard deviation (SD) unknown), and symptom onset 
to treatment as 8.82 months (SD +/- 11.41, range 1–48 months). These intervals were based 
on reports by the participants within the survey. McEwan et al. sampled participants from a 
prior quantitative study (n=394) assessing the time to diagnosis in breast cancer patients. 12 
of the 15 participants selected for the interview study had experienced a ‘delay’ in their 
diagnosis, either during the appraisal, help-seeking, diagnostic or pre-treatment interval. 
However, the authors did not define the meaning of ‘delay’ and details were not provided 
regarding the length of the intervals. Nakagami & Akashi did not seek to quantify the time from 
symptom onset to diagnosis and instead described occasions where behaviours and 
investigations may have lengthened or shortened the time to diagnosis.  
 
Health literacy 
As discussed in Chapter 2, a recent systematic review identified 17 definitions of health literacy 
published between 1998 and 2009168, highlighting the lack of consensus in health literacy 
research. I observed this in the systematic review, as the definition of health literacy differed 
between the three included studies. Nakagami & Akashi and Tecu & Potter defined the concept 
based on previous literature while McEwan et al. used their own definition (Table 3.5). Tecu & 
Potter used the definition provided by the US Department of Health and Human Services261, 
which identifies health literacy as “the degree to which individuals have the capacity to obtain, 
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process, and understand basic health information and services needed to make appropriate 
health decisions”. The study by Nakagami & Akashi referenced seven papers, with six unique 
definitions of health literacy within their study, and incorporated three in their assessment of 
health literacy185,195,260. Their definition reflected health literacy across the patient pathway 
including the ability to acquire, understand, read and evaluate medical and health information, 
and to take the role of a patient. McEwan et al. discussed health literacy in terms of symptom 
interpretation and knowledge networks, yet in the analysis the authors also explored other 
related factors without associating them with health literacy. This included social networks, 
patient-provider communication and navigation of the healthcare system, which are important 
aspects of health literacy as identified by current definitions168,183.  
 
The study by Tecu & Potter was the only one that used a validated measurement tool, the 
REALM-SF203, to evaluate health literacy. As described in Chapter 2, the REALM-SF is a 
reading recognition test designed to assess pronunciation of medical words. Although it has 
been widely used in health literacy research, it is primarily an assessment of comprehension 
rather than an assessment of ability to obtain and use health information. This shortened 
version has 66 words organised in ascending difficulty203. The scores are based on USA high 
school reading grades and the results can be used to estimate the patient’s literacy ability in a 
medical setting. The other two studies explored concepts of health literacy via participant 
interviews and in relation to the health literacy definitions proposed in the study (Table 3.5).  
 
Influence of health literacy on time to diagnosis 
As described, the three studies approached the definition of health literacy very differently and 
as such took different approaches in exploring how it influenced timely diagnosis. Nakagami & 
Akashi focused on how health literacy influenced the pathways to diagnosis251, McEwan et al. 
explored many factors, including health literacy, to understand women’s experience of breast 
cancer diagnosis and treatment delays250, and Tecu & Potter explored health literacy as a 
factor contributing to delay in diagnosis and treatment256. 
 
Patient interval 
All studies explored symptom interpretation, awareness and knowledge, and considered how 
health literacy may influence appraisal and help-seeking; and therefore the pathways to 
diagnosis. Tecu & Potter used the REALM-SF to determine if there was an association 
between health literacy and the PI, while Nakagami & Akashi reviewed the patient’s narratives 
and used a Grounded Theory approach265, as proposed by Strauss & Corbin, 1998, to identify 
where and how health literacy ability was important. McEwan et al. used a conceptual 
framework, the ‘social ecological model’, to analyse and present their data. The model, 
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proposed by Scheidner in 2006263, suggests that “individuals are embedded within a system 
of sociocultural relationships that influence, directly or indirectly, their ability to take action”. 
Within the framework, the authors examined intrapersonal (person centred), interpersonal 
(social), organisational (patient-healthcare provider communication) and policy (health system) 
factors affecting the time to diagnosis and treatment. Health literacy was classified as an 
intrapersonal factor in the model, specifically related to patient beliefs around risk factors for 
breast cancer. However, the authors also used their own definition of health literacy to explore 
symptom interpretation and knowledge. 
 
Tecu & Potter found that many women (n=24) had multiple symptoms prior to diagnosis with 
the most common being bleeding (57%) and pain (19%). However, approximately 65% of 
women did not attribute their symptoms to cancer and instead believed them to be other benign 
causes such as menopausal menstrual changes (35%) or an infection/STD (22%). The survey 
also explored help-seeking and concluded that only a third of women utilised their knowledge 
in order to seek help and treatment from a physician or clinic, with the average PI calculated 
as 5.26 months. All studies identified that where participants attributed a benign cause to 
symptoms, their action was to ‘watch and wait’, which often resulted in a lengthening of the 
appraisal interval. Nakagami & Akashi proposed that during this period health literacy skills 
were used to process symptom information, consider prior knowledge and experience, and 
understand and evaluate symptoms so that a ‘disease hypothesis’ could be formed. 
 
When symptoms persisted or worsened, further information would be obtained from other 
sources such as medical books or friends and family, to re-evaluate and contextualise their 
symptoms in relation to the new information. Social influence is an important aspect of current 
health literacy models 266, with all three studies finding that help-seeking could be prompted by 
knowledge obtained from social networks. However, only Nakagami & Akashi discussed these 
findings in relation to health literacy and how new knowledge could influence the ‘disease 
hypothesis’. McEwan et al. went on to consider risk factor knowledge in relation to health 
literacy. Participants identified multiple risk factors for breast cancer, although many believed 
the cancer had been caused by being angry or upset. The PI was longer when participants did 
not think they were at risk of cancer, with the authors concluding that delays were increased 
where health literacy was low.  
 
In their analysis of the REALM-SF, Tecu & Potter found the mean score was 60.08 (SD 12.63, 
range 0-66), with eight (22%) women scoring 54 or less, therefore suggesting low health 
literacy. Based on the study analysis, there was no statistically significant correlation between 
the REALM-SF scores and the PI across the whole cohort. A sub-group analysis of the eight 
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women with low health literacy found that four of the women waited 6-12 months from symptom 
onset to first presentation, although this was not contextualised in relation to the 29 women 
who scored more than 54 on the REALM-SF. 
 
Diagnostic interval 
Nakagami & Akashi described the use of watchful waiting within the diagnostic interval, 
particularly if patients sought help from a hospital without a specialist department (e.g. 
Gastroenterology). At these non-specialist hospitals, it was more likely for an alternative 
diagnosis to be suggested with the patient either monitored or given medication for their 
symptoms, which would suggest a lengthening of the diagnostic interval. In these instances 
patients had to rely on their health literacy ability by re-starting the process of understanding, 
evaluating and acting on their symptoms, with one patient only receiving their correct cancer 
diagnosis when they went to a specialist hospital. Tecu & Potter calculated that the average 
time from symptom onset to receipt of first treatment was 8.82 months (range 1 - 48 months), 
while McEwan et al. attributed significant delays in diagnosis to the complexity of the 
healthcare system and previous bad experiences with healthcare providers. However, these 
findings were not specifically related to health literacy within the studies.  
 
Summary 
Where health literacy was assessed in the studies, the authors concluded that health literacy 
was likely to influence cancer diagnosis, with lower ability increasing the time from symptom 
onset to presentation and/or diagnosis as participants assessed their symptoms as non-
serious or waited longer to consult. However, all three studies were of poor quality, with the 
strength of the conclusions limited by the methodological weaknesses.  
 
Nakagami & Akashi provided a clear definition of health literacy and related their results to this; 
however, they acknowledged that their sample was inadequate to reach theoretical saturation 
according to the Grounded Theory approach used265, particularly as the inclusion of five non-
symptomatic patients did not directly relate to the aim of the study. Within this sample 
(diagnosed following routine hospital based check-ups or as part of local health checks) the 
authors could not explore health literacy in relation to initial detection of symptoms. This 
resulted in a limited analysis of this group, with the authors concluding that the patient’s health 
literacy enabled them to utilise health services and acquire information via the regular check-
ups. Whilst attendance at health checks could reflect the aspect of ‘taking the role of a patient’, 
four of the five patients did not use the check-up to acquire, understand or evaluate health 
information in relation to their cancer diagnosis as it was a routine blood and/or stool test that 
resulted in further examination and diagnosis. The authors’ analysis therefore did not 
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accurately reflect the data and instead attempted to fit the data to reflect the conclusions drawn 
from the symptomatic patients. The experiences of symptomatic vs non-symptomatic patients 
are unique and the authors could have attempted to better understand health literacy within 
the non-symptomatic patients in order to compare experiences between these patient 
populations.  
 
In their selection of the REALM-SF, Tecu & Potter chose a widely used measurement tool, yet 
it did not reflect the definition of health literacy that the study was based on. As previously 
described, the US Department of Health and Human Services’ health literacy definition261 
focuses on how individuals obtain, process and use health information and services, whereas 
the REALM-SF is a test of comprehension and is therefore not intended to measure application 
of health information. This is reflected in the author’s recognition of the REALM-SF limitations 
and suggestion that a more comprehensive assessment of health literacy would be useful 
when exploring the pathways to diagnosis. In considering the results, the analysis is primarily 
restricted to descriptive statistics relating to the symptoms experienced, knowledge about 
symptoms and help-seeking behaviours without any statistical analysis of how these factors 
may correlate with the time from symptom onset to first presentation or treatment. The study 
did not find any statistically significant correlation between health literacy scores and symptom 
recognition or help-seeking; however, it is unclear how this was assessed as the methods are 
not described. The sub-group analysis of eight women scoring ≤54 on the REALM-SF was not 
contextualised, so it was not possible to draw conclusions from this analysis regarding health 
literacy and the PI or to conclude on the influence of health literacy when considering the 
study’s findings based on the overall REALM-SF scores. 
 
Although smaller sample sizes are generally expected for qualitative studies, McEwan et al.  
did not discuss ‘saturation’ or the more recently termed ‘information power’ of the sample267 
when analysing the data. The conclusions to be drawn from the authors’ assessment of health 
literacy in this study are limited, in part due to the multiple definitions of health literacy proposed 
within the study. As discussed, the social ecological model categorises health literacy as an 
intrapersonal factor, with the authors assessing this in relation to symptom interpretation and 
risk factors. The authors discussed how the PI could be lengthened where symptoms were 
interpreted as non-serious or where there was low health literacy around risk factors, yet they 
did not adequately describe how they reached this conclusion in relation to the data.  
 
Based on these conclusions, the results should not be interpreted as an accurate assessment 
of the influence of health literacy on time to diagnosis; however, the studies can be used as a 
guideline for exploring health literacy in future studies. The three very different approaches to 
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health literacy used in the studies highlights the complexity of conducting health literacy 
research. A recent systematic review of health literacy in adolescents and young adults 
discussed how current literature focuses on quantifying health literacy, usually assessing 
abilities as adequate or inadequate, whereas a qualitative approach could help to understand 
the wider concept and factors influencing health literacy ability268. Tecu & Potter opted to use 
the REALM-SF to quantitatively assess health literacy within their study, yet concluded that a 
more comprehensive tool would have been more appropriate to the study aims. While the other 
studies qualitatively assessed health literacy, the results raise important questions as to how 
health literacy is defined and analysed when a recognised assessment tool is not used. 
McEwan et al. proposed a very narrow definition, yet indirectly assessed other important 
aspects of health literacy such as social networks, patient-provider communication, and 
navigation of the healthcare system. In comparison, Nakagami & Akashi had a clear definition 
of health literacy yet were limited in their conclusions based on not reaching theoretical 
saturation. When relating health literacy research to ‘time to diagnosis’, these studies also 
demonstrate the importance of adhering to the principles proposed by the Aarhus 
Statement142, particularly in relation to accurately defining the time points and intervals along 
the pathways to diagnosis. 
 
Other factors and time to diagnosis 
In addition to exploring the role of health literacy, the studies also examined the influence of 
other factors on time to diagnosis and treatment and found that fear, initial misdiagnosis and 
financial constraints all had a negative effect on the patient pathway, which reflects previous 
research in this area149,269-271. Fear was identified as fear of healthcare rather than fear of the 
cancer diagnosis and lead patients to postpone help-seeking or diagnostic procedures250. 
Initial misdiagnosis either in primary or secondary care lengthened the diagnostic interval while 
patients either tried medication for their symptoms or undertook a period of watchful waiting. 
In both scenarios, obtaining the correct diagnosis relied on the patient re-assessing their 
symptoms and re-presenting, sometimes to an alternative healthcare provider or hospital250,251. 
Financial constraints were also shown to be problematic where private healthcare systems are 
prominent, with patients either postponing initial help-seeking or their treatment until a time 
when they could afford it250,256. Tecu & Potter also examined current and previous healthcare 
use as well as knowledge of cervical cancer risk factors and screening, although they did not 
assess the impact of these factors on time to diagnosis. 
 
3.4. Discussion 
Previous health literacy research in the cancer field has explored the role of health literacy in 
non-cancer patients considering screening options217,219, and in cancer patients relative to their 
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quality of life221,222 or their ability to evaluate treatment options219,272. This systematic review 
sought to explore how health literacy influences the time to diagnosis in symptomatic patients, 
particularly as health literacy may influence a person’s ability to access and understand cancer 
symptom information, appraise the information in relation to their own bodily changes, and 
navigate the healthcare system to obtain a diagnosis and access the specialist care required. 
The review found that: 
 There is limited research in this area;  
 Studies were methodologically poor; 
 It was not possible to evaluate the influence of health literacy on time to diagnosis.  
These points are considered below. 
 
3.4.1. Limited research 
The inclusion of only three studies in this systematic review identifies an important gap in the 
literature when considering the role of health literacy in early diagnosis of cancer. The search 
strategy was broad to avoid unintentionally excluding articles, and with the additional search 
strategies used in relation to the included articles, I am confident that all relevant studies were 
identified in relation to the aim of the review. However, of the 23 full text articles excluded from 
the review, nine were excluded because they did not report on time to diagnosis as specified 
in the inclusion criteria, with two of these articles reporting on health literacy in relation to 
cancer stage at diagnosis235,238, which I have considered below. 
 
Health literacy and stage at diagnosis 
It has been suggested that detecting cancer at an earlier stage could be achievable through 
earlier symptomatic diagnosis134 and so it could follow that late stage at diagnosis would be 
the result of less timely diagnosis. However, we have recently seen from the ‘waiting time 
paradox’, where patients with aggressive or more advanced cancers are referred quickly and 
diagnosed with late stage disease, that this is not necessarily the case273,274. A recent 
systematic review by Neal et al., 2015, across many cancer types also provided mixed 
evidence on the association between time to diagnosis and disease stage275. Studies of breast, 
testicular, bladder, head and neck, cervical, endometrial, melanoma and non-melanoma skin 
cancer, and upper tract urothelial carcinoma found a positive association and/or no association 
between shorter time to diagnosis and earlier stage at diagnosis, while studies of gastric, renal 
and ovarian cancer found no association or a negative association. No association was found 
for cancer types including pancreatic and prostate cancer, while evidence was presented 
across the spectrum (positive, negative, and no-association) for cancers such as lung, 
colorectal and oesophageal.  
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From the two studies assessing health literacy and stage at diagnosis, Bennett et al., 1998235, 
used the REALM-SF203 to evaluate the association between poor literacy and stage of prostate 
cancer in low income men in two cities in the USA. 31% of participants within the study (66 of 
212 men) had low health literacy as indicated by a score of ≤44 out of 66 on the REALM-SF, 
and these men were more likely to present with advanced stage metastatic prostate cancer 
(stage IV) than men with high health literacy (54.5% vs 37.7%; p=0.02). Busch et al., 2015238, 
used the shortened version of the Test of Functional Health Literacy in Adults (S-TOFHLA)276 
to evaluate the association of health literacy with disease stage and receipt of treatment in 
colorectal cancer patients. Similar to the Bennett et al. study, 30% of participants (105 of 347) 
had marginal or inadequate health literacy ability, scoring ≤22 out of 36 on the S-TOFHLA. In 
contrast, late stage disease was classed as stage III or IV, and participants were distributed 
across a range of income levels from <$20,000 to $60,000+. This study did not find an 
association between health literacy and stage at diagnosis; however, it did find that stage III/IV 
patients with adequate health literacy were more likely to receive chemotherapy than those 
with marginal/inadequate health literacy (57% vs 42%, p=0.02). As with the systematic review 
by Neal et al., 2015, these two studies provide conflicting evidence on the influence of health 
literacy on stage at diagnosis, and as stage may not be an accurate indicator of time to 
diagnosis, it was not possible to include this evidence within the current systematic review. 
 
I now turn to the methodological issues with the three studies included in the review, as well 
as an evaluation of the findings and any limitations of the systematic review. 
 
3.4.2. Methodological issues 
The overall quality of the included studies were poor to adequate, with key aspects of the study 
design, data collection and analysis not adequately described or evaluated. This highlights the 
need to be clear on the aim of the study from the outset and to fully describe areas of the study 
design such as the setting, sampling strategy and both the inclusion and exclusion criteria. 
Data collection in time to diagnosis research should follow the principles of the Aarhus 
Statement142, clearly defining both intervals along the pathway and the time points that indicate 
the beginning and end of each interval. Where health literacy is explored, researchers should 
be clear in advance of data collection as to the definition of health literacy being followed and 
the definition should be reflected in the methods and the analysis of the data.   
 
3.4.3. Evaluation of findings 
All studies suggested that health literacy could influence cancer diagnosis; however, due to 
the low quality of the studies it is not possible to accurately describe the influence of health 
literacy on time to diagnosis from the results presented. Further methodologically robust 
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research is therefore needed to fully assess the influence of health literacy on the pathway to 
cancer diagnosis.  
 
3.4.4. Limitations of the systematic review 
The definition of health literacy varies considerably in health literacy research and as seen 
from McEwan et al., studies may explore aspects of health literacy as proposed by more recent 
definitions of the concept, without defining them as ‘health literacy’. The strategy used for this 
review specifically searched for ‘health literacy’ or variations of the term, therefore papers 
exploring aspects of health literacy yet not classifying them as such, would not have been 
identified. It is only in recent years that the definition of health literacy has expanded to a multi-
dimensional concept and it is possible that studies exploring time to diagnosis of cancer, 
particularly using qualitative methodology, could have investigated areas that are linked to 
health literacy yet not identified them within this context.  
 
Whilst this systematic review was limited to identifying research where the authors specifically 
discussed health literacy, it could be informative to conduct a further review investigating 
qualitative research on time to diagnosis, and evaluating the results in respect to a recent multi-
dimensional definition of health literacy. 
 
3.5. Conclusion 
Although it is not possible to draw robust conclusions on the influence of health literacy on time 
to diagnosis of cancer, the studies provide a starting point for research within this area and 
identify important aspects that need to be addressed in future studies. When exploring time to 
diagnosis, studies should refer to the Aarhus Statement142 and researchers should be aware 
of the concept of health literacy and how this may relate to their research. Where health literacy 
is specifically explored, it is essential for studies to identify the definition used, and to reflect 
on this and the aim of the research when choosing the measurement instrument or method to 
be applied.  
 
In the following chapters I describe the development and assessment of a questionnaire to be 
used with patients newly diagnosed with oesophageal or gastric cancer as part of the 
POSTCARD study, exploring the Pathway to Oesophageal and STomach CAnceR Diagnosis. 
Starting in Chapter 4, I review and critically appraise health literacy instruments to identify a 
suitable one for use in the study questionnaire, while in Chapter 5 I describe the design and 
development of the questionnaire, along with the think aloud study used to pilot and refine it. 
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Chapter 4: Review of health literacy instruments 
 
 
In this chapter I describe my review and critical appraisal of health literacy instruments, which 
helped to inform the development of the questionnaire (Chapter 5) for use in the POSTCARD 
study (Chapter 6). Many health literacy instruments focus on assessing skills such as 
numeracy or reading comprehension; although, in recent years, new instruments have been 
developed to evaluate health literacy as a multi-dimensional concept. Instruments can either 
be generic and therefore applicable to any population, or targeted to a certain disease or 
condition, language, population, or context. For example, cancer related instruments can either 
be relevant to any cancer (general cancer) or specific to a certain type of cancer. The design 
and validation of health literacy instruments determines whether it can be completed alone by 
the participant (self-administered) or requires observation or verbal administration.  
 
I start by outlining the aim and methods of the review before turning to discuss the instruments 
identified and the process of shortlisting for inclusion in the critical appraisal. I conclude the 
chapter with the critical appraisal of the selected instruments along with a summary of the 
review and the next steps.  
 
4.1. Aim 
To identify and evaluate generic or general cancer health literacy instruments, in order to 
create a shortlist for further critical appraisal and to select an appropriate instrument for use in 
a questionnaire with patients newly diagnosed with oesophageal or gastric cancer. 
 
4.2. Methods 
I used two methods to identify health literacy instruments for the review. Firstly I identified all 
instruments evaluated in five previous literature reviews published between 2011 and 2015. 
These identified both generic and targeted health literacy instruments available to the end of 
2013 (and to April 2014 for generic self-administered instruments)226,277-280. Secondly I 
searched the literature to identify additional articles published between January 2014 and 
September 2015, focusing on generic health literacy instruments or those suitable for use in a 
general cancer patient population.  
 
Strategy for literature search 
My database choice and search strategy was influenced by the previous reviews, all of which 
had searched the literature using Medline (or PubMed as an equivalent) in combination with 
PsycINFO (4), CINAHL (3) and/or Embase (2). One review had also searched the Educational 
Resources Information Center (ERIC) and Web of Knowledge226, while another had included 
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PHARMLINE and the Cochrane Database of Systematic Reviews280. I therefore chose to 
search the four databases that were used in more than one review: Medline, Embase, 
PsycINFO and CINAHL.  
 
For the search strategies, all of the previous reviews used the term ‘health literacy’ (or Health 
Literacy[MeSH]) combined using the Boolean operator ‘AND’, with measurement (or measur*), 
instrument or assessment (or assess*). Two used additional terms to describe health literacy, 
for example health competen*, critical or functional or communicat*, or Educational 
Measurement[MeSH]226,280, and three used additional definitions for ‘instrument’, such as 
screening, tool, or indices226,278,279. As I was searching from 2014 onwards I would expect 
current literature to incorporate the term ‘health literacy’ when developing a new instrument for 
this area so I decided to limit the search to ‘health literacy’ terms rather than include additional 
search terms as per the previous reviews. This would have been a useful way to identify 
research when the concept of health literacy was developing; however, I did not think the 
additional terms would be required to search more recent research. I included all possible 
terms relevant to describing an instrument, as there is variability with this description. Table 
4.1 gives details of the search strategy that I used in Ovid Medline and Ovid Embase, with the 
search terms adapted where necessary for the remaining databases (Appendix 8).  
 
Table 4.1. Ovid Medline/Embase search strategy 
No Search 
1 exp. Health Literacy/ 
2 “Health Literacy”.mp 
3 1 OR 2 
4 Instrument.mp 
5 Tool.mp 
6 Assessment.mp 
7 Measure*.mp 
8 Indices.mp 
9 Screening.mp 
10 Or/4-9 
11 3 AND 10 
12 Limit 11 to yr=”2014-current” 
Current = September 2015 
 
4.2.1. Inclusion and exclusion criteria for studies 
Studies identified from the previous reviews and literature search were assessed for inclusion 
in the review of health literacy instruments. I included studies if they were relevant to an adult 
population (18 years and older) and described the development of an instrument suitable for 
measuring an individual’s health literacy ability in a generic OR general cancer population. 
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Studies were excluded if they did not describe the development of a health literacy instrument, 
the instrument did not measure an individual’s health literacy ability, or it was developed: 
 For a specific disease or condition; 
 In a language other than English; 
 For children or adolescents (<18 years); 
 For a specific population or context.  
 
4.2.2. Inclusion criteria for health literacy instruments 
Having identified relevant studies based on the inclusion and exclusion criteria above, I 
assessed each instrument against the following criteria to determine which instruments would 
be included in the critical appraisal. 
 
Instruments had to fulfil all of the following criteria: 
 Self-administered – designed for independent completion by the participant rather than 
verbally administered or requiring observation during completion; 
 Multi-dimensional – designed to assess the multi-dimensional concept of health literacy 
rather than exclusively focusing on individual aspects of health literacy such as 
functional health literacy or numeracy; 
 Available – for use in a research setting and designed for administration via a paper 
questionnaire, not reliant on other resources such as a computer or internet access. 
 
4.2.3. Critical appraisal of shortlisted instruments 
The aim of the critical appraisal was to evaluate the properties of the shortlisted instruments. 
This included a consideration of the health literacy conceptual basis (definition and conceptual 
model), the appropriateness for use in my intended patient population (newly diagnosed 
oesophageal and gastric cancer patients), and the instrument’s psychometric properties 
(validity and reliability).  
 
4.3. Results 
4.3.1. Previous literature reviews 
In total, the five previous reviews identified 100 studies describing the development of 103 
instruments; 91 newly developed (original) instruments and 12 shortened versions of an 
original instrument. Although the aims of the reviews were different, there was some overlap 
in instrument identification as shown in Table 4.2. Jordan et al., 2011277, and Altin et al., 
2014226, sought to identify papers that described the development of generic health literacy 
instruments, with Jordan et al. identifying 19 instruments published in the literature between 
1990 and 2008, and Altin et al. identifying 17 published between 2009 and April 2013. 
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Haun et al., 2014278, O’Neill et al., 2014279, and Duell et al., 2015280, identified generic and 
targeted health literacy instruments with Haun et al. searching for publications between 1999 
to the end of 2013 and using additional snowballing techniques to identify 51 instruments 
dating from 1961 to 2013. O’Neill et al. focused on self-administered health literacy 
instruments, identifying 35 instruments published up to April 2014, while the systematic review 
by Duell et al. identified 43 instruments published to July 2013 for use in a clinical setting.  
 
I reviewed the titles and abstracts of the 100 papers from the five previous reviews and applied 
the inclusion and exclusion criteria for studies to identify those describing the development of 
generic or general cancer health literacy instruments. From this I identified 43 studies 
describing 44 generic or general cancer health literacy instruments (38 original, 6 shortened), 
which I included in the next stage of my review (Table 4.3). The remaining 57 papers (59 
instruments) were excluded as they either referenced an existing instrument rather than 
describing a new one (n=2), were not health literacy specific (n=7), or were not generic or 
general cancer instruments. These included instruments that were targeted for certain 
diseases or conditions (n=15), for non-English speakers (n=8), for children or adolescents 
(n=5) or for certain populations or contexts (n=22) (Table 4.4). The 7 papers that did not 
describe the development of a health literacy instrument were all identified in the review by 
Duell et al280. These instruments focused on assessing knowledge of specific diseases or 
conditions285,361, comprehension independent of health literacy295, patient activation343,344, 
general literacy ability372,373 and the planning and provision of health services309 rather than 
health literacy. Table 4.5 gives full details of the instruments and reasons for exclusion. 
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4.3.2. Updated literature review 
The literature review from January 2014 to September 2015 identified 2432 references, of 
which 1075 were duplicates. I screened 1357 titles and abstracts against the inclusion and 
exclusion criteria for studies to identify five articles describing the development of six 
instruments; three newly developed (two generic, one cancer), two short-forms (one generic, 
one cancer), and one alternative format to an existing generic instrument (written 
administration of a previous verbal instrument) (Table 4.6).  
 
Table 4.6. Included studies and instruments from the literature review 
Instrument Author, Year Generic Cancer Short-
form 
Alternative 
format 
BHLS Brief Health Literacy 
Screen376 
Sand-Jecklin & 
Coyle, 2014 
●    
CHAS Comprehensive Health 
Activities Scale377 
Curtis et al., 
2015 
●    
CHLT-30 Cancer Health Literacy 
Test378 
Dumenci et al., 
2014 
 ●   
CHLT-6 Cancer Health Literacy 
Test378 
Dumenci et al., 
2014 
 ● ●  
S-NUMi Numeracy Understanding 
in Medicine Instrument 
Short Form379 
Schapira et al., 
2014 
●  ●  
- Three item health literacy 
screening - written380 
Dageforde et 
al., 2015 
●   ● 
 
I added the five studies identified from the literature search to the 43 studies identified from 
previous reviews, to provide a total of 48 studies describing the development of 50 health 
literacy instruments. Figure 4.1 provides an overview of the inclusion and exclusion process 
outlined above. I subsequently evaluated each instrument against the inclusion criteria for 
health literacy instruments, to identify the ones suitable for full critical appraisal. 
 
4.3.3. Review of health literacy instruments for critical appraisal 
On reviewing the 50 health literacy instruments, I excluded 46 instruments from the critical 
appraisal based on the inclusion criteria for health literacy instruments. Twenty were excluded 
as they were either not designed or validated to be self-administered, instead relying on verbal 
administration or observation during completion. A further 19 instruments were excluded as 
they did not assess a multi-dimensional concept of health literacy, and 7 were excluded as 
they were not available for use in a research setting or for administration using a paper 
questionnaire format (Table 4.7). Four instruments were therefore included in the critical 
appraisal (Figure 4.2). 
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Figure 4.1. Flowchart for inclusion and exclusion of studies   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Previous reviews 
Studies and instruments identified  
(n=100; 103) 
Studies and 
instruments excluded  
(n=57; 59) 
Studies and instruments included in the 
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Literature search 
References identified  
(n=2432)
Duplicates excluded 
(n=1075) 
Titles/abstracts screened 
(n=1357)
References excluded  
(n=1352) 
Studies and instruments included in the 
review of health literacy instruments 
(n=5; 6) 
Total studies and instruments included in the review of health literacy instruments 
(n=48; 50) 
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Figure 4.2. Flowchart for instrument inclusion in the critical appraisal 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.4. Critical appraisal 
Instruments were critically appraised according to the conceptual basis, appropriateness for 
use and psychometric properties (validity and reliability). To determine how the authors 
designed and developed the multi-dimensional content of each instrument, I explored the 
health literacy definition and the conceptual basis used. Multi-dimensional content can result 
in long instruments with many questions; however, as the study questionnaire was to be used 
with newly diagnosed cancer patients it was important to consider the question burden on 
participants at a difficult time and to choose an instrument that was brief yet still informative.  
 
The psychometric properties of each instrument were explored, with validity assessed in 
relation to: 
 Face validity, whether an instrument appears to measure what was intended; 
 Content validity, whether all relevant concepts are measured;  
 Construct validity, whether the instrument performs as expected.  
 
 
Stage 1 (n=50) 
Is the instrument designed to be self-administered? 
Stage 2 (n=30) 
Does the instrument assess a multi-dimensional 
concept of health literacy? 
Stage 3 (n=11) 
Is the instrument available for use in a research setting? 
Instruments excluded (n=20) 
Instruments excluded (n=19) 
Instruments excluded (n=7) 
Total instruments included in the critical appraisal 
(n=4) 
Yes 
No
Yes 
No
Yes 
No
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Criterion validity was not assessed (correlation with a ‘gold standard’) as developing multi-
dimensional tools for health literacy is a new field, so a gold standard was not available for this 
purpose.  
 
Reliability was assessed based on: 
 Internal consistency, whether items in the scale measure the same concept; 
 Test-retest reliability, whether items are reliable over time.  
 
Internal consistency is usually measured using Cronbach’s alpha where a value of 0.7 or above 
indicates reliability of the scale; however, for psychological constructs a value of 0.5 or above 
is usually acceptable due to the diverse nature of the constructs measured381. Test-retest 
reliability was assessed where possible, although with a construct such as health literacy this 
can be difficult to examine as health literacy ability can change over time, therefore a low 
correlation could reflect a genuine change rather than indicating poor reliability of the 
instrument.  
 
The four instruments identified for critical appraisal included three original instruments (two 
generic, one general cancer) and one shortened (general cancer). These were the: 
 Health Literacy Questionnaire (HLQ)266 – generic instrument; 
 European Health Literacy Questionnaire (HLS-EU-Q)321 – generic instrument; 
 Cancer Health Literacy Test (CHLT-30 & CHLT-6)378 – general cancer (original and 
shortened). 
The instruments are discussed in turn below, with details of the instrument length, conceptual 
basis and assessment of validity and reliability summarised in Table 4.8.  
 
4.4.1. Health Literacy Questionnaire 
The HLQ was developed in Australia as a comprehensive instrument to measure health 
literacy. Design of the questionnaire was based on a conceptual model of health literacy, which 
was informed by patients, the general public, healthcare professionals and policymakers, and 
resulted in a 44 item instrument set across nine domains of health literacy266. The development 
of the instrument showed good validity and reliability across the questionnaire and within the 
individual domains.  
 
Prior to the HLQ, the authors developed the Health Literacy Management Scale (HeLMS) to 
address the limitations of existing health literacy instruments that focus primarily on literacy 
and numeracy skills, yet do not encompass wider aspects of health literacy316.  
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Following the development of the HeLMS the authors identified that the instrument did not fully 
assess health literacy as intended. This subsequently led to the development of the HLQ 
involving an eight stage process starting with re-analysis of the HeLMS data in combination 
with workshop data gathered at an international conference to define the conceptual basis for 
the HLQ.  
 
The HeLMS was based on in-depth patient interviews (n=48) and concept mapping workshops 
with 15 participants to understand how patients seek, understand and use health information 
when faced with a health problem316. The interviews and workshops identified that health 
literacy was influenced by both individual abilities as well as contextual factors, such as social 
support and socioeconomic status, leading to the development of a conceptual framework that 
informed the domains of health literacy to be included in the HeLMS. The group workshops 
subsequently conducted with 12 patients and 15 healthcare professionals at an international 
conference for outcome measurement in rheumatology extended the conceptual mapping 
process to include additional contextual factors and also health professional factors382. 
Throughout the development of the HLQ, the authors referenced the health literacy definition 
as proposed by the World Health Organisation (1998) to focus on how people engage with 
healthcare to understand, access and use information and services: 
 
“The cognitive and social skills which determine the motivation and ability of 
individuals to gain access to, understand and use information in ways which 
promote and maintain good health.”180  
 
The re-analysis phase and evaluation of health literacy constructs identified 11 domains of 
health literacy within which the authors generated scales with 7 to 10 items each, to assess 
the full range of health literacy ability (from low to high). The draft instrument consisting of 91 
items was reviewed by experts for face and content validity and was tested by 634 participants 
(69% female, mean age 64.7) from hospital and community settings. The results were subject 
to statistical analysis using confirmatory factor analysis and Raykov’s statistical theory, in place 
of Cronbach’s alpha, to confirm construct validity and internal consistency. Scales were 
assessed for difficulty in completion, and items were removed where necessary to improve the 
model fit, resulting in a 55 item (10 domain) questionnaire. This was evaluated via interviews 
with 11 participants before being tested with 412 participants (13.7% response rate, 61% 
female, mean age 49.2) attending an emergency department between two and six months 
earlier. Analysis of this data showed good reliability with eight of the domains demonstrating 
composite reliability of ≥0.8, and the other two domains, ‘appraisal of health information’ and 
‘health focus’ scoring 0.77 and 0.78 respectively. However, due to scale weakness and overlap  
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with other domains, the ‘health focus’ domain was removed from the questionnaire resulting in 
the final questionnaire consisting of nine domains with 44 items (Appendix 9). Five of the 
domains are scored based on a four-point disagree/agree Likert scale, with the other four 
domains scored on a five-point difficulty Likert scale. Each item is scored independently and 
the mean score is calculated for each domain, resulting in nine mean scores relating to specific 
aspects of health literacy rather than one overall score for the questionnaire. The items in the 
disagree/agree Likert scales demonstrated clear distinctions between inter-factor correlations 
in the statistical analysis (0.43-0.78), which was less evident for the four domains scored on a 
difficulty Likert scale (0.83-0.93). In assessing the difficulty of the items and scales using item 
response theory, the hardest item to complete was in the ‘navigating the healthcare system’ 
domain. The hardest scale overall was the ‘appraisal of health information’ domain where four 
of the five items had a difficulty of 30% or more (calculated based on the proportion of 
participants disagreeing with the item compared to those agreeing). The easiest domain was 
‘understanding health information’ where the hardest question (16% difficulty) was still easier 
than the easiest question in the appraisal domain (18% difficulty). 
 
In the period between the publication of the HLQ development in 2013266 and my review of 
health literacy instruments in 2015, three studies have been published using the HLQ. The first 
study by Bo et al., 2014, explored health literacy in Denmark using two domains from the HLQ: 
ability to actively engage with healthcare providers (engagement) and understanding health 
information well enough to know what to do (understanding). This study demonstrated that it 
was possible to use the domains of the HLQ individually in order to assess aspects of health 
literacy, rather than using the complete version to assess the full concept of health literacy. 
The two domains were included as part of the Danish National Health Survey, which was sent 
to 46,354 people aged 25 and over. 29,473 people responded (63.6% response rate, 52.5% 
female, mean age 54.8) and the analysis showed that up to 20% of Danish adults have difficulty 
understanding health information and engaging with healthcare providers. A clear socio-
economic gradient was observed, particularly when accounting for lower income and lower 
education. The second study by Beauchamp et al., 2015, was conducted to assess the health 
literacy of 813 adults (63% female, mean age 72.1) in rural and urban health and community 
settings across Victoria, Australia, with the questionnaire either orally or self-administered175. 
The authors also found that participants with lower education or no private health insurance 
scored lower in the understanding domain than those with higher education or with health 
insurance. They also scored lower in finding or appraising information, actively managing 
health and social support. The final study by Kayser et al., 2015, used the HLQ to assess the 
health literacy of eight couples (participant age range 55-70, spouse age range 55-68) in  
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Denmark where the participant was part of an active surveillance program to monitor 
progression of their prostate cancer383. The HLQ was administered as part of individual 
interviews with each participant and spouse, with the questionnaire completed aloud and used 
as a framework for assessing experiences in the active surveillance program. Three themes 
emerged from the interviews relative to six of the HLQ domains, demonstrating the importance 
of health literacy in the couples’ experience; although the scores derived from the 
questionnaire did not consistently represent the interview reflections, particularly when 
discussing GP communication issues.   
 
4.4.2. European Health Literacy Questionnaire  
The HLS-EU-Q was developed through a collaboration between nine research institutes with 
the intention of measuring and comparing health literacy in general populations across 
selected European countries (Austria, Bulgaria, Germany, Greece, Ireland, the Netherlands, 
Poland and Spain). The HLS-EU-Q consists of 47 items designed to measure core health 
literacy items, and was administered in the European Health Literacy Survey (HLS-EU) in 2011 
along with an additional 39 items which together were labelled as the HLS-EU-Q86. Details 
around the design and development of the HLS-EU-Q were published in 2013321 with the 
results of the HLS-EU published in April 2015384. The study identified that 12.4% of the 
participants (n=8000) across the eight European countries had inadequate health literacy, 
ranging from 1.8% of the population in the Netherlands to 26.9% in Bulgaria. The existence of 
a social gradient for health literacy was also confirmed, adding evidence to the link between 
low health literacy and more deprived groups, such as those with low socio-economic status 
and low education171,385.  
 
The HLS-EU-Q is based on the multi-dimensional definition and conceptual model of health 
literacy proposed by Sorensen et al. in 2012. As described in Chapter 2, the new definition 
combined key aspects of 17 existing definitions: 
 
“Health literacy is linked to literacy and entails people’s knowledge, motivation and 
competences to access, understand, appraise, and apply health information in 
order to make judgments and take decisions in everyday life concerning 
healthcare, disease prevention and health promotion to maintain or improve quality 
of life during the life course.”168 
 
The conceptual model developed by Sorensen et al. (Chapter 2; Figure 2.9), relates the four 
processes of accessing, understanding, appraising and applying health information to the three 
proposed domains of healthcare, disease prevention and health promotion. This model was 
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used in developing the HLS-EU-Q to ensure that the questionnaire items addressed all 
processes within each domain. 
 
Having established the conceptual basis for the HLS-EU-Q, the questionnaire was developed 
and tested in a seven stage process which demonstrated good validity and internal consistency 
(reliability), although it did not assess reproducibility (test-retest or inter-rater reliability). As 
discussed previously, reproducibility could be difficult to test with a health literacy instrument 
as health literacy ability evolves over time; therefore, test-retest may not be an accurate 
measure of reliability. The validation process started with an iterative multi-stage technique 
(Delphi procedure) involving nine European research institutes to generate items for inclusion 
in the questionnaire that adequately reflected all areas of the conceptual model. 136 items 
were initially proposed and subsequently reduced to 43 items, which were tested for face 
validity across focus groups involving 19 students and academic staff at three universities in 
Ireland, Greece and the Netherlands. Based on feedback a 47 item questionnaire was field 
tested in Ireland and the Netherlands (n=99, 42% male, mean age 43.8 years), which 
demonstrated satisfactory construct validity using Principal Component analysis (explaining 
59% of variance) and adequate internal consistency across the health literacy scales 
(Cronbach alpha range: 0.51-0.91). In addition to the field testing, a national advisory panel of 
25 experts was consulted regarding the content and format. Following the pre-testing and 
evaluation of the questionnaire, changes were made to the wording of the questionnaire, and 
content validity was confirmed. The pre-final version consisted of 47 items and reflected all 
areas of the conceptual model. This version was assessed by the National Adult Literacy 
Agency in Ireland to ensure the questions were easy to read and understand.  
 
The final version of the questionnaire reflects its conceptual basis and includes questions 
related to each area of the conceptual model; accessing, understanding, appraising and 
applying health information within healthcare, disease prevention and health promotion 
(Appendix 9). The question/answer format is based on a four-point Likert scale. The questions 
are asked in relation to, “On a scale from very easy to very difficult, how easy would you say it 
is to: …” with the answer options ranging from very difficult (1) to very easy (4), and an 
additional ‘don’t know’ category for use when the questionnaire is administered face-to-face. 
Prior to use in the European Health Literacy Survey, the questionnaire was translated in to 
seven languages and adapted to be culturally specific to the country of administration.  
 
The 2015 publication of HLS-EU-Q results briefly describe the scoring system for the 
questionnaire, with the scores from the 47 items transformed to a 0-50 scale representing four 
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levels of health literacy: inadequate (0–25), problematic (>25–33), sufficient (>33–42) and 
excellent (>42–50)384. However, the initial scoring process for the 47 items was not described. 
The HLS-EU-Q is intended for use in its full 47 item form, with an average completion time of 
20-30 minutes during the initial testing of the questionnaire321. Administration of the survey in 
2011 used computer-assisted or paper-assisted interviews384, although it has now been utilised 
in an online questionnaire in Japan demonstrating its suitability for self-administration386.  
 
4.4.3. Cancer Health Literacy Test 
The Cancer Health Literacy Test instruments (CHLT-30 and CHLT-6) were developed together 
in the USA; the CHLT-30 to measure “cancer health literacy along a continuum” and the CHLT-
6 to determine a patient’s cancer health literacy378. Unlike the HLQ and HLS-EU-Q, these 
instruments were developed specifically for a cancer patient population in recognition of the 
complex information and decisions that these patients are faced with following a cancer 
diagnosis, and the impact this has on outcomes. The CHLT-30 consists of 30 questions with 
multiple choice answers relating to areas such as understanding common cancer terms, 
treatment and cancer statistics. The CHLT-6 was derived from the CHLT-30 and consists of 
six core multiple choice questions chosen from the original thirty. 
 
The authors based the instrument on the health literacy definition proposed by the Institute of 
Medicine in 2004: 
 
“The individuals’ capacity to obtain, process and understand basic health 
information and services needed to make appropriate health decisions.”182 
 
Both instruments were developed between April 2011 and April 2013 in a multi-stage process 
using both qualitative and quantitative methods, and they demonstrate good validity and 
reliability. The qualitative phase started by exploring the definition of cancer health literacy with 
a panel of healthcare providers and researchers (n=11) and six focus groups with cancer 
patients (n=39). The transcripts were analysed by the research team and used in combination 
with health literacy reports, patient education literature and relevant hospital documents to 
produce 112 possible test items, which were evaluated via interviews with 25 cancer patients. 
76 items were retained following the evaluation, and these items were tested with 1306 cancer 
patients (54.8% female, nine cancer types or ‘other’/unknown) recruited from oncology clinics, 
with the test administered on a touchscreen device. Exploratory factor analysis was used to 
evaluate the data and reduce the number of items from 76 to 30. These items were further 
evaluated using confirmatory factor analysis, which demonstrated a good model fit, with item 
difficulty assessed and found to be acceptable using a two-parameter logistic model. Of the  
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original 1306 participants, 98 took part in a two-week re-test of the instrument and 60 
completed a six-month re-test producing test-retest reliability scores of 0.90 and 0.92 
respectively, along with an internal consistency score of 0.88 using Cronbach’s alpha. The 
CHLT-30 is scored from 0-30 based on the number of correct answers, with scores found to 
be related to patients’ self-confidence when engaging with healthcare decisions. However, it 
is unclear how levels of cancer health literacy are classified from the scores. The six questions 
used within the CHLT-6 were identified from the two-parameter logistic model as the most 
informative items in relation to cancer health literacy. The score obtained from completing the 
CHLT-6 relate to the probability of having limited or adequate cancer health literacy; however, 
the classification of this is unclear. 
 
Although the instrument was administered in the study using a touchscreen device, the format 
of the questions is such that it could be administered in paper format (Appendix 9), as unlike 
some of the other computer based instruments, it does not have an audio or visual component 
to the test322,323. Between its publication in 2014 and my review of instruments in September 
2015, the CHLT has not been used in any other published studies.  
 
4.4.4. Instrument selection 
Of the four critically appraised health literacy instruments, all had good psychometric 
properties; however, only two were suitable for use as a brief instrument: the HLQ and the 
CHLT-6. The domains of the HLQ can be used individually or in combination, with the shortest 
scales comprising four items and the longest, six items. The CHLT-6 in its full form consists of 
six items. Both instruments are designed to assess a multi-dimensional concept of health 
literacy, with the CHLT-6 specific to cancer health literacy. However, the items are particularly 
relevant to assessing patients’ health literacy following their diagnosis and prior to treatment, 
such as “If a patient has stage 1 cancer, it means the cancer is…”378. In comparison, the HLQ 
evaluates health literacy domains that are relevant prior to diagnosis, such as understanding 
and appraisal of health information, social support, and engagement with healthcare providers. 
The HLQ has been used in three published studies exploring health literacy in a general 
population in Australia175, and in Denmark with both a cancer specific383 and general 
population171, with the latter study exploring aspects of health literacy through two domains of 
the HLQ; engagement and understanding. In comparison, there have not been any studies 
published so far on the use of the CHLT. I therefore chose the HLQ to inform the development 
of a questionnaire for use with patients newly diagnosed with oesophageal or gastric cancer. 
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4.5. Summary 
In this review, I identified 48 studies describing the development of 50 health literacy 
instruments developed for use in a general population or general cancer population. I included 
four instruments in the critical appraisal, which I used to evaluate the conceptual basis, 
psychometric properties and appropriateness for use in my intended patient population. Having 
selected an instrument, the HLQ, I now turn to discuss the development of the questionnaire 
for the POSTCARD study, and the inclusion of the HLQ for assessing health literacy. 
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Chapter 5: Questionnaire study development 
 
 
As identified in my background review (Chapter 2), there is limited research from the patient’s 
perspective on the timely diagnosis of oesophageal and gastric cancers, with none exploring 
the influence of health literacy. To address the gaps in the literature I aimed to answer the 
following research questions, from a patient’s perspective:  
 
What factors influence the pathways to diagnosis for oesophageal and gastric 
cancer patients, how do these factors impact timely diagnosis and what is the role 
of health literacy? 
 
To explore the pathways to diagnosis from a patient’s perspective, I designed the POSTCARD 
study, a multi-methods retrospective study incorporating a questionnaire and case note review, 
along with interviews with patients newly diagnosed with oesophageal and gastric cancer. The 
questionnaire informed the selection of participants for interview, with both methods exploring 
symptom experience, behaviours and the influence of health literacy on the time to diagnosis.  
 
In this chapter I focus on the development of the questionnaire study, starting with an overview 
of using surveys in research and how this informed the POSTCARD study, along with the 
general principles of questionnaire development. I present the study aims, objectives and 
hypotheses before discussing the design and testing of the questionnaire prior to its use in the 
POSTCARD study, which I describe in Chapter 6. 
 
5.1. Using surveys in research 
A survey is a useful approach for collecting and analysing data to explore a topic directly with 
individuals in a standardised way. When planning a survey, the overall design and 
implementation of the research should be considered, which is influenced by the research goal, 
target population, timing and mode of data collection387. These are outlined in Figure 5.1, along 
with the advantages and disadvantages of conducting surveys388. I reflected on these points 
and alternative options for data collection when considering a survey approach for the 
POSTCARD study. An alternative option could have been to collect data from medical records, 
either directly from primary and secondary care or using large databases such as the CPRD 
and the Hospital Episodes Statistics database. However, these approaches are costly and the 
data would be limited to exploring the pathways to diagnosis based on symptoms presented 
to healthcare providers, along with dates of consultations, referral and diagnosis. I had limited 
funding available for my study, and a key aspect was to explore the pathways from the patient’s 
perspective, which could only be achieved by collecting data directly from individuals.  
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Figure 5.1. Considerations for survey research 
 
 
While surveys may lack depth of information on their own, when combined with qualitative 
methods they can contribute to a rich dataset, which is the approach I took for the POSTCARD 
study. I decided that a self-administered paper-based questionnaire survey would be most 
appropriate for the study. Patients may not want to be approached by a researcher for a face-
to-face or telephone survey following a cancer diagnosis, whereas a self-administered 
questionnaire can be completed in private and at an appropriate time for the patient. I decided 
against an online based survey as this would exclude those without computer access or who 
find this format difficult. My concern with a paper-based questionnaire was the potential 
exclusion of patients with low health literacy, although I attempted to minimise this by providing 
the option to call the research office and complete it by phone if they preferred this method. 
  
5.1.1. Principles of questionnaire development 
When developing items for inclusion in a questionnaire, they should be directly relevant to the 
study aim and must have good psychometric properties (validity and reliability), as described 
in Chapter 4. Table 5.1 outlines key considerations when developing items and considering 
the format of a questionnaire387. For this purpose, it is beneficial to reflect on established 
questionnaires and to use previously validated items, and formats, where possible.  
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Table 5.1. Considerations when developing questionnaires 
Items & formats Consideration 
Item wording Avoid complex language. Instead, opt for language that is appropriate and 
commonly used by the target population. 
Item structure Structure items in a clear and consistent manner, to assist with comprehension 
and completion. 
Item type Consider the inclusion of both open (free-text) and closed (e.g. multiple choice, 
yes/no) items, acknowledging that while open items incorporate the participant’s 
own words, this can make responses difficult to interpret and analyse.  
Reference period Ensure that time periods are clear and appropriate for the context, for example, 
is it reasonable for events to be recalled within the specified time period? 
Response format Ensure the response (answer) format is applicable to the item, with categories 
covering all possible options, yet remaining mutually exclusive (no overlap).  
Overall format Where a questionnaire is self-administered, it should: 
 Be logical to work through; 
 Have a simple, consistent design; 
 Include a front and back page, incorporating the study title and any logos; 
 Provide instructions for returning the questionnaire. 
Based on guidelines developed by the University of Wisconsin, 2010387  
 
Once a questionnaire has been developed, it is important to test the items and format with a 
sample of people that are representative of the target population. This is to assess the face 
validity and usability, and to refine the questionnaire prior to use with the intended population.  
 
Having briefly outlined the use of surveys in research and the general principles of 
questionnaire design, I now turn to discuss the POSTCARD study aims, objectives and 
hypotheses in relation to the research questions, and how this informed the design and 
development of the questionnaire.  
 
5.2. Study aim, objectives and hypotheses 
5.2.1. Aim 
Based on the research questions, as described, the aim of the POSTCARD study was to 
explore the factors influencing the time to diagnosis for oesophageal and gastric cancer from 
the patient’s perspective.  
 
Reflecting on the MoPT140,141, the time to diagnosis includes the appraisal and help-seeking 
intervals (patient interval, PI), from first bodily change/symptom to first consultation, and the 
diagnostic interval (health system interval, HSI), from first consultation to diagnosis (Figure 
5.2). This period is collectively referred to as the total diagnostic interval (TDI), from first bodily 
change/symptom to diagnosis. 
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     Figure 5.2. Interval definitions 
 
 
5.2.2. Objectives 
The primary objective was to explore the TDI to determine how participant, healthcare and 
disease factors, such as symptom experience, appraisal, self-treatment behaviours, help-
seeking decisions and health literacy influence timely diagnosis. Secondary objectives 
included: 
 Evaluating the PI and HSI to determine the factors influencing these intervals;  
 Exploring the role of health literacy in symptom appraisal, self-treatment behaviours 
and help-seeking decisions. 
 
5.2.3. Hypotheses 
My hypotheses were based on my background review exploring oesophageal and gastric 
cancer, timely diagnosis and health literacy (Chapter 2). I hypothesised that: 
A. For patients newly diagnosed with oesophageal or gastric cancer, the participant, 
healthcare and disease characteristics (predictors) outlined in Table 5.2 (Part 1a) will 
influence the TDI or component intervals (PI and/or HSI) (outcomes) and be 
associated with longer or shorter time intervals;  
B. Health literacy (predictor) ability will influence symptom experience, medication use 
and number of consultations prior to diagnosis (outcomes) (Table 5.2, Part 1b). 
 
The participant, healthcare and disease characteristics as described in Table 5.2 (Part 1) may 
also act as confounders or modifiers influencing the effect of other predictors on the TDI, PI or 
HSI, or of health literacy on symptom experience, medication use or consultations. Table 5.2 
(Part 2) outlines potential confounders and modifiers for consideration in the study. 
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5.3. Questionnaire design  
In considering the POSTCARD study aim, patient population and timing, it was important for 
the study questionnaire to be short, yet still informative, to reduce the burden on participants 
at a difficult time and to encourage patients of all health literacy levels to participate. The 
content needed to reflect the research questions and hypotheses, including consideration of 
the confounders and modifiers; therefore, core content requirements included: 
 Identifying the start date of the PI/TDI and HSI; 
 Exploring symptom experience, frequency and management; 
 Exploring help-seeking, including the number of consultations prior to diagnosis; 
 Investigating patient factors such as socio-demographics, comorbidities and health 
literacy ability that may influence the pathway. 
 
5.3.1. Format 
The format of the POSTCARD study questionnaire was based on the SYMPTOM study 
questionnaires (Appendix 10), recently used in several large prospective UK cohort studies391-
393. The questionnaires explored symptom experience, appraisal and help-seeking among 
people referred to specialist care with possible symptoms of lung, colorectal or pancreatic 
cancer. They were developed from the Cancer Symptom Interval Measure (C-SIM) 
questionnaire, originally designed for use among people recently diagnosed with a number of 
cancers in Wales394.  
 
The SYMPTOM questionnaires included a consent form followed by the questionnaire, 
exploring symptom experience (part 1), along with socio-demographics and other health 
related aspects (part 2). In part 1, symptoms were investigated individually, including when the 
symptom was first noticed and first presented to a doctor or nurse (if at all), which created a 
fairly long questionnaire. I therefore adapted the format to shorten the POSTCARD study 
questionnaire, as I describe in Section 5.3.2.  
 
I included a standard consent form on the first page of the study questionnaire, which could be 
detached once returned, followed by 12 items (questions) exploring help-seeking (3 
questions), symptom experience (2), medication use (1), socio-demographics (4), 
comorbidities (1) and health literacy (1). Specific questions were included to determine the 
duration of the PI, from when the patient first noticed a bodily change or symptom, to their 
consultation in primary care (Boxes 1-6 and Appendix 11). As participants would complete the 
questionnaire having received their diagnosis, I designed the questionnaire to take the 
participant back through their journey, asking them firstly to think of recent help-seeking, and 
then prompting further reflection on symptoms and medication use prior to that.  
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In the following section I describe the development of each question included in the study 
questionnaire and provide further detail in relation to the design, format and content.  
 
5.4. Questionnaire items 
5.4.1. Help-seeking 
Box 1: Questions to explore help-seeking in the POSTCARD questionnaire 
1. Did you tell your GP about any symptoms which you think are related to your diagnosis? 
Please tick one box. Yes / No 
2. Before you went to hospital for your diagnosis, how many times in the past 12 months 
did you see your GP about your symptoms? Please tick one box only. Multiple choice 
3. What was the first symptom (or symptoms) you told your GP about? Free text  
A. When did you first notice this? Exact/estimate date 
B. When did you first tell your GP? Exact/estimate date 
 
It was important for the study questionnaire to establish whether the participant had seen their 
GP about their symptoms prior to diagnosis, as subsequent questions about help-seeking in 
primary care would not be relevant for participants taking an alternative route, such as an 
emergency admission. I therefore included a newly developed question to determine primary 
care help-seeking (Box 1; Question (Q) 1) where the answer directed the participant to the 
next appropriate question; Q2 if a primary care consultation had taken place, or Q4 if not. 
 
The second question (Box 1; Q2) was based on a validated question from the 2014 National 
Cancer Patient Experience Survey to explore use of primary health care prior to referral395 and  
the patient reported number of consultations prior to diagnosis. As described, previous studies 
have found that gastric cancer patients experience a relatively long primary care interval 
compared to 27 other common or rarer cancers396, and up to a third of oesophageal and gastric 
cancer patients have three or more consultations before referral (oesophageal 22.6%; gastric 
32.1%)42. It was therefore important to explore primary healthcare experience in the 
questionnaire as this can impact on the time to diagnosis. To focus on the period leading up 
to diagnosis, I added the time frame of ‘the past 12 months’ to the question. This also reflects 
recent literature identifying that symptoms of oesophago-gastric cancer can be apparent for 
up to six-months prior to diagnosis, with some, such as dysphagia, associated with cancer up 
to nine-months prior66.  
 
I went on to explore details around the first symptom presented to the GP, including date of 
onset and date of consultation (Box 1; Q3), using a validated question from the SYMPTOM 
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study. This would identify the trigger symptom for help-seeking, along with an exact or 
estimated date to determine the start of the diagnostic interval, as defined by the MoPT140,141.  
 
5.4.2. Symptom experience 
Box 2: Questions to explore symptom experience in the POSTCARD questionnaire 
4. Did you have any of these symptoms? Please tick one box for each symptom. 
Symptom list with a three-point ‘frequency’ Likert scale  
5. What was the first thing or symptom you noticed that made you think something might 
be wrong? This could be from the list above or something different. Free text 
A. When did you first notice this? Exact/estimate date 
 
To explore symptom experience with participants (Box 2; Q4), I firstly identified relevant 
symptoms for possible inclusion in the questionnaire. I therefore referred to the symptom 
literature that I described in Chapter 2 (Table 2.1), collated from the following sources: 
1. 2015 revised NICE guidelines for suspected cancer41 (Appendix 2); 
2. Literature related to oesophageal and gastric cancer symptoms  
a) Peer-reviewed literature identified as part of my background review 
b) Patient literature, such as the Cancer Research UK (CRUK) website56,70 and the 
2015 National Public Health England ‘Be Clear on Cancer’ campaign for oesophago-
gastric cancer69 (Appendix 3); 
3. Widely validated GerdQ, to aid the diagnosis and management of GORD11 (Appendix 1). 
 
In Chapter 2 I described 25 symptoms associated with oesophageal or gastric cancer (Table 
2.1), which I outline again in Table 5.3. I also identified two important blood test results: 
anaemia and raised platelets. Anaemia was found to be a clinical predictor of oesophago-
gastric cancer in men and women65,79, and is described on the CRUK, Macmillan and NHS 
Choices websites for gastric cancer as a possible cause for feeling tired and/or breathless70-
72. Raised platelets were also predictive of oesophago-gastric cancer when combined with 
symptoms such as dysphagia or epigastric pain66. However, as blood test results cannot be 
directly identified by patients as symptoms, I excluded them from the symptom list.  
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Table 5.3. Oesophageal and/or gastric cancer symptom list 
Part 1: Symptoms included in the 2015 NICE guidelines41 
Abdominal/upper abdominal pain or discomfort 
Difficulty swallowing [Dysphagia] 
Indigestion [Dyspepsia] 
Lump or swelling in the stomach  
Nausea  
Reflux  
Vomiting 
Vomiting blood [Haematemesis] 
Weight loss 
Part 2: Other symptoms 
Bloating or feeling full 
Blood in stool 
Breathlessness 
Burping 
Changes in bowel habit (including constipation and diarrhoea) 
Cough  
Fatigue or tiredness 
Heartburn 
Hoarseness 
Jaundice  
Loss of appetite 
Neck lump 
Pain/discomfort in the chest or back 
Pain when swallowing [Odynophagia] 
Regurgitation 
Venous thromboembolism 
Square brackets [ ] indicate the medical terminology 
 
Having reviewed the evidence for the 25 symptoms, I decided to explore 12 in the study 
questionnaire: upper abdominal pain, bloating/feeling full, difficulty swallowing, fatigue/ 
tiredness, indigestion, loss of appetite, nausea, pain when swallowing, reflux/heartburn, 
vomiting, vomiting blood, and weight loss. I chose these as they include most of the symptoms 
described in the 2015 NICE guidelines41 (except for lump or swelling in the stomach), and/or 
are frequently described in peer-reviewed and patient literature. I excluded ‘lump or swelling 
in the stomach’ as a lump would be a symptom noticeable to a healthcare provider, rather than 
a patient, and ‘swelling’ may be interpreted as ‘bloating’. The other symptoms were excluded 
as they are infrequently described in the literature, therefore I did not consider them as key 
symptoms to explore.  
 
For the twelve symptoms selected, it was important to describe them in language appropriate 
to the patient, as patients often find it difficult to understand medical terminology397. However, 
previous research has also shown that non-medical terminology or ‘lay language’ can also be 
difficult to understand. As mentioned, one study identified that the majority of patients with 
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GORD do not understand the term ‘heartburn’ and of those that denied having heartburn, 23% 
actually had symptoms that would clinically indicate the condition14. In my review of the 
symptom literature I identified varying definitions for both reflux and dyspepsia, with reflux 
linked to heartburn and regurgitation, which in turn was described as acid regurgitation or liquid 
or food coming back up11,13,21,66,76. Dyspepsia was described as an individual symptom or as a 
collection of symptoms including feeling full or bloated, nausea, heartburn and 
regurgitation57,66,72,87. For these complex symptoms I therefore decided to focus on symptom 
descriptions, rather than directly asking for experience of ‘heartburn’ or ‘indigestion’, as these 
terms may be ambiguous or have varying meanings to patients.  
 
To determine the symptom descriptions, I referred to the literature that I used to collate the 
initial symptom list, particularly focusing on descriptions used in the patient literature, such as 
on the CRUK, Macmillan, and NHS websites56,57,70-72,86. I also consulted with the study advisory 
group and the patient representatives. Table 5.4 outlines the symptoms, relating them to the 
definition included in the questionnaire and referencing the supporting evidence used to 
determine the wording of the symptom descriptions. 
 
Having selected the symptoms for inclusion, and determined the descriptions to be used, I 
considered the format for exploring symptom experience. Based on the requirement for a short 
questionnaire, and in contrast to the format of the SYMPTOM study questionnaires, I decided 
to evaluate symptom experience using a list format (Box 2; Q4). To explore the presence or 
absence of symptoms, I initially considered a yes/no answer format; however, on reflection 
and consultation with the study patient representatives, this was changed to the following three 
answer choices for each symptom: ‘all or most of the time’, ‘some of the time’ or ‘rarely or 
never’. These options were chosen to explore symptom experience along with symptom 
burden, and to reflect that patients tend to seek medical help when symptoms become 
uncontrollable, or interfere with everyday life13,149. The difference between experiencing a 
symptom ‘all or most of the time’ compared to ‘some of the time’ could therefore be important 
in understanding symptom appraisal and help-seeking.  
 
Following the above symptom questions, I also explored the initial things/symptom(s) noticed 
by participants, along with the exact or estimated date of onset (Box 2; Q5) using an open 
question format as validated in the SYMPTOM study. This question was included to determine 
the first thing or symptom noticed that made the participants think something might be wrong, 
which may precede the first symptom presented to the GP as explored in Q3. Based on the 
intervals as defined by the MoPT140,141, this date represents the start of the PI. 
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5.4.3. Medication use 
Box 3: Question to explore medication use in the POSTCARD questionnaire 
6. In the past 12 months, did you use any medicine for your symptoms?  
A. Medicine given to you by your doctor. Yes / No and free text 
B. Medicine you bought for yourself. Yes / No and free text 
 
I developed a new item to determine medication use (Box 3; Q6), as previous research has 
suggested most individuals with dyspepsia, and associated symptoms such as heartburn, 
initially manage the symptoms themselves398. In an interview study of people consulting and 
not consulting with symptoms of GORD in the USA, UK, France, and Germany, around half of 
the participants (except in Germany) initially sought help or advice from a pharmacist. They 
tried a variety of OTC medication, and only consulted the doctor if symptoms worsened or 
became uncontrollable, or where OTC medication was seen as a short term solution13. The 
use of prescribed medication is also important as the patient may receive repeat prescriptions 
for medication such as PPIs, which could mask symptoms until they became more severe or 
other symptoms develop.  
 
Stapley et al. identified that in the year prior to diagnosis, patients subsequently diagnosed 
with oesophageal or gastric cancer consulted more frequently than the control group within the 
study (p <0.001) suggesting that symptoms may worsen due to the progression of the cancer, 
therefore prompting consultation66. The item that I developed for the questionnaire therefore 
asked about prescription and OTC medication use in the previous 12 months, with the wording 
validated in a think aloud study prior to administering the questionnaire (Section 5.4). Limiting 
the time period would identify recent treatments used leading up to diagnosis, where the 
increasing size of the tumour and cancer stage may interfere with the normal functionality of 
the upper GI tract.   
 
5.4.4. Socio-demographics  
Box 4: Questions exploring socio-demographics in the POSTCARD questionnaire 
7. Are you male or female? Male / Female 
8. What is your highest level of education? Please tick one box only. Multiple choice 
9. What is your ethnic group? Please tick one box only. Multiple choice 
10. Do you live alone? Yes / No and free text 
 
The questions included in the study questionnaire to capture socio-demographic details were 
validated in the SYMPTOM study, with the exception of Q7 (gender; Box 4), which  reflected 
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the wording used in the 2014 National Cancer Patient Experience Survey395. I added this 
question to avoid any uncertainty that may arise from determining gender from the participant’s 
name on the consent form, for example if the participant only provided initials and surname.  
 
Other socio-demographic details included educational level, ethnic group and living 
arrangements (Box 4; Q8-10), with ethnic group updated in line with the revised Office for 
National Statistics (ONS-18) classification. On the consent form I also collected postcode, to 
enable Index of Multiple Deprivation (IMD) calculation as a representation of deprivation, and 
date of birth to calculate age at consent. Older age, deprivation, low education and cultural 
barriers have all been linked to low health literacy and poor health outcomes170,183,219,276,384,399-
402; hence it was important to explore these socio-demographic data in the questionnaire. I 
included the question on living arrangements as recent health literacy research and newly 
developed instruments have recognised the importance of social networks on health literacy266. 
The SYMPTOM study questionnaires also inquired about employment status yet I decided to 
exclude this question because, although low income has been associated with low health 
literacy171, employment status does not link directly to income. For instance, some groups not 
in employment (e.g. retired, looking after family/home) may have other sources of income 
available to them, whilst others in full time employment could be low income. A more direct 
approach would be to ask for income levels, although this could be perceived by patients as 
an irrelevant or invasive question within the context of the questionnaire.     
  
5.4.5. Comorbidities 
Box 5: Question exploring comorbidities in the POSTCARD questionnaire 
11. Are you suffering from, or have you suffered from, any of the following in the past 2 
years? Please tick any that apply to you. Comorbidity list  
 
The question on comorbidities was also validated in the SYMPTOM study; however, to reduce 
question burden on the participants and to shorten the questionnaire I selected six (of 11) to 
include: lung disease, heart disease, anxiety or depression, cancer (other than oesophageal 
or stomach), peptic ulcer, arthritis (Box 5; Q11). I also added ‘Barrett’s oesophagus or reflux 
disease’ as this is specifically relevant to oesophago-gastric cancer. I decided to include these 
seven comorbidities as they may influence the patient and/or healthcare provider appraisal of 
oesophageal or gastric cancer symptoms, therefore impacting on patient help-seeking 
behaviours or healthcare provider referral decisions. The rationale for selecting these seven 
comorbidities is discussed in detail below. 
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Lung disease and heart disease 
Symptoms localised to the chest area, such as pain from heartburn could be attributed to lung 
or heart issues. Studies in healthcare seeking for symptoms of GORD have suggested that 
concern about the possibility of heart disease prompted help-seeking, therefore potentially 
shortening the appraisal and help-seeking intervals13,403. However, where a patient has 
previously been diagnosed with (or investigated for) lung or heart disease, symptoms may be 
attributed to the comorbidity therefore potentially lengthening the PI or the diagnostic interval 
if the doctor initiates (‘inappropriate’) tests based on lung or heart disease concerns149. 
 
Anxiety or depression 
Depression and psychiatric illness in general have both been associated with later diagnosis 
in patients with oesophageal cancer. A retrospective cohort study by O’Rourke found the time 
to diagnosis (from onset of alarm symptoms) for patients with psychiatric illness was 90 days 
(range 20-162 days) compared with 35 days (0-76 days) for those without (p=0.002), with 
depression alone also found to be predictive of later diagnosis49. Additionally these patients 
were more likely to present with advanced metastatic disease.  
 
Patients with anxiety or depression may present more frequently with symptoms such as 
heartburn or dysphagia as these symptoms can be side effects of psychiatric medication or 
the disease itself404,405. It is therefore possible that patients may subsequently identify these 
symptoms with the psychiatric illness, rather than attributing them to a new illness and 
therefore not seek help, extending the PI. This process of ‘normalising’ symptoms has been 
described in cancer symptom literature where patients feel the symptom is to be expected, 
either from past experience or due to age or lifestyle factors, and therefore do not seek 
help389,390. GPs may also attribute the symptoms to the psychiatric illness and adopt a ‘watch 
and wait’ approach prior to referral, therefore lengthening the diagnostic interval. 
 
Cancer (other than oesophageal or stomach) 
Previous studies and systematic reviews have shown that the PI can be increased when 
people do not recognise the seriousness of symptoms, or when they fear the consultation with 
a GP, either through embarrassment (that the symptoms may be seen as trivial or they affect 
a sensitive area) or that cancer will be diagnosed269,406. Patients with a previous diagnosis of 
cancer may be more self-aware and confident to approach the GP with embarrassing or 
seemingly trivial symptoms, therefore shortening the PI, although initial recognition of 
symptoms could still be difficult. 
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Peptic ulcer  
Symptoms of peptic (stomach and duodenal) ulcers are similar to the symptoms that people 
may experience with oesophageal or gastric cancer, for example, pain in the stomach, 
heartburn, indigestion, and nausea. If a patient has previously been treated for a peptic ulcer, 
suspecting a reoccurrence may either lead patients to self-medicate, therefore increasing the 
PI, or could prompt patients to seek help for their symptoms sooner, therefore reducing the 
time to presentation. However, the previous medical history could lead to an initial 
misdiagnosis and treatment of the symptoms by the healthcare providers, which could 
lengthen the diagnostic interval149.  
 
Arthritis 
Heartburn can be a side effect of nonsteroidal anti-inflammatory drugs used to treat arthritis, 
therefore heartburn may be a normal symptom for patients to experience or manage with PPI 
medication. It may not be appraised as a symptom to consult a healthcare provider about until 
it becomes unmanageable or other symptoms are also noticed. This would lengthen the PI and 
potentially the diagnostic interval if PPI dosage was altered and a watchful waiting approach 
taken prior to further investigation.  
 
Barrett’s oesophagus or reflux disease 
Reflux symptoms have been associated with an increased risk of oesophageal cancer21,34 and 
can sometimes lead to the development of Barrett’s oesophagus, a cellular change in the 
oesophagus, which can develop into oesophageal adenocanrcinoma34. Once Barrett’s 
oesophagus has been diagnosed, routine monitoring may identify cancerous changes early, 
therefore reducing the time to diagnosis and potentially improving outcomes for oesophageal 
cancer.  
 
5.4.6. Health literacy 
Box 6: Question to explore aspects of health literacy in the POSTCARD questionnaire
12. Thinking about how you manage your health, please indicate how difficult or easy the 
following tasks are for you now. Please tick one box for each statement. 
10 questions with a five-point ‘difficulty’ Likert scale 
 
From the review and critical appraisal of health literacy instruments in Chapter 4, I chose the 
HLQ266 as a validated instrument to assess the participant’s health literacy ability in the study 
questionnaire. The HLQ consists of 44 items across nine domains of health literacy; however, 
based on the format and assessment of the items, the domains can be used individually to 
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assess specific aspects of health literacy. I chose the latter approach for use of the HLQ in the 
study questionnaire, in order to focus on specific aspects of health literacy and also to limit the 
question burden on participants at a difficult time. 
 
Having obtained the full questionnaire and a licence to use the HLQ, I reviewed the items to 
fully understand the content of each domain. Following this, I related each HLQ domain to the 
appraisal, help-seeking and diagnostic intervals as defined by the MoPT140,141 to determine 
where each aspect of health literacy might exert the most influence on the pathway. As can be 
seen from Figure 5.3, six of the nine domains were relevant across at least two intervals, for 
example ‘social support for health’ may influence all three intervals as family/friends/others 
may assist with appraising symptoms, encourage help-seeking, and provide support at 
healthcare appointments. The four HLQ domains that were relevant to the appraisal or 
appraisal/help-seeking intervals (domains 2, 3, 5, 8) broadly related to having access to good 
quality information and the ability to use that information to maintain health. How patients find 
and appraise information and act on this knowledge is very important when exploring appraisal 
and help-seeking for potential cancer symptoms. However, these domains could be influenced 
by a more basic level of health literacy relating to ‘understanding health information well 
enough to know what to do’ (domain 9). This domain assesses participants’ understanding of 
written and verbal health information including instructions from healthcare providers. Osborne 
et al. found this domain to be the easiest one to complete266; hence, difficulties identified in this 
domain would indicate problems with basic health literacy, which would likely impact other 
domains. This domain was therefore selected for the study questionnaire with the aim of 
providing an indication of basic health literacy ability.  
 
The remaining four domains related to interaction with the healthcare system (domains 1, 6, 
7) and social support (domain 4). Previous research has already explored the influence of 
social networks on the pathways to diagnosis145,250,406,407, therefore I decided not to use this 
domain in my questionnaire. Instead I focused on patients’ interaction with the healthcare 
system, either their relationship or engagement with healthcare providers, or navigation of 
healthcare systems. It is important for patients to feel they have a supportive relationship with 
their healthcare providers to avoid barriers to help-seeking such as feeling that they are 
wasting the doctor’s time5,144, and also to feel confident in navigating the healthcare system. 
This is particularly relevant when choosing appropriate healthcare services, an idea that was 
promoted in the 2013 national ‘Choose well this winter’ campaign408. However, as discussed 
in Chapter 2, communication and engagement with healthcare providers can have implications 
on diagnosis as patients’ can use a range of language to describe their symptoms. This often  
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does not match medical terminology, potentially leading to symptom misinterpretation 
13,143,149,407. Understanding a patient’s ability to communicate with healthcare providers could 
therefore be an essential aspect of health literacy influencing the pathways to diagnosis; thus, 
‘engagement’ was chosen as the second HLQ domain to include in the study questionnaire 
(Box 6; Q12). 
 
The choices of engagement and understanding also reflect the domains used in the study by 
Bo et al.171, which established the acceptability of using these as stand-alone domains from 
the full HLQ266. These domains followed the five-point Likert scale response, from ‘cannot do 
or always difficult’ (1) to ‘always easy’ (5). However, Bo et al. excluded ’cannot do’ following 
discussions with the authors of the HLQ; therefore, I chose to follow this example and define 
the lowest response option as ‘always difficult’. 
 
In addition to the questionnaire, I used the HLQ as a framework for exploring health literacy 
with participants in the interview strand of the POSTCARD study, as I discuss in Chapter 7. 
 
5.4.7. Summary 
Having developed the study questionnaire using new and previously validated items relating 
to symptom appraisal, self-treatment, help-seeking, socio-demographics and health literacy, it 
was important to assess the draft version for face validity and usability. This would highlight 
any problems with understanding or completing the questionnaire, which could be used to 
improve the questionnaire prior to administering it to study participants. To assess the 
questionnaire, I conducted a think aloud study, which I describe in the following section. 
 
5.5. Think aloud study 
As the questionnaire was developed by combining items from existing questionnaires with new 
items, I conducted a think aloud study to assess the questionnaire with a group of participants, 
prior to submitting my application for ethical approval. Think aloud studies require participants 
to verbalise their thoughts as they complete a task, which gives an accurate reflection of the 
thought process at the time without interfering with the task or including explanations or 
rationalisations that tend to come with retrospective reports409,410. Think aloud studies are 
therefore useful for testing face validity, “the extent to which a measure reflects what it is 
intended to measure”411, and for identifying problems that participants encounter when 
completing questionnaires412,413. An alternative method for testing the questionnaire would be 
a pilot study; administering the questionnaire to participants in the same way as intended in 
the main study414. This could be with a group of volunteers, asking for feedback following the 
task, or as a feasibility stage prior to the study. However, neither of these approaches would 
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capture the participants’ immediate thoughts or difficulties encountered when completing the 
questionnaire, which is important when assessing the interpretation and understanding of 
questions, particularly newly developed items. These methods were therefore deemed 
unsuitable for the aim and scope of the questionnaire validation.  
 
5.5.1. Aim 
The aim of the think aloud study was to assess the face validity and usability of the 
questionnaire that I developed to survey patients newly diagnosed with oesophageal or gastric 
cancer. Problems identified could be reflected upon to improve the questionnaire prior to use. 
 
5.5.2. Objectives 
 To evaluate the participants’ comments to ensure that the questionnaire captured the 
intended information; 
 To identify unclear text or questions that were difficult to understand or answer;  
 To update the questionnaire to ensure that the final version was valid and acceptable 
for use. 
 
5.5.3. Methods 
Recruitment 
The study was conducted between December 2015 and February 2016. Participants were 
recruited via patient representatives and upper gastrointestinal cancer patient groups in 
Cambridge and Middlesbrough. I purposively recruited participants who were familiar with the 
cancer patient pathway, either having received a cancer diagnosis themselves in the past, or  
 
having experience from a close family member diagnosed with cancer. Two of the participants 
had previously been diagnosed with oesophageal cancer. It was important that the participants 
understood the pathways to diagnosis, as the questionnaire aims to explore factors affecting 
appraisal and help-seeking behaviour.  
 
Based on the sample sizes of previous think aloud studies412,413, I recruited eight participants; 
50% male, mean age 72.1 years (range 61-86). I visited participants (n=2) who preferred to 
participate in their own home, and invited the other participants (n=6) to the research office. 
Participants were reimbursed for travel expenses and given a £20 voucher for their time.  
 
Study procedure 
I began by giving participants a brief overview of my research and the reason for conducting 
the think aloud study. Once I had answered any questions, I explained the format of the task 
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using instructions developed for the study and based on the text in Green & Gilhoody, 1996415. 
This ensured that all participants received the same instructions for completing the task. The 
instructions were as follows: 
 
“I have developed a questionnaire for my study and I want to check that people 
understand the questions and feel comfortable with the questionnaire.  
 
To do this, I am going to ask you to complete the questionnaire as though you have 
read the study information sheet and are a participant in the study. As you complete 
the questionnaire, I want you to tell me everything you are thinking. This is called 
‘thinking aloud’ and it helps me to see what your initial thoughts are about the 
questions and any difficulties you have in answering them.  
 
I don’t want you to plan out what you say or try to explain to me what you are 
saying. Just act as if you are alone in the room speaking to yourself. If you are 
silent for any long period of time, I will ask you to keep talking. I will be recording 
you as you speak, so please try to speak as clearly as possible. Do you understand 
what I want you to do?” [Participant: yes or no] “Do you have any questions?” 
[Participant: free to ask questions]. 
 
Before the participants completed the study questionnaire, they were given an example 
questionnaire to practice with, to make sure they were comfortable with the process of thinking 
aloud (Appendix 12). The practice task required the participant to complete the short-form of 
the Spielberger State-Trait Anxiety Inventory416, as this follows a similar format to the study 
questionnaire (reading text and responding to tick box questions). Some participants had a  
 
period of silence during the task, which required a prompt to ‘keep talking’. Ericsson & Simon 
noted that this brief prompt is less disruptive than asking participants to say what they are 
thinking417. The participants were then asked to complete the study questionnaire, including 
the consent form on page 2. Following the think aloud task, I conducted a short interview with 
the participants to explore any difficulties they had encountered and to assess their thoughts 
and feelings towards the questionnaire. All think aloud tasks and interviews were audio 
recorded and analysed from the audio, rather than transcribing the audio (described below). 
 
5.5.4. Analysis 
Having conducted the study with the first three participants, difficulties were apparent in 
completing the first part of the questionnaire. I therefore analysed the first three think aloud 
interviews, and updated the questionnaire (Stage 1), as discussed in Section 5.4.5 below. I 
then tested the new version of the questionnaire with a further five participants (Stage 2). 
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For the analysis, data were anonymised through assigning a unique study ID to each 
participant (‘P’ followed by a number e.g. P1), with gender (M or F) and age range recorded 
for description purposes. While listening to the audio file, I tabulated the participant’s thoughts 
on an item-by-item basis. Where relevant, I identified sections of the recording that I 
transcribed verbatim to provide an overall summary of the item in the participant’s own words. 
Having tabulated the participant’s thoughts, I then categorised the comments based on the 
coding framework developed by French et al., 2007412, and updated by van Oort et al., 2011413 
(Table 5.5). The categories defined the types of problems experienced when completing the 
questionnaire, which helped to identify questions that were particularly difficult to understand 
or answer. I chose not to fully transcribe each audio file because listening to the audio while 
summarising and categorising the comments was sufficient for the objectives of the study. 
 
Table 5.5. Coding framework 
Category Description 
1. None No significant problems identified 
2. Reread/ 
stumbled 
Participant reread question, or seriously stumbled (i.e., stammered or stuttered 
because of misreading) in answering it (problems in understanding question). 
Category divided into three by Van Oort et al., 2011: 
    A. Reread question or stumbled in reading it 
    B. Experienced difficulty generating an answer 
    C. Experienced difficulty responding by means of numbers  
3. Context Questioned context of question (problem with how question was worded) 
4. Inconsistent Answered a different question from the one that was asked, or gave reasoning 
inconsistent with the answer given (problems in comprehending / answering 
questions; misinterpretation of question) 
Developed by French et al., 2007412; updated by van Oort et al., 2011413 
 
5.5.5. Results 
Stage 1 
As described, three participants took part in Stage 1 of the think aloud study, with interviews 
lasting between 30-60 minutes. Where I refer to question numbers in Stage 1 of the think aloud 
study, this is relevant to the original version of the questionnaire, as detailed by the 
questionnaire items in Table 5.6. This table also summarise the difficulties identified with the 
original version of the questionnaire. Most difficulties were identified in part 1 of the 
questionnaire, with participants particularly confused by what they saw as repetition between 
Q1 and Q3, as illustrated by the quotes below. Each quote is followed by the study ID, gender 
and age range of the participant. 
 
“This seems to be quite a repetition of the information in section 1 because it was 
the same symptoms.” (P2: M, 71-80) 
 
 134 
“Interesting thing is about question 3a is how that differs from the answer to 
question 1.” (P3: M, 61-70) 
 
The intention of Q1 was to identify the start of the appraisal interval; the first thing (or symptom) 
noticed that could potentially be attributed to the cancer. Q3 aimed to identify the trigger 
symptom and start of the help-seeking interval; the first thing (or symptom) the participant had 
spoken to their GP about, which may not be the same as the first thing that was noticed. 
Participants were not able to distinguish between the two time points and spent considerable 
time thinking and talking through their confusion about the questions and what they should 
write. 
 
The participants found it easy to identify symptoms they had experienced (Q4 – list of 
symptoms), except for “pain in the centre of the upper stomach.” 
 
“Where’s my stomach, there…what do they think is my upper stomach? I’m going 
to put question marks there, I’m not sure.” (P1: F, 61-70) 
 
“…pain in the centre of the upper stomach, I wouldn’t know how to answer that.” 
(P3: M, 61-70) 
 
For this question the participants felt the location was too specific, as people may experience 
pain (or tenderness) to the right or left hand side of the upper stomach. They were therefore 
unsure whether to tick yes or no to that question. 
 
The number of GP visits (Q6), was also ambiguous because the participants were unsure of 
the timeframe that this question referred to, particularly as the question followed one where 
the time period was specified. 
 
“This still applies to the last year does it? How many times, because the heading 
is within the last year. Oh this is number 6, a different heading. Ok so it doesn’t, so 
what, I’m not sure what time period is covered by this question”  
(P2: M, 71-80) 
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Overall the responses to the remainder of the questionnaire were positive. Q12 was the most 
difficult question in part 2, primarily because the questions refer to ‘healthcare providers’ and 
the participants found it difficult to know which healthcare provider to think about. 
 
“It’s a bit difficult to talk to a doctor but easier to talk to a nurse, so I’d better put 
sometimes difficult.” (P1: F, 61-70) 
 
“Discuss things with healthcare providers until you understand all you need to. Erm, 
sometimes difficult because doctors don’t have much time but Macmillan nurse has 
more time so a bit mixed.” (P2: M, 71-80) 
 
As Q12 is part of the HLQ266 I could not change the wording of the items; however, I was able 
to expand the question to include a description of healthcare providers. 
 
Following the first three interviews and analysis, I updated the questionnaire based on the 
difficulties identified, primarily re-ordering part 1 to make it easier to understand and complete 
(Table 5.7). The new version of the questionnaire therefore started by exploring the 
participants’ experience with the GP, then moved on to the symptoms experienced prior to 
help-seeking, and finished by asking about medication use. A few minor updates were made 
to the text in the rest of the questionnaire and the consent form, and the use of colour (white 
text on dark purple background) was amended, as one participant thought that others might 
find it difficult to read in its current format.  
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Stage 2 
I tested the new questionnaire with a further five participants and no further significant 
problems were identified. The think aloud study and interviews for these participants lasted 
between 20-30 minutes. The new version of the questionnaire was straightforward for 
participants to complete and when reflecting on the task, they were positive about the 
questions asked, and the layout.  
 
“Very clear…my impression was fine, ok, I didn’t find it off-putting, it’s not too 
complicated…” (P6: M, 61-70) 
 
“I would have found that not threatening at all so I would have been quite happy to 
fill that in.” (P7: F, 71-80) 
 
5.5.6. Summary  
The aim of the think aloud study was to assess the face validity and usability of the 
questionnaire prior to its use with patients diagnosed with oesophageal or gastric cancer. The 
initial three think aloud interviews identified difficulties in both the questionnaire’s usability and 
face validity as the participants found it difficult to understand the questions and answer them 
in the intended way. The questionnaire was therefore updated and a new version was tested 
with a further five participants. The new version was both valid and easy to use, requiring no 
further updates (Appendix 11). I discuss the use of the questionnaire in the following chapter.    
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Chapter 6: Questionnaire study 
 
 
Having described the development and testing of the study questionnaire in Chapter 5, I now 
discuss the design, conduct and results of the POSTCARD study. In this chapter, I focus on 
the survey and the review of participant’s secondary care medical records, before discussing 
the in-depth patient interviews in Chapter 7.  
 
6.1. Study design 
6.1.1. Setting 
As the aim of the study was to explore the pathway to oesophageal and gastric cancer 
diagnosis, I designed the study to recruit patients in secondary care following their diagnosis 
(within four weeks where possible). Recruiting from secondary care was the approach used by 
a previous qualitative study exploring the pathways to diagnosis of 63 patients diagnosed with 
melanoma407 and the SYMPTOM studies, recruiting almost 4,000 patients with symptoms 
suggestive of lung, colorectal or pancreatic cancer391-393. In these studies, recruitment was 
coordinated in secondary care by the clinical teams involved.  
 
However, the intended outcomes of the POSTCARD study also relate to primary care; 
therefore recruiting from secondary care could be seen as out of context. In their systematic 
review of factors influencing the diagnosis of upper gastrointestinal cancer, Macdonald et al., 
2006, observed that most of the studies were conducted in secondary care yet reported results 
relevant to the PI and primary care HSI149. Although recruiting from primary care would set the 
study in the context of the intended outcomes, it would not be practical, as it would be difficult 
to recruit patients within four weeks of diagnosis and it would require participation of a large 
number of general practices, therefore increasing costs and resources beyond those available.  
I aimed to include at least two secondary care providers (hospitals) in the study to enable 
recruitment from different areas of England, therefore providing social and geographical 
diversity of the patient population. Social diversity can be broadly assessed using the IMD, an 
area-level assessment of relative deprivation, or disadvantage. It assesses seven domains to 
determine a relative measure across neighbourhoods in England: income, employment, 
education and skills, health, crime, housing and living environment418. The IMD has been 
widely used in previous research exploring timely diagnosis of cancer146,391-393. When deciding 
on the hospitals to approach for participation in the study, I focused on regional hospitals, as 
patients from local hospitals are discussed at the regional multi-disciplinary team (MDT) 
meetings and often referred to the regional hospitals for diagnosis and treatment. These 
hospitals therefore have access to a larger patient population than individual local hospitals.  
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Having discussed potential hospitals with my supervisors, I initially invited participation from 
two regional hospitals, providing care across the East and North East of England: 
 Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, 
Cambridge, UK;  
 James Cook University Hospital, South Tees Hospitals NHS Foundation Trust, 
Middlesbrough, UK. 
 
Two of my supervisors (FW and Professor Greg Rubin, GR) had existing research relationships 
with consultants in the Gastroenterology departments at these hospitals, which facilitated the 
invitation to participate in the study. The hospitals also represented two very different areas of 
England, with Middlesbrough identified as an area with one of the highest proportions of 
disadvantaged neighbourhoods based on the 2015 IMD report, while Cambridge is one of the 
regions with the least disadvantaged neighbourhoods418. Both hospitals agreed to participate 
and provided data on the number of patients diagnosed with oesophageal and gastric cancer 
in 2014; 274 patients at Addenbrooke’s Hospital (Addenbrooke’s) and 259 patients at James 
Cook University Hospital (James Cook). Based on this data and my sample size calculation 
(discussed below), recruitment of additional hospitals was not required.  
 
6.1.2. Sample size 
On consultation with a statistician, I determined that 200 responses would be required to 
conduct multivariable analysis on the sample. This decision was based on Altman’s rule of 
n/10 allowing modelling of up to 20 variables in a multivariable analysis of the total cohort419. 
When analysing by cancer type, this approach would allow approximately 10 variables per 
cancer if the sample size was equal between oesophageal and gastric participants.  
 
In considering the 2014 hospital data provided by Addenbrooke’s and James Cook (totalling 
533 patients), a 40% recruitment rate over 12 months would give a sufficient sample size for 
the study. This estimate was based on experience in previous studies conducted by my primary 
supervisor (FW), where response rates ranged from 19.5-24% for the SYMPTOM 
questionnaire studies391-393 and 50.2% for a melanoma interview study407. These studies 
recruited via hospitals, using postal methods. As I planned for patients to be approached face-
to-face (Section 6.1.4), I expected an increased response rate in comparison to the SYMPTOM 
studies, although lower than responding to an interview invitation. I therefore estimated a 
response rate of 40%.  
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6.1.3. Participant recruitment 
All patients aged 18 or over and newly diagnosed with oesophageal or gastric cancer were 
eligible for inclusion in the study. Patients were excluded if they were assessed as unsuitable 
by their diagnosing clinician (for example as a result of serious co-morbidity, mental health 
problems, unable to communicate in English).  
 
I consulted with the hospital teams at Addenbrooke’s and James Cook, and reflected on the 
routes patients may follow into healthcare in order to determine an appropriate time to identify 
and recruit eligible patients. There are a number of pathways via primary and/or secondary 
care that patients may follow prior to obtaining their diagnosis and treatment (Figure 6.1). From 
primary care, GPs could either refer on an urgent basis using the NICE referral guidelines for 
suspected cancer41, where patients are seen within two weeks, or use a routine referral if 
cancer is not suspected, with waiting times of up to 18 weeks. Other routes include the patient 
presenting as an emergency to an accident and emergency department, where they may be 
admitted, or they could be admitted from another clinic within the hospital.  
 
Once in secondary care (at a local or regional hospital), patients usually have an endoscopy 
including biopsies, and are discussed at the weekly regional upper GI MDT meeting if cancer 
is suspected, with further investigations planned, or the diagnosis confirmed and treatment 
options discussed. Based on this pathway, the MDT meeting was identified as the most 
appropriate time for the hospital teams at Addenbrooke’s and James Cook to identify eligible 
patients for the study. Patients were subsequently approached at a clinic visit, within four 
weeks of the date of diagnosis where possible. Recruitment was coordinated by a Research 
Nurse at Addenbrooke’s and by two Specialist Nurses at James Cook, with the nurses 
determining an appropriate time to approach patients, once the patient had been informed of 
their diagnosis (Figure 6.2). 
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Figure 6.2. The POSTCARD study recruitment process 
 
 
At Addenbrooke’s a member of the administrative team would track oncology and surgical 
clinic visits of eligible patients, to identify recruitment opportunities for the Research Nurse 
(Figure 6.3). Visits were also monitored to approach patients at subsequent visits, if it was not 
possible to approach them at the initial visit. In comparison, there was limited administrative 
and research support available at James Cook; therefore, the Specialist Nurses could only 
approach patients at the weekly upper GI surgical clinic, where they were present. 
 
When introducing the study to patients, the nurse would briefly explain the research to the 
patient and give them a study pack. In the pack, there was a study information sheet (Appendix 
13) giving further information about the purpose of the study and how to participate. It also 
outlined data protection, confidentiality and ethical approval details, along with contact 
information for the research team and an independent complaints service. Additionally, the 
study pack contained the study consent form and questionnaire (Appendix 11) to complete 
should they agree to take part, and a freepost envelope to return the documents to the research 
team. The nurse did not complete the documents with the patients. However, as the study 
aimed to recruit participants with varying health literacy abilities, patients were given the option 
to call the study researcher to give verbal consent and complete the questionnaire over the 
phone, as previously mentioned. 
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Figure 6.3. Recruitment pathway 
 
GI = gastrointestinal 
 
Each consent form and questionnaire was labelled with a unique Study ID, generated by a 
data manager at the University of Cambridge. The format used a three letter code to identify 
the recruiting hospital (ADD, Addenbrooke’s; JCH, James Cook) followed by three numbers 
starting from 001 and increasing sequentially, with a randomly generated letter at the end of 
the ID. The hospital team used an electronic patient log to record the Study ID of each patient 
approached (Figure 6.3), along with the patient’s age, gender and cancer type. I collected this 
data from the hospitals at the end of the study to examine details of responders versus non-
responders.  
 
Update to recruitment strategy 
Following the first three months of the study, I identified a limitation with the recruitment 
strategy: it was not possible to approach patients discussed at the MDT meetings when their 
care was managed in local hospitals. This was because these patients did not attend a clinic 
at the recruiting hospital following their diagnosis. I therefore updated the recruitment strategy, 
and obtained ethical approval, to permit the recruiting hospitals to approach eligible patients 
at local hospitals. This involved the hospital teams contacting the local hospitals to confirm that 
recruitment was appropriate and the patient had been informed of their diagnosis. Following  
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the confirmation, the recruiting hospital mailed an invitation letter and study pack to the 
patients. Postal recruitment commenced at the beginning of February 2017, in addition to face-
to-face recruitment of patients attending clinics at the recruiting hospitals. The recruitment 
period was extended to 18 months to allow a sufficient period for participation from postal 
invitations and to increase recruitment following the initial limitations. As previously described, 
postal recruitment was successfully used in the melanoma interview study (50.2% response 
rate)407, and the SYMPTOM studies (19.5-24% response rate)391-393. 
 
6.1.4. Consent 
Patients provided written consent by returning their completed consent form and questionnaire 
to the research team at the University of Cambridge, or verbal consent by calling to participate. 
With the latter approach, I would discuss the study with the patient before reading the consent 
form and questionnaire to them, recording their responses and noting on the form that it had 
been completed verbally.  
 
The consent form followed the standard template as recommended by the Health Research 
Authority (HRA) and included: 
1. Confirmation of reading the study information sheet; 
2. Understanding of the voluntary nature of the study and the option to withdraw; 
3. Permission for study team access to medical records; 
4. Agreement for participation in the study; 
5. Optional consent for participation in the qualitative study. 
 
Participants initialled each statement and included their name and signature on the form along 
with the date, their date of birth and postcode, as well as their contact details if they had 
initialled statement five. The participant’s date of birth was used to calculate age at consent, 
postcode was used to determine their IMD score, and their name and date of birth were used 
to identify the correct secondary care medical record for the case note review, as described 
below. 
 
Informed consent was required for all aspects of the study, therefore if the consent form was 
returned blank or partially completed, I would photocopy the consent form and give the original 
to the recruiting hospital for the participant to complete at their next clinic visit (if possible). The 
consent form would then be returned and the participant’s data used within the study. Where 
it was not possible to obtain a fully completed consent form, the questionnaire data were 
excluded. Participants were free to withdraw for any reason and at any time and non-
responders were not given any reminders for participation. 
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6.1.5. Case note review 
I contacted the participating hospitals each week throughout the study to obtain the cancer 
type and date of diagnosis for new participants. At the mid-point and end of the study I collected 
the following additional details from all participant’s medical notes (with the assistance of the 
study teams at the recruiting hospitals): date and type of referral, histologic type, disease stage 
at the time of histological diagnosis and disease stage prior to treatment (pre-treatment). The 
pre-treatment stage was confirmed following all necessary investigations, discussed at the 
MDT meeting, and was used to guide the treatment plan, whether curative or palliative.    
 
6.1.6. Ethical considerations 
When designing the study, I consulted with my supervisors, along with colleagues in the 
Primary Care Unit, two patient representatives and the consultants and nurses at the 
participating hospitals, to ensure that all ethical issues had been considered. As discussed in 
Chapter 4, the study questionnaire was assessed for face validity and usability in a think aloud 
study with a group of eight patients to ensure it was appropriate for use.  
 
A particular consideration was the ethical issues around approaching patients soon after a 
diagnosis of cancer. Many oesophageal and gastric cancers have poor outcomes, and patients 
may potentially be quite unwell at diagnosis, or be about to undergo surgery. As previously 
outlined, my supervisor’s melanoma interview study used this recruitment strategy, with the 
clinical team approaching newly diagnosed patients407, as did another qualitative study 
published in 2015420. This study explored the experiences of 27 adults (aged 18 or over) 
diagnosed with cancer following presentation at a hospital emergency department (emergency 
presentation). One-year relative survival is known to be significantly lower for patients 
presenting via emergency routes421; however, the authors of the qualitative study found that 
many patients wanted to participate even when they were frail or unwell as they wanted to talk 
about their experiences420. Recruitment of patients at a difficult time should therefore not be a 
barrier to research participation, although it should be managed in a sensitive and appropriate 
manner. For the POSTCARD study I followed the recruitment strategy of these previous 
studies with the hospital teams deciding on an appropriate time to approach patients.  
 
The study was approved by the East of England Cambridge Central Research Ethics 
Committee (16/EE/0086) on the 6th April 2016. Following this, I received research governance 
approval from each participating NHS Trust. I also applied for a research passport and was 
given a letter of access for each hospital, with permission to access patient medical records. 
The substantial amendment for altering the recruitment strategy was given a favourable 
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opinion on the 1st November 2016; however, due to implementation delays at the recruiting 
hospitals, postal recruitment commenced at the beginning of February 2017. 
 
6.2. Study procedures 
Prior to starting the study, I created a database for participant identifiable data (PID database) 
collected on the consent form and from the participant’s medical records. I created a second 
database for the anonymised questionnaire data (study database). At all times the University 
of Cambridge's clear guidelines on arrangements to respect confidentiality of personal data 
were followed, as well as the requirements of the Data Protection Act 1998 and the NHS Code 
of Confidentiality.  
 
6.2.1. Data management 
I processed consent forms and questionnaires as soon as possible following receipt, with 
unopened returns locked in a filing cabinet if they could not be processed immediately.  
 
Data entry 
For each completed consent form and questionnaire received, I entered the consent form data 
in to the PID database, and flagged the participants willing to be approached for the interview 
study (discussed in Chapter 7). Following this, I entered the questionnaire data in to the study 
database exactly as it appeared in the questionnaire.  
 
Data collected from participant’s medical records were also entered into the PID database. At 
Addenbrooke’s I collected the information from the electronic medical records with assistance 
from the research team where required. At James Cook, I arranged a time with the Specialist 
Nurses to collate and record this information together. These different approaches were guided 
by local preferences.    
 
Data checking 
To ensure accurate data entry, each questionnaire was entered in to the study database twice. 
I entered the data following receipt of each questionnaire and completed the double data entry 
for approximately half of the questionnaires (n=60, 47.2%). This involved entering the 
questionnaire data for a second time at least one day after the first entry. Another member of 
the study team entered the data for the remaining 67 (52.8%) questionnaires. The study 
database was designed to maintain the unique Study ID and therefore not allow the same 
Study ID to be added twice, unless the corresponding ‘Duplicate ID’ field was updated to ‘2’. 
This prevented any errors occurring through entering the same unique Study ID multiple times,  
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and also allowed the database to distinguish between the first and second entry. The initials 
of the person entering the data along with the date of entry were recorded when creating a 
new or duplicate participant in the database. Following all data entry, I randomly screened the 
double data of 15% of participants to check accuracy and consistency of the data. As I did not 
find any errors, further checks were not required.  
 
Data storage 
To ensure that confidentiality and data protection requirements were adhered to, the PID 
database was hosted on the Secure Data Hosting Service (SDHS) at the University of 
Cambridge (School of Clinical Medicine). The SDHS is a dedicated network, separated from 
the main network by a firewall, and is used for storing sensitive personal data in a manner 
compliant with University policies. Access was restricted to members of the study team and 
required a user ID, password and two-factor authentication token for use. The study database 
was stored on the Departmental computer network, with access restricted to the study team. 
 
Following electronic data entry, the consent form was detached from the questionnaire and 
these were stored separately in a locked filing cabinet in the study team office, which was also 
locked overnight. The keys for the filing cabinet were kept in a secure location, available only 
to the study team. 
 
6.2.2. Statistical analysis 
Having entered the data in the study database, I exported it to an Excel spreadsheet to review 
and clean the data for analysis. This involved checking the data for errors, for example 
ensuring that all data were within the expected range. Where data were missing, I replaced 
the blank cells with ‘999’, with this number chosen as it would not appear in the data as a ‘true’ 
data value. Following this I uploaded the data to IBM SPSS Statistics version 25 for descriptive, 
univariable and multivariable analysis.  
 
Descriptive analysis 
I used descriptive analysis to examine the participant, healthcare and disease characteristics 
(predictors/variables) as outlined in Chapter 5 (Table 5.2). This included exploring the number 
of participants assigned to each variable/category (Table 6.1) based on cancer type 
(oesophageal or gastric) and across the total cohort (combined). Region (East or North East) 
and histology (adenocarcinoma, SCC or other) data were collected, in addition to the variables 
defined in Chapter 5, to provide further descriptive analysis of the participant population and 
exploration of disease characteristics. 
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Table 6.1. Variables for descriptive analysis 
Variable Category 
Participant characteristics 
Age <60 
60-74 
≥75 
Gender Male 
Female 
Highest education level None/Other 
A level/GCSE/O level 
PhD/Degree/Diploma 
Ethnic group White 
Other 
Living alone No 
Yes 
Region East 
North East 
Deprivation (IMD) Least deprivation 
Mid-deprivation 
Most deprivation 
Healthcare characteristics 
Comorbidities Arthritis 
Cancer (other than OG) 
Heart disease 
Lung disease 
Anxiety or depression 
Barrett’s or reflux disease 
Peptic ulcer 
Any of the above 
Prescription medication None 
PPI/similar 
Other 
OTC medication None 
Antacid/similar 
Other 
Reported GP consultations None 
1-2 
≥3 
Referral route Urgent (2WW pathway) 
Routine 
Other 
IMD = Index of Multiple Deprivation; OG = oesophago-gastric; PPI = proton 
pump inhibitor; OTC = over-the-counter; 2WW = two-week wait 
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Table 6.1. Variables for descriptive analysis 
Variable Category 
Disease characteristics 
Symptoms Difficulty swallowing 
Fatigue or tiredness 
Regurgitation 
Weight loss 
Pain swallowing 
Decreased appetite 
Heartburn 
Fullness or bloating 
Upper abdominal pain 
Nausea 
Vomiting 
Vomiting blood 
Experiencing  ≥1 symptom  
First presented to the GP 
Stage (pre-treatment) I/II 
III/IV 
Histology Adenocarcinoma 
SCC 
Other 
SCC = squamous cell carcinoma 
 
Age at diagnosis data was collected for all participants, based on their date of birth and consent 
date, and I converted this to three age groups: <60, 60-74, ≥75. I chose these age groups 
based on UK oesophageal and gastric cancer incidence data (2012-2014)2,3 (Figure 6.4). The 
combined number of cases more than doubles between the 55-59 and 75-79 age groups, with 
oesophageal cancer incidence increasing until 65-69, while gastric incidence increases until 
75-79. I therefore assigned the middle age group for the study to have an upper limit between 
these data points (the 70-74 group) and to include the first point at which incidence significantly 
increases between data points (60-64). The lower and upper age groups for the study were 
based around the middle group (60-74). 
 
Categories for education level, ethnic group, living alone, cancer stage and the format for 
reporting comorbidities were based on the SYMPTOM studies391-393. However, I used stage 
prior to treatment (pre-treatment) rather than stage at (histological) diagnosis as pre-treatment 
stage provides a more accurate assessment of disease in relation to treatment intent: curative 
or palliative. This is important when considering outcomes for these cancers.  
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Figure 6.4. Average number of new oesophageal and gastric cancer cases per 
year by age at diagnosis, UK, 2012-20142,3 
 
 
Gender, medication and referral route were based on the format of data collected in the 
questionnaire and from the medical records. I used participant postcodes to calculate IMD 
scores and assign each participant to an IMD quintile418: least deprivation/disadvantaged (1st 
IMD quintile), mid-deprivation (2nd and 3rd IMD quintiles), most deprivation (4th and 5th IMD 
quintiles). As a relatively small sample size was expected for the study, I combined the groups 
to form three categories, rather than five. The categories for reported GP consultations were 
based on previous literature to allow comparison of results422.  
 
I explored symptom experience based on symptom frequency, symptom(s) first presented to 
the GP (trigger symptom(s)), mean number of symptoms prior to diagnosis and association 
with disease stage.  
 
Descriptive analysis was used to evaluate health literacy in relation to the participant, 
healthcare and disease characteristics outlined in Table 6.1. Participant responses to the two 
domains (engagement and understanding; five items each) of the HLQ266 that I included in the 
study questionnaire were assessed using a five-point difficulty Likert scale, with a mean score 
calculated for each domain, as per the HLQ scoring system. If a response was missing for 
three or more items on a scale, the mean was not calculated and the scale was excluded from 
the analysis.  
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Univariable analysis 
I used univariable analysis to test the study hypotheses, as outlined in Chapter 5, and therefore 
to determine: 
A. If the time to diagnosis differed based on participant, healthcare or disease 
characteristics;  
B. If health literacy scores differed based on symptom experience, medication use or the 
number of consultations prior to diagnosis. 
 
Participant, healthcare and disease characteristics, as outlined in Table 6.1,  were coded as 
categorical variables (Table 6.2), while health literacy (engagement and understanding) data 
were analysed as continuous variables based on participant mean scores (range of 1.0-5.0). 
Comorbidities and symptom experience were coded as binary variables in the analysis based 
on presence or absence (yes or no), as each comorbidity or symptom could be experienced 
independently from others. Categories with less than 10 participants were excluded, as the 
sample size was too small for analysis. Variables with two categories were included in the 
univariable analysis if each category contained ≥20% of the total number of study participants 
(Figure 6.5a). Variables with three categories were included if each category contained ≥20% 
of the data (as above), or, if two categories each contained ≥20% of the data, these categories 
were included, with the third excluded (Figure 6.5b). 
 
Figure 6.5. Univariable analysis inclusion/exclusion flowchart 
 
 157 
Table 6.2. Coding for categorical variables 
Variable Category Coding 
Participant characteristics 
Age 
 
<60 
60-74 
≥75 
0 
1 
2 
Gender Male 
Female 
0 
1 
Highest education level None/Other 
A level/GCSE/O level 
PhD/Degree/Diploma 
0 
1 
2 
Ethnic group White 
Other 
0 
1 
Living alone No 
Yes 
0 
1 
Deprivation  Least deprivation 
Mid-deprivation 
Most deprivation 
0 
1 
2 
Healthcare characteristics 
Comorbidities 
Each comorbidity 
 
No 
Yes 
 
0 
1 
Prescription medication None 
PPI/similar 
Other 
0 
1 
2 
OTC medication None 
Antacid/similar 
Other 
0 
1 
2 
Reported GP consultations None 
1-2 
≥3 
0 
1 
2 
Referral route Urgent 
Routine 
Other 
0 
1 
2 
Disease characteristics 
Symptoms 
Each symptom 
 
No 
Yes 
 
0 
1 
Stage I/II 
III/IV 
0 
1 
PPI = proton pump inhibitor; OTC = over-the-counter 
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In exploring time to diagnosis, I refer to the interval definitions as I outlined in Figure 5.2. These 
intervals were analysed as continuous variables. The study questionnaire was designed to 
identify the start of the PI and TDI (from Q5), the first thing/symptom noticed, while Q3a 
identified the first symptom(s) participants told their GP about, known as the trigger symptom 
(Box 7). The trigger symptom is often noticed later than the first thing/symptom and usually 
prompts the participant to think about to seeking help.  
 
Box 7: Questions to explore date of first symptom 
Trigger symptom: 
C. What was the first symptom (or symptoms) you told your GP about? Free text and dates
A. When did you first notice this? 
B. When did you first tell your GP?  
First thing/symptom noticed: 
5. What was the first thing or symptom you noticed that made you think something might 
be wrong? This could be from the list above or something different. Free text and date 
A. When did you first notice this?  
 
Although the questionnaire had been tested for face validity in a think aloud study (Chapter 5) 
and updated accordingly, on review of the data I found inconsistencies between participant 
reporting of symptoms and dates in Q3a, and Q5, which I discuss further in Section 6.4.2. I 
therefore excluded Q5 from the analysis. However, in excluding this question I could no longer 
define the start of the PI or TDI as the ‘first thing/symptom noticed’. Instead, I used the date of 
the trigger symptom (Q3a) as the start date of the intervals. To acknowledge this change, I 
identify these intervals as the POSTCARD PI (pPI), from first noticing the trigger symptom(s) 
to first consultation in primary care, and POSTCARD TDI (pTDI), first noticing the trigger 
symptom to the date of diagnosis in secondary care (Figure 6.6). In referring to the ‘date of 
diagnosis’, this is the date of histological diagnosis, as this was used as confirmation of the 
diagnosis at the recruiting hospitals, and to determine when a patient could be approached for 
the study. The HSI reflects widely used definitions of this interval, and could be accurately 
measured from the study questionnaire data. As the description was not specific to the 
POSTCARD study, I refer to this interval as the HSI.  
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Figure 6.6. POSTCARD total diagnostic interval and component intervals 
 
Based on the intervals proposed by the MoPT140,141 
 
To calculate the pTDI and the component intervals (pPI, HSI), I used the patient reported dates 
from Q3a and Q3b of the study questionnaire (Box 7) and the date of histological diagnosis, 
obtained from the medical records. The study questionnaire gave the option of providing an 
exact date or an estimated date i.e. 3 months ago. The date type determined how the pTDI 
and component intervals were calculated: 
 Where exact dates were given, these could be used to calculate the exact number of 
days between two time points;  
 Where an estimated date was given for one or both of the questions, the analysis codes 
used in the SYMPTOM study were applied, in order to convert the estimated dates to 
estimated exact dates (Appendix 14)391-393. If a participant used the same estimated 
date for both questions, for example ‘Mid-May 2016’, both dates would be converted to 
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the same estimated exact date (i.e. 15th May 2016). As these dates were used to 
calculate the PI, this resulted in an interval duration of 0 days.  
 
Where a participant had not completed one or both of the dates in the questionnaire, it was not 
possible to calculate all three interval durations, therefore the missing intervals were excluded. 
Intervals greater than two years in length (>730 days) were also excluded. Again, this applied 
the strategy used in the SYMPTOM studies391-393, and reflected previous research on colorectal 
and lung cancer symptom lead times to determine that symptoms experienced for longer than 
two years were unlikely to be associated with the cancer diagnosis423,424. A previous case-
control study by Stapley et al., 2013, of 7471 UK patients aged 40 or over and diagnosed with 
oesophageal or gastric cancer (controls=32,877) also limited their review of electronic primary 
care records to the one year prior to diagnosis66.  
 
Statistical methods 
The median and inter-quartile range (IQR) were calculated using SPSS (Tukey’s Hinges 
approach) to explore the pPI, HSI and pTDI for each categorical variable. The Mann Whitney 
U test for independent samples and simple linear regression were used to determine 
differences in time to diagnosis, as described below.  
 
The Mann Whitney U test is a non-parametric test suitable for small independent datasets, 
which ranks the data and bases the analysis on the ranks rather than the actual data, therefore 
removing the effects of outliers. I used the Mann Whitney U test to determine: 
 If the median time to diagnosis (pPI, HSI and/or pTDI) differed between the categories 
defined for the categorical (participant, healthcare or disease) variables425; 
 If mean scores for health literacy engagement or understanding differed based on 
symptom experience, medication use or the number of consultations. 
SPSS calculated the U test statistic based on the data entered, along with the z-score and p-
value. A p-value of <0.05 was considered significant. Using the z-score and total number of 
participants in the sample, I calculated the effect size (r) using the following equation: r = z/√N.  
 
I used a simple linear regression analysis to determine the influence of health literacy 
engagement and understanding (continuous variables) on time to diagnosis. Prior to 
conducting the analysis I checked the required linear regression data assumptions using 
SPSS, which included: 
 Confirmation that both variables were continuous; 
 Assessment of a linear relationship between the variables; 
 Ensuring there were no significant outliers in the data; 
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 Using the Durbin-Watson statistic to determine the independence of observations; 
 Using scatterplots to confirm that the data showed homoscedasticity; 
 Using p-plots to check that the distribution of the data, as normal distribution is required 
for regression analysis.  
 
As the time to diagnosis data was not normally distributed, I used bootstrap estimation in the 
linear regression to account for this, thereby allowing for more accurate inferences to be drawn 
from the data, particularly with a small sample size. The bias corrected and accelerated 
bootstrap function in SPSS was used to estimate 95% confidence intervals, based on a 1000 
sample replication, with a p-value of <0.05 considered significant. 
 
Multivariable analysis  
Multiple regression analysis was planned yet not conducted due to limitations with the sample 
size. The analysis would have explored the influence of confounders and modifiers on 
individual predictors as identified in Chapter 5 (Table 5.2 Part b). For hypothesis A, the model 
would have included: age, gender, health literacy (engagement and understanding), 
medication use (prescription and OTC), reported GP consultations and disease stage. 
Individual comorbidities and symptoms would have been included where they were significant 
at the 20% level in the univariable analysis. The model for hypothesis B would have included: 
age, highest education level, ethnic group, living alone, deprivation and referral route. Both 
models would have explored each cancer individually and the total cohort if possible.  
 
6.3. Results 
6.3.1. Recruitment 
In total, 894 patients were discussed at Addenbrooke’s and James Cook MDT meetings 
between May 2016 and September 2017 (518 and 376 patients respectively). Of these, 321 
patients were approached for the study; 174 at Addenbrooke’s and 147 at James Cook (Table 
6.3).   
 
Table 6.3. Number of patients approached and recruited at each hospital 
Patients ADD† JCH† Combined† 
Approached 174 (54.2) 147 (45.8) 321 (100) 
Recruited 77 (60.6) 50 (39.4) 127 (100) 
Recruitment rate (%) 44.3 34.0 39.6 
†Values are n (%) unless otherwise stated. ADD = Addenbrooke’s; JCH = James Cook. 
 
Recruitment closed at the end of October 2017, to allow time for questionnaires and consent 
forms to be returned by post. 130 questionnaires were returned to the study team (127 by post, 
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3 completed by phone), a response rate of 40.4% based on the number of patients 
approached. However, three were excluded as the consent was incomplete, resulting in a total 
of 127 participants in the study (39.6% recruitment rate); 77 from Addenbrooke’s, and 50 from 
James Cook. Figure 6.7 details the monthly recruitment from each hospital. 71 (55.9%) 
participants were approached and consented to participate within four weeks of their diagnosis, 
and 109 (85.8%) consented within six weeks of diagnosis.   
 
While the recruitment rate was similar to the estimated 40% for the study, the final participant 
number was lower than the planned sample size of 200 participants. Based on the original 
sample size calculation, I had expected over 500 patients to be approached within a 12 month 
period. However, 573 (64.1%) patients discussed at the MDT meetings could not be 
approached, as they were managed at their local hospital, therefore it was only possible to 
approach 321 (35.9%) patients over an 18 month period. Figure 6.8 illustrates the total 
recruitment during the study as well as recruitment before and after updating the recruitment 
strategy: Phase 1, nine months from May 2016 - January 2017, face-to-face recruitment only; 
Phase 2, nine months from February 2017 - October 2017, face-to-face and postal recruitment. 
In Phase 1, 344 (70%) patients discussed at MDT were not approached, decreasing to 229 
(56.8%) patients in Phase 2 following the introduction of postal invitations.  
 
In Phase 2 the number of patients approached (n=174) increased by 27 patients compared to 
Phase 1 (n=147), with gender, age and cancer type of potential participants remaining 
comparable (Male 71% vs 72%; Age 60-74 50% vs 51%; Oesophageal cancer 71% vs 72%). 
The number of non-responders were similar in both phases (n=89, 60.5% vs n=102, 58.6%). 
 
57 (38.8%) participants were recruited in Phase 1, with 70 (40.2%) recruited in Phase 2, an 
increase of 13 participants between phases. Participant characteristics and disease stage 
were comparable between each phase, with a slight increase in recruitment of gastric cancers 
in Phase 2 compared to Phase 1 (n=16, 23% vs n=9, 16%). This could be attributable to the 
postal invitations as gastric cancer patients may have been managed at their local hospital 
with chemotherapy prior to surgery, therefore excluding recruitment during Phase 1. I had 
expected that the percentage of participants at a later disease stage, where surgery was not 
a treatment option, would increase in Phase 2 with the postal invitations. However, the 
percentage of participants with stage III/IV cancers was similar (50.9% Phase 1 vs 50% Phase 
2). It is possible that the patients approached in Phase 2 did include a higher proportion of 
people with stage III/IV cancers, with these patients choosing not to participate due to the 
burden of their condition. However, as stage data were not collected for non-responders, this 
cannot be verified. 
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Due to the extra administrative support at Addenbrooke’s, they sent substantially more postal 
invitations than James Cook (Table 6.4). Addenbrooke’s recruited 30 patients by post 
representing a 39.5% recruitment rate for postal invitations compared to a 47 patients (48.0%) 
recruited face-to-face. The opposite was observed at James Cook; although the data could be 
skewed by the small sample size. Seven patients were approached by post with 3 (42.9%) 
responding to the postal invitation, while 47 (33.6%) patients were recruited face-to-face. 
Overall, the combined recruitment rate across hospitals was equivalent for face-to-face or 
postal invitations (39.5% vs 39.8%). 
 
Table 6.4. Comparison of recruitment strategies 
 Face-to-face recruitment† Postal recruitment† 
Patients ADD JCH Combined ADD JCH Combined 
Approached 98 140 238 76 7 83 
Recruited 47 47 94 30 3 33 
Recruitment rate (%) 48.0 33.6 39.5 39.5 42.9 39.8 
†Values are n unless otherwise stated. ADD = Addenbrooke’s, JCH = James Cook. 
 
Comparing responders (participants and exclusions) to non-responders, there were fewer 
females (n=25, 19.4% vs n=52, 29.2%), a higher proportion of 60-74 year olds (n=79, 61.2% 
vs n=83, 46.6%) and fewer responders aged less than 60 (n=12, 9.3% vs n=33, 18.5%) (Table 
6.5). In using the Pearson’s chi-squared test, age was significantly associated with 
participation in the study (χ(2) = 8.043, p 0.018). Gender and cancer type were not significant 
(gender: χ(1) = 3.849, p 0.050; cancer type: χ(1) = 2.874, p 0.090).  
 
Table 6.5. Characteristics of responders compared to non-responders  
 Responders† Non-responders† 
Oesophageal 
(n=103) 
Gastric 
(n=26) 
Combined 
(n=129)a 
Oesophageal 
(n=127) 
Gastric 
(n=51) 
Combined 
(n=178)a 
Age 
<60 
60-74 
≥75 
 
11 (10.7) 
66 (64.1) 
26 (25.2) 
 
1 (3.8) 
13 (50.0) 
12 (46.2) 
 
12 (9.3) 
79 (61.2) 
38 (29.5) 
 
26 (20.5) 
69 (54.3) 
32 (25.2) 
 
7 (13.7) 
14 (27.5) 
30 (58.8) 
 
33 (18.5*) 
83 (46.6*) 
62 (34.8*) 
Gender       
Male 
Female 
87 (84.5) 
16 (15.5) 
17 (65.4) 
9 (34.6) 
104 (80.6) 
25 (19.4) 
94 (74.0) 
33 (26.0) 
32 (62.7) 
19 (37.3) 
126 (70.8) 
52 (29.2) 
†Values are n (%) unless otherwise stated. *Percentages subject to rounding error. 
a Missing data: 1 responder (exclusion) and 13 non-responders with unknown age/gender/cancer type 
 
Considering the incidence of oesophageal and gastric cancer by age in the UK from 2012-
2014, patients aged 60-74 were over-represented in the study and those aged less than 60, or 
75 and over were under-represented (Figure 6.9)2,3.  
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Figure 6.9. Cancer incidence by age group, UK 2012-2014 and study participants 
    
 
 
A. Oesophageal cancer 
 
 
B. Gastric cancer 
 
  
 
 
C. Oesophageal and gastric cancer  
 
 
Incidence by age group for: 
A. Oesophageal cancer cases in the UK 
2012-2014 compared to oesophageal 
cancer study participants 
 
B. Gastric cancer cases in the UK 2012-
2014 compared to gastric cancer study 
participants 
 
C. Combined oesophageal and gastric 
cancer cases in the UK 2012-2014 
compared to all study participants 
 
 
 
 
6.3.2. Time to diagnosis 
In this section I discuss the results for hypothesis A; exploring differences in time to diagnosis 
based on participant, healthcare and disease characteristics. Using data from the 
questionnaire and secondary care medical records, the pTDI could be calculated for 107 
(84.3%) participants, while the pPI and HSI could be calculated for 103 (81.1%) and 106 
(83.5%) participants respectively. The median pTDI across the cohort was 81 days (IQR 45–
137.5) with a median pPI of 21 days (IQR 2.5–59.5) and a median HSI of 33.5 days (IQR 16–
89). Intervals were calculated for all variables (Appendix 15); however, in the univariable  
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analysis only variables with two or more categories containing ≥20% (n ≥ 26) of the total cohort 
(n=127) were included. The following variables were therefore excluded from the univariable 
analysis: cancer type, gender, living alone, reported GP consultations, referral route and 
histology.  
 
I now describe the participant, healthcare and disease characteristics in turn and discuss the 
results of the univariable analysis in relation to time to diagnosis. 
 
Participant characteristics 
Participants in the study were aged between 44 and 96 years old (median age 71) and were 
predominantly male (n=102, 80.3%) (Table 6.6). There was a higher percentage of male 
oesophageal patients than gastric (n=86, 84.3% vs n=16, 64.0%), with the median age 
comparable across each cancer type (oesophageal median age 70, range 44-87; gastric 
median age 72, range 54-96). Most participants (n=99, 78%) lived with someone and 30 
(23.6%) participants lived in an area with low deprivation. 64 participants (50.4%) were 
educated to GSCE/O level or above. Ethnic group was almost entirely White (n=124, 97.6%) 
so I excluded this variable from any further analysis. This is slightly higher than the 2011 UK 
Census data for White ethnic group in the East (90.7%) and North East of England (95.3%), 
combined 92.1%426. However, as described in Chapter 2, the incidence of oesophageal cancer 
is highest in White ethnic groups, with gastric cancer also prevalent in this population.  
 
As described, I used the Mann Whitney U Test to explore if the median time to diagnosis 
differed based on age, education or deprivation (Table 6.7, Part 1), while the influence of health 
literacy was explored using linear regression with bootstrap estimation (Table 6.7, Part 2). No 
significant differences were identified for the pPI, HSI or pTDI based on participant 
characteristics. 
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Table 6.6. Participant characteristics  
 Oesophageal (n=102)† Gastric (n=25)† Combined (n=127)† 
Age, median (range) 70 (44-87) 72 (54-96) 71 (44-96) 
<60 
60-74 
≥75 
11 (10.8) 
65 (63.7) 
26 (25.5) 
1 (4.0) 
13 (52.0) 
11 (44.0) 
12 (9.4*) 
78 (61.4*) 
37 (29.1*) 
Gender    
Male 
Female 
86 (84.3) 
16 (15.7) 
16 (64.0) 
9 (36.0) 
102 (80.3) 
25 (19.7) 
Highest education levela    
None/Other 
A level/GCSE/O level 
PhD/Degree/Diploma 
41 (40.2) 
31 (30.4) 
24 (23.5) 
16 (64.0) 
6 (24.0) 
3 (12.0) 
57 (44.9) 
37 (29.1) 
27 (21.3) 
Ethnic group    
White 
Other 
100 (98.0) 
2 (2.0) 
24 (96.0) 
1 (4.0) 
124 (97.6) 
3 (2.4) 
Living aloneb    
No 
Yes 
83 (81.4) 
18 (17.6) 
16 (64.0) 
8 (32.0) 
99 (78.0) 
26 (20.5) 
Deprivation (IMD)c    
Least deprivation 
Mid-deprivation 
Most deprivation 
26 (25.5) 
36 (35.3) 
25 (24.5) 
4 (16.0) 
11 (44.0) 
7 (28.0) 
30 (23.6) 
47 (37.0) 
32 (25.2) 
Region    
East 
North East 
65 (63.7) 
37 (36.3) 
12 (48.0) 
13 (52.0) 
77 (60.6) 
50 (39.4) 
†Values are n (%) unless otherwise stated. *Percentages subject to rounding error. a-c Missing data (n participants 
based on cancer type): a 6 oesophageal; b 1 oesophageal, 1 gastric; c 15 oesophageal, 3 gastric. 
IMD = Index of Multiple Deprivation. Least deprivation = IMD quintile 1; Mid-deprivation = IMD quintiles 2 & 3; Most 
deprivation = IMD quintiles 4 & 5.  
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Healthcare characteristics 
The study questionnaire included seven comorbidities and asked if participants were suffering 
from or had suffered from any of them in the previous two years. 73 (57.5%) participants gave 
a positive indication of at least one comorbidity, with arthritis as the most commonly 
experienced (n=38, 29.9%) (Table 6.8). Almost half of the participants indicated they had taken 
prescription medication (PPIs/similar or other) for their symptoms in the previous 12 months 
(n=61, 48%) and 38 (29.9%) participants had used an OTC medicine, predominantly an 
antacid or similar (n=30, 23.6%). Most participants reported one or two consultations with their 
GP prior to diagnosis, while 21 (16.5%) reported three or more. The majority of participants 
across both cancer types were referred by their GP via the urgent two-week wait suspected 
cancer pathway (n=89, 70.1%). 
 
Table 6.8. Healthcare characteristics 
 Oesophageal (n=102)† Gastric (n=25)† Combined (n=127)† 
Comorbidities    
Arthritis 
Cancer (other than OG) 
Heart disease 
Lung disease 
Anxiety or depression 
Barrett’s or reflux disease 
Peptic ulcer 
Any of the above 
25 (24.5) 
16 (15.7) 
14 (13.7) 
11 (10.8) 
12 (11.8) 
9 (8.8) 
1 (1.0) 
56 (54.9) 
13 (52.0) 
6 (24.0) 
3 (12.0) 
2 (8.0) 
1 (4.0) 
1 (4.0) 
1 (4.0) 
17 (68.0) 
38 (29.9) 
22 (17.3) 
17 (13.4) 
13 (10.2) 
13 (10.2) 
10 (7.9) 
2 (1.6) 
73 (57.5) 
Prescription medicationa    
None 
PPI/similar 
Other 
48 (47.1) 
39 (38.2) 
9 (8.8) 
12 (48.0) 
9 (36.0) 
4 (16.0) 
60 (47.2) 
48 (37.8) 
13 (10.2) 
OTC medicationb    
None 
Antacid/similar 
Other 
63 (61.8) 
21 (20.6) 
8 (7.8) 
16 (64.0) 
9 (36.0) 
0 
79 (62.2) 
30 (23.6) 
8 (6.3) 
Reported GP consultationsc    
None 
1-2 
≥3 
6 (5.9) 
79 (77.4) 
16 (15.7) 
7 (28.0) 
12 (48.0) 
5 (20.0) 
13 (10.2) 
91 (71.7) 
21 (16.5) 
Referral routed    
Urgent (2WW) 
Routine 
Other 
73 (71.6) 
15 (14.7) 
5 (4.9) 
16 (64.0) 
3 (12.0) 
3 (12.0) 
89 (70.1) 
18 (14.2) 
8 (6.3) 
†Values are n (%) unless otherwise stated. a-d Missing data (n participants based on cancer type): a 6 oesophageal; 
b 10 oesophageal; c 1 oesophageal, 1 gastric; d 9 oesophageal, 3 gastric  
OG = oesophago-gastric; Barrett’s = Barrett’s oesophagus; PPI = proton pump inhibitor; OTC = over-the-counter; 
2WW = two-week wait suspected cancer pathway.  
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Healthcare characteristics included in the univariable analysis were arthritis as a comorbidity 
and use of prescription or OTC medication. When exploring the time to diagnosis, participants 
using prescribed PPI (or similar) medication for symptoms within 12 months of diagnosis 
experienced a longer pTDI and HSI, compared to those not using prescription medication 
(Table 6.9): 
 pTDI median = 82 days vs 64 days, U = 1,322.00, z = 2.033, p = 0.042, r = 0.21; 
 HSI median = 46.5 days vs 22.5 days, U = 1,405.00, z = 2.783, p = 0.005, r = 0.29.  
 
Caution should be taken when interpreting these findings as the effect size was small. No other 
differences were identified for the pPI, HSI or pTDI based on healthcare characteristics. SPSS 
outputs for the above results can be found in Appendix 16. 
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Disease characteristics 
73 (71.6%) of oesophageal cancer participants, and 24 (96%) of gastric cancer participants, 
were diagnosed with adenocarcinomas. 64 (50.4%) of the total cohort were confirmed with 
stage III or IV cancer prior to treatment (oesophageal n=60, 58.8%; gastric n=4, 16%) (Table 
6.10). This was lower than expected in comparison to 2014 UK data, where 73% of patients 
with a known stage were diagnosed with stage III or IV cancer (74% oesophageal, 72% 
gastric)2,3.  
 
Symptoms were primarily defined based on symptom experience from a list of 12 symptoms 
included in the questionnaire (Table 6.10); although, I also explored the first symptom 
presented to the GP (free text response), which I describe later in this section. 
 
Table 6.10. Disease characteristics 
 Oesophageal (n=102)† Gastric (n=25)† Combined (n=127)† 
Histologya    
Adenocarcinoma 
Squamous cell carcinoma 
Other 
73 (71.6) 
25 (24.5) 
3 (2.9) 
24 (96.0) 
n/a 
0 
97 (76.4) 
25 (19.7) 
3 (2.4) 
Stage (pre-treatment)b    
I/II 
III/IV 
39 (38.2) 
60 (58.8) 
20 (80.0) 
4 (16.0) 
59 (46.5) 
64 (50.4) 
Symptoms (list)    
Difficulty swallowing 66 (64.7) 8 (32.0) 74 (58.3) 
Fatigue or tiredness 52 (51.0) 20 (80.0) 72 (56.7) 
Regurgitation 52 (51.0) 10 (40.0) 62 (48.8) 
Weight loss 49 (48.0) 13 (52.0) 62 (48.8) 
Pain swallowing 55 (53.9) 4 (16.0) 59 (46.5) 
Decreased appetite 43 (42.2) 11 (44.0) 54 (42.5) 
Heartburn 40 (39.2) 12 (48.0) 52 (40.9) 
Fullness or bloating 38 (37.3) 12 (48.0) 50 (39.4) 
Upper abdominal pain 35 (34.3) 10 (40.0) 45 (35.4) 
Nausea 22 (21.6) 7 (28.0) 29 (22.8) 
Vomiting 20 (19.6) 3 (12.0) 23 (18.1) 
Vomiting blood 3 (2.9) 0 3 (2.4) 
†Values are n (%) unless otherwise stated.  
a-b Missing data (n participants based on cancer type): a1 oesophageal, 1 gastric; b 3 oesophageal, 1 gastric 
 
I collected disease stage at diagnosis and pre-treatment from the participants’ medical records, 
to compare the completeness of data at each time point. As shown in Table 6.11, the disease 
stage at diagnosis was unavailable for ten participants, with a further eight participants initially 
categorised as stage II/III as their TNM staging data were incomplete. Prior to treatment, only 
four participants had missing data, with staging complete for all other participants. 
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Table 6.11. Disease stage at diagnosis and pre-treatment 
 Oesophageal (n=102)† Gastric (n=25)† Combined (n=127)† 
Stage Diagnosis Pre-treatment Diagnosis Pre-treatment Diagnosis Pre-treatment
I/II 40 (39.2) 39 (38.3) 18 (72.0) 20 (80.0) 58 (45.7*) 59 (46.5) 
II/IIIa 6 (5.9) 0 2 (8.0) 0 8 (6.3*) 0 
III/IV 47 (46.1) 60 (58.8) 4 (16.0) 4 (16.0) 51 (40.2*) 64 (50.4) 
Missing 9 (8.8) 3 (2.9) 1 (4.0) 1 (4.0) 10 (7.9*) 4 (3.1) 
†Values are n (%). *Percentages subject to rounding error. aCombined stage where TNM staging was incomplete. 
 
In the univariable analysis I explored disease stage and most symptoms, except for vomiting 
and vomiting blood as these categories did not contain sufficient data. The pTDI was longer 
for participants experiencing nausea compared to those not experiencing this symptom (Table 
6.12 and Appendix 16):  
 Nausea (median = 122 days) vs not reported (median = 78.5 days), U = 1,127.50, z = 
2.058, p = 0.040, r = 0.21. 
 
As with the healthcare characteristics analysis, the effect size for this finding was small and 
caution should be taken when interpreting these findings, particularly as there is only one 
significant finding among many non-significant findings.  
 
I used descriptive analysis to further explore participant symptom experience from the 
questionnaire data, focusing on symptom frequency, language used to describe the trigger 
symptom, and symptom experience in relation to disease stage.  
 
Symptom frequency 
As described, general symptom experience was explored using the list of symptoms in the  
study questionnaire, which was based on a three point frequency Likert scale to determine if 
participants experienced symptoms ‘all or most of the time’ (frequently), ‘some of the time’ 
(occasionally) or ‘rarely or never’. 116 (91.3%) participants experienced at least one of the 12 
symptoms prior to their diagnosis (Table 6.13C). Of these participants, 71 (55.9%) had 
experienced at least one of the symptoms frequently, while 111 (87.4%) participants reported 
experiencing at least one symptom occasionally. Participants noticed weight loss and 
decreased appetite as the symptoms most frequently experienced (n=31, 24.4%; n=25, 
19.7%), while the most common occasional symptoms were difficulty swallowing (n=54, 
42.5%) and fatigue or tiredness (n=49, 38.6%). These were also the most common symptoms 
experienced overall (n=74, 58.3%; n=72, 56.7%).  
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When exploring symptom experience between oesophageal and gastric cancer, the most 
common symptoms reported by oesophageal participants were difficulty swallowing (n=66, 
64.7%) and pain when swallowing (n=55, 53.9%) (Table 6.13A). In comparison, gastric 
participants most commonly reported fatigue or tiredness (n=20, 80%) and weight loss (n=13, 
52%) (Table 6.13B). 
 
First symptom presented to GP  
The free-text responses relating to the first symptom(s) presented to the GP showed that the 
participants used a range of language (Figure 6.10), providing insights in to how symptoms 
may be described in consultations with healthcare providers. Multiple terms were used to 
describe difficulty swallowing, with participants also discussing a range of other symptoms from 
breathlessness to belching, acid reflux, feeling sick and pain. The symptoms reported in this 
question were important to the participants as they were seen as the ‘trigger symptom’ for 
prompting the participant to seek help. Therefore, all of these symptoms had significance to 
the participant in their discussion with the healthcare provider.  
 
Figure 6.10. Participant descriptions of the first symptom presented to the GP 
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As these trigger symptoms were reported using a free-text response, I categorised them 
according to the general list of symptoms in the questionnaire (Table 6.14, symptom (list)) in 
order to compare the data. For example, ‘trouble swallowing’, ‘difficulty swallowing’ and ‘food 
sticking’ were all categorised as ‘difficulty swallowing’. Where participants described other 
symptoms, I report these separately under ‘symptoms (free text)’ (Table 6.14). These included 
pain or discomfort (usually chest pain or unspecified), hiccups or belching, indigestion, bowel 
symptoms or other symptoms such as a cough. 
 
In Table 6.14 I compare the trigger symptom (first presented) with the reported symptom 
experience, based on the data from Table 6.13 (frequent and occasional symptoms combined). 
With most symptoms, very few participants presented the symptom to the GP, despite many 
experiencing the symptom frequently or occasionally. For example, only 9 (8.8%) oesophageal 
participants reported pain when swallowing to the GP compared to the 55 (53.9%) participants 
experiencing this symptom (Table 6.14A). Difficulty swallowing was the trigger symptom for 
most oesophageal participants (n=43, 42.2%). However, 66 (64.7%) participants reported 
experiencing this symptom prior to diagnosis, therefore 23 of these either did not report it at 
their first consultation, or experienced it as a subsequent symptom. For gastric participants, 
fatigue or tiredness was one of the most common symptoms reported by participants (n=20, 
80%) yet only 2 (8%) participants initially presented it to their GP (Table 6.14B). It was not 
possible to identify a prominent trigger symptom for gastric participants as there was little 
variation between the symptoms first presented to the GP (Table 6.14B). In exploring the 
combined symptom data (Table 6.14C), weight loss and heartburn were reported as a frequent 
or occasional symptoms experienced by 62 (48.8%) and 52 (40.9%) participants respectively. 
However, only 10 (7.9%) participants reported weight loss and 12 (9.4%) reported heartburn 
as the first symptom they told their GP about. 
 
To explore symptom experience further, I calculated the mean number of other symptoms that 
participants experienced prior to diagnosis. This demonstrates how participants often 
experience their symptoms in combination, which often evolves from experiencing ‘vague’ or 
less specific symptoms to those that are more serious and trigger help-seeking. On average 
participants experienced approximately five symptoms in addition to the trigger symptom 
(mean 5.1, SD 2.9), with a small variation between oesophageal (mean 4.7, SD 2.6) and gastric 
participants (mean 6.4, SD 3.4) (Table 6.15). Oesophageal participants experiencing nausea 
or vomiting reported the most additional symptoms (mean 7.0 and 6.8) while those with 
difficulty swallowing or bowel symptoms reported the least additional symptoms (mean 3.7 and 
3.0) (Table 6.15A). For gastric participants those with vomiting or regurgitation experienced 
the most additional symptoms (mean 9.5 and 9.0) compared to those with fatigue or tiredness, 
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bowel or other symptoms (all means 4.0) (Table 6.15B). The combined data showed similar 
results (Table 6.15C). However, with the exception of difficulty swallowing, this analysis is 
based on small numbers of participants reporting the individual trigger symptoms.   
 
Symptoms and disease stage 
When considering pre-treatment disease stage in relation to the symptoms experienced 
frequently or occasionally prior to diagnosis, participants with stage I or II cancer generally 
reported experiencing symptoms less than participants with stage III or IV cancer (Table 6.16). 
For example, when considering participants with oesophageal cancer, eight symptoms were 
reported by 40% or more of those with stage III/IV cancer, compared to three symptoms 
reported by at least 40% of those with stage I/II cancer (Table 6.16A). It was difficult to compare 
the stage data for gastric participants as there were only four participants diagnosed with stage 
III/IV cancer (Table 6.16B). The combined data is similar to that of the oesophageal participants 
(Table 6.16C). This data likely reflects the increase in symptom burden as the cancer 
progresses.   
 
Having discussed the results for hypothesis A, I now move on to discuss hypothesis B; to 
determine if health literacy differed based on symptom experience, medication use or the 
number of consultations prior to diagnosis. 
 
6.3.3. Health literacy  
The study questionnaire included two domains from the HLQ: ability to actively engage with 
healthcare providers (engagement) and understanding health information well enough to know 
what to do (understanding)266.  
 
121 participants completed the health literacy scales (96 oesophageal, 25 gastric) with a mean 
score for the total cohort of 4.18 (SD 0.29, range 1.0-5.0) for engagement and 4.28 (SD 0.34, 
range 1.0-5.0) for understanding (Table 6.17). Mean scores were slightly higher for participants 
with oesophageal cancer compared to gastric (engagement mean 4.22 vs 4.01, understanding 
mean 4.36 vs 3.95). Participants taking non-PPI prescription medication (‘other’) for their 
symptoms in the 12 months prior to diagnosis had a lower mean score for engagement and 
understanding compared to those taking PPIs or not taking medication (engagement mean 
3.71 vs 4.08 and 4.39; understanding mean 3.82 vs 4.26 and 4.44). Participants who reported 
not visiting their GP prior to diagnosis scored less for engagement and understanding than 
those who reported consulting 1-2 times or 3 or more times (engagement mean 3.92 vs 4.26 
and 4.11; understanding mean 3.79 vs 4.39 and 4.26). 
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Additional descriptive analysis identified that the mean score for engagement was slightly 
lower in participants aged less than 60 compared to those aged 60-74 or 75 and over 
(engagement mean 3.80 vs 4.26 and 4.12). In comparison, gastric participants aged 75 and 
over had a lower mean score for understanding compared to those aged 60-74 (understanding 
mean 3.66 vs 4.20). Health literacy engagement and understanding scores were comparable 
between males and females (engagement mean 4.20 vs 4.09; understanding mean 4.29 vs 
4.21). 
 
Overall the scores were higher than expected with participants rarely scoring less than 3.0 on 
either domain (engagement n=6, understanding n=4).  
 
For the univariable analysis, I used the Mann Whitney U test to explore whether health literacy 
differed based on symptom experience and medication use (Table 6.18). I had also planned 
to explore if health literacy differed based on the number of GP consultations prior to diagnosis; 
however, in the combined data there were less than 20% of participants in two of the three 
categories, so this variable had to be excluded from the analysis.  
 
Table 6.18. Health literacy based on symptom experience and medication use 
 Oesophageal and gastric cancers combined 
 Engagement† P-value Understanding† P-value 
Symptom      
Difficulty swallowing 4.22 0.691 4.33 0.274 
Fatigue or tiredness 4.08 0.357 4.15 <0.05 
Regurgitation 4.07 0.066 4.24 0.355 
Weight loss 4.07 0.446 4.19 0.330 
Pain swallowing 4.30 0.104 4.41 0.165 
Decreased appetite 4.11 0.679 4.23 0.714 
Heartburn 4.09 0.198 4.15 <0.05 
Fullness or bloating 4.18 0.670 4.23 0.108 
Upper abdominal pain 4.21 0.644 4.22 0.050 
Nausea 4.11 0.503 4.34 0.768 
Prescription medication  0.100  0.151 
None 4.39  4.44  
PPI/similar 4.08  4.26  
OTC medication  0.069  0.149 
None 4.25  4.34  
Antacid/similar 4.09  4.24  
†Mean values. PPI = proton pump inhibitor; OTC = over-the-counter 
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Health literacy understanding was lower in participants reporting fatigue/tiredness or heartburn 
than participants not reporting these symptoms. However, the effect size was small, and as 
seen in the analysis of mean number of symptoms (Table 6.15), these symptoms are not 
experienced in isolation; therefore, these results should be interpreted with caution. 
 Fatigue/tiredness reported (mean = 4.15, median = 4.00) vs not reported (mean = 4.46, 
median = 4.75), U = 1,089.00, z = -2.293, p = 0.022, r = -0.22; 
 Heartburn reported (mean = 4.15, median = 4.00) vs not reported (mean = 4.41, median 
= 4.60), U = 1,071.50, z = -2.343, p = 0.019, r = -0.23. 
 
I reported the mean and median for each category as the median is a more appropriate statistic 
for non-parametric tests; however, the HLQ output is based on mean scores of the items in 
each scale. No other differences were identified between health literacy scores and symptom 
experience or medication use, although upper abdominal pain was marginal with a p-value of 
0.050. SPSS outputs for the results above can be found in Appendix 16. 
 
6.4. Discussion 
The findings suggest that participants experienced a number of symptoms prior to diagnosis, 
yet they reported presenting very few to their GP at their initial consultation. Symptoms may 
evolve or accumulate prior to diagnosis, with a more serious trigger symptom often required to 
prompt help-seeking. Difficulty swallowing appeared to be one of these trigger symptoms for 
oesophageal participants as it was associated with a low mean number of other symptoms.   
 
Time to diagnosis 
In exploring the differences in the pPI, HSI and pTDI based on participant, healthcare and 
disease characteristics, only nausea and use of prescription PPI medication lengthened the 
time to diagnosis (pTDI and pTDI/HSI respectively). Experiencing nausea increased the pTDI 
for oesophageal and gastric cancers combined, although the effect size was small. Nausea 
was not widely reported by participants, although when it was, participants experienced an 
average of seven other symptoms. However, I was not able to adjust for the effect of multiple 
symptom combinations on time to diagnosis to fully explore the influence of these symptoms. 
Use of prescription PPI medication within the 12 months prior to diagnosis also increased the 
pTDI and HSI, again with a small effect size. However, the design of the study questionnaire 
could influence the prescription medication findings, as described in Section 6.4.2. 
 
Health literacy 
In the analysis of health literacy differences based on symptom experience, medication use 
and number of consultations, participants reporting fatigue/tiredness or heartburn had lower 
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health literacy scores for understanding than those not reporting these symptoms. However, 
as these symptoms are not experienced in isolation and it was not possible to explore symptom 
combinations in the analysis, these results should be interpreted with caution. No differences 
were identified for health literacy engagement.  
 
6.4.1. Strengths  
Recruitment 
The study successfully recruited 127 participants, with 109 (85.5%) participants consenting 
within six weeks of their diagnosis. Receiving a cancer diagnosis is a difficult time for patients, 
particularly as these cancers have poor outcomes and therefore patients can potentially be 
very unwell at diagnosis or be about to undergo intensive treatment. Despite this, the study 
achieved a recruitment rate of 39.6%, maintaining recruitment momentum across the 18-month 
period. The research teams at Addenbrooke’s and James Cook gave invaluable support, 
helping to identify and approach eligible patients. The study was successfully integrated at the 
MDT meetings and within the clinics for approaching patients face-to-face, although postal 
recruitment did require more resources.  
 
Symptoms 
Despite the small sample size, the descriptive analysis was useful in highlighting subtle 
differences in the symptom experience for patients with oesophageal cancer compared to 
gastric cancer, and identifying how participants with either cancer experienced multiple 
symptoms prior to presentation and diagnosis. I also evaluated heartburn experience, finding 
that few participants (n=11, 8.7%) reported heartburn ‘all or most of the time’, despite this being 
the primary message of the Be Clear on Cancer campaign to encourage awareness of 
oesophago-gastric symptoms: “Heartburn most days for three weeks or more? Tell your 
doctor”69. Although a further 41 (32.3%) participants in the study reported experiencing 
heartburn ‘some of the time’, the Be Clear on Cancer campaign message may not resonate 
with this group as ‘most days’ may suggest frequent rather than occasional heartburn. I have 
explored this in further detail in Chapter 7. In exploring symptoms, I assessed participants’ 
experience based on symptom frequency, rather than limiting this section to the presence or 
absence of each symptom using a yes/no response. While it was not possible to evaluate the 
significance of symptom frequencies in the univariable analysis, using this approach in a larger 
study may provide important insights in to how participants experience symptoms. 
 
Symptoms and help-seeking 
By including a free-text option in the questionnaire to determine symptoms first presented to 
the GP, it was possible to review the range of language that participants use to describe their 
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symptoms. This provides insights into how patients may communicate with GPs when help-
seeking, which I explore further in the qualitative strand of the study.  
 
The analysis also highlighted that at the point of first seeing their GP, it is possible that patients 
present fewer symptoms compared to the number they actually experience. The participants 
may have presented the symptoms to the GP yet did not record this on the questionnaire, or 
they chose to focus on the trigger symptom with the GP, rather than elaborating on other 
symptoms experienced. This could identify a need for further symptom exploration within 
primary care consultations. Alternatively, the additional symptoms may have been experienced 
following the initial consultation. This would support the requirement of ‘safety-netting’ in 
primary care; where patients are encouraged to re-consult if symptoms persist, worsen or 
additional symptoms are experienced.  
 
6.4.2. Limitations 
Sample size 
Although the study had a good recruitment rate (39.6%), the sample size of 127 participants 
was small, therefore limiting the analysis and subsequent conclusions. Across the study, 
females, younger patients, non-White ethnic groups and gastric cancers were under-
represented, with slightly fewer females and younger patients (<60 years) choosing to 
participate in the study (based on non-responder data). It was therefore not possible to conduct 
the univariable analysis for the time to diagnosis data based on these variables. With a sample 
size of less than 200 participants, it was also not possible to conduct multivariable analysis on 
the data as originally planned.  
 
The questionnaire was designed to explore differences between frequent and occasional 
symptom experience as it is known that patients are more likely to seek medical help when 
they perceive symptoms as serious, when symptoms become uncontrollable, or when they 
interfere with everyday life13,149. With the small sample size, symptom experience could not be 
fully explored, yet the descriptive analysis did highlight some differences, as described.  
 
Diagnostic intervals 
The analysis identified some issues around the definition and measurement of the intervals. In 
the questionnaire, Q3 explored the first symptom presented to the GP (trigger symptom), while 
Q5 was intended to prompt recall of earlier bodily changes or symptoms experienced. Although 
the questionnaire was tested for face validity prior to use, most participants either recorded the 
same symptom(s) and dates for each question, or later symptoms and dates in Q5. I therefore 
had to exclude the question, which impacted on the definition of the PI and TDI within the 
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study. Therefore, these intervals were re-labelled as the pPI and pTDI to identify the interval 
start date as the identification of the trigger symptom. On reflection, when using survey-based 
methods to identify the first symptom noticed, it would be more appropriate to follow the format 
of the questionnaires used in the SYMPTOM studies391-393. 
 
Questionnaire 
I identified a few limitations with the questionnaire in addition to the diagnostic interval issue 
described above. Based on Q3, where participants gave exact or estimated dates for noticing 
the trigger symptom and reporting it to the GP, dates were included in the analysis if they were 
within two years of diagnosis, and excluded if not. However, Q2 asked: “how many times in 
the past 12 months did you see your GP about your symptoms?” This question was based on 
a validated question from the 2014 National Cancer Patient Experience Survey395, with the ’12 
month’ time frame informed by previous literature66 and included to explore the period directly 
prior to the diagnosis. However, in retrospect it may have been more appropriate to increase 
this time period to ‘two years’ to reflect the exploration of the time to diagnosis within the rest 
of the study. 
 
In regard to the data collected for medication use, this may unintentionally represent 
medication taken pre- and post-referral, therefore caution should be taken when interpreting 
this data. The questionnaire asked: “In the past 12 months, did you use any medicine for your 
symptoms? – medicine given to you by your doctor / medicine you bought for yourself”. While 
the question intended to enquire about medication in the 12 months prior to referral, 
participants were sometimes given medication at the hospital following their endoscopy. This 
was before their diagnosis and therefore prior to receiving the study questionnaire. It is possible 
that participants subsequently reported this medication in the questionnaire. On reflection, the 
question could have asked: “In the 12 months before you were sent to the hospital, did you 
use any medicine for your symptoms?” 
 
When exploring comorbidities, although the analysis was based on the presence or absence 
of comorbidities (yes/no), it is possible that the ‘no’ category in the analysis includes missing 
data. This is again due to the questionnaire format as the comorbidity question was a list of 
symptoms with participants asked to tick any that apply. Where participants ticked some 
comorbidities but not others, this could feasibly be interpreted as indicating yes and no 
responses; however, where there was no response to the question, this could either represent 
no comorbidities or the participant missed or chose not to answer the question. A more 
appropriate format would have been a Yes/No tick box for each of the comorbidities. It would 
also have been appropriate to include diabetes on the comorbidity list, as patients may be 
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prescribed PPI medication in relation to it. As shown from previous research51,73,91,149,159,161, 
and described in the study, use of PPI medication has been linked to increasing the time to 
diagnosis, therefore diabetes and the associated medication use could be an important 
consideration in timely diagnosis research.  
 
Use of the HLQ 
The questionnaire data showed little variation between participants in their health literacy 
ability for engagement and understanding. The mean scores on the scales suggested that 
participants had high health literacy ability in these domains, with most participants scoring 
three or above on the scales. While the scores may accurately reflect the participant’s health 
literacy ability, it could be that the format of the questionnaire unintentionally excluded patients 
with lower health literacy, despite the option of completing it by phone. It may also be possible 
that in the weeks between referral, diagnosis and subsequently receiving the questionnaire, 
the participants were upskilled in their health literacy ability. During this period participants 
would have attended multiple healthcare appointments and received information about their 
diagnosis, so their health literacy scores for engagement and understanding information may 
reflect this period, rather than the intended pre-diagnostic period. However, it is not possible 
to determine this from the questionnaire data. Alternatively, the scales may not be very 
sensitive for detecting variation in this population. A recent population based survey in 
Denmark (n=29,473) assessed engagement and understanding using the HLQ and found that 
of participants with a long term health condition (six conditions, including cancer) those with 
cancer had fewer difficulties in these domains than participants with other conditions427. During 
the HLQ development, the ‘understanding health information’ domain was the easiest to 
complete, while the ‘appraisal of health information’ domain was reported as the hardest266. 
Inclusion of the appraisal domain may have been more sensitive for identifying differences in 
health literacy ability between participants, and would have been relevant to the study aims, 
as appraisal of health information is necessary for evaluating symptoms in the PI. 
 
6.5. Summary 
In this chapter I outlined the set-up and conduct of the POSTCARD study and the results of 
the questionnaire study, including the strengths and limitations of the research. The findings 
identified that participants experience multiple symptoms prior to diagnosis, along with subtle 
differences in symptoms between those with oesophageal and gastric cancer. A longer pTDI 
was identified for participants using prescription PPI medication or experiencing nausea, 
although the effect size was small and as there were only two significant findings in a series of 
non-significant findings, these results must be interpreted with caution. In the following chapter, 
I move on to describe the qualitative strand of the study. 
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Chapter 7: Interview study 
 
 
I designed the interview study to explore the pathways to diagnosis in further detail with a sub-
group of questionnaire respondents, focusing on symptom experience, decision-making, 
health literacy, the role of family and friends, and the participants’ experience in healthcare. 
Through the interviews I was able to consider variations and explore subtle differences in 
experiences across all participants and between age groups, gender and cancer type. 
 
In this chapter, I start by considering the use of interviews (qualitative methods) in healthcare 
research, before moving on to discuss the methods and results of the POSTCARD study 
interviews. 
 
7.1. Methods 
7.1.1. Qualitative methods in research 
Qualitative research incorporates a wide range of approaches, such as interviews, focus 
groups, observations, audio, and other visual or written data. The use of these methods can 
generate an in-depth understanding of a topic, contextualised from the participant’s 
perspective and seeking to explain behaviours, evaluate how things work or to generate new 
ideas428 (Figure 7.1).  
 
Figure 7.1. Focus of qualitative research 
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I included a qualitative strand in the POSTCARD study as the aim was to explore the time to 
diagnosis from the patient’s perspective and to understand experiences and behaviours along 
the pathway. To fully explore this topic, a qualitative aspect was essential. I chose to interview 
participants as this method is suitable for reflecting on the pathway with participants and 
understanding the time leading up to their diagnosis, while also respecting the sensitive and 
private nature of the topic. For this reason, focus groups would not have been appropriate, 
while other methods would not have allowed the opportunity to interact with the participants. 
 
7.1.2. Sampling and recruitment 
Participants were selected for interview from those responding to the study questionnaire. A 
question on the consent form asked participants to confirm their understanding that they ‘might 
be contacted about meeting and talking to the study researcher’. These participants also 
supplied a telephone number and/or email address as a means of contact.  
 
I aimed to recruit up to 40 participants for the interview study. The sample size was informed 
by the qualitative expertise of my supervisors (FW and JB), other qualitative studies exploring 
timely diagnosis of cancer144,406,429 and the guidance by Malterud et al. in relation to the 
information power of a qualitative sample267. These authors suggest that sample size is 
influenced by the information contained within the interviews, which in turn is influenced by the 
study aim, participant group (specificity), theoretical perspective, quality of the interviews 
(dialogue) and the strategy for analysis. Therefore, while a sample size is useful for guiding 
the study, the final size relies on continual evaluation of the sample’s information power 
throughout the data collection, to ensure the analysis is able to address the aim of the study.  
 
I purposively sampled participants based on cancer type, age range, gender and region. I 
sampled by cancer type to compare experiences between participants with these cancers, 
while including different regions aimed to provide social diversity in the study. Additionally, 
sampling by age and gender ensured a range of participants and therefore, experiences in the 
study, particularly as these characteristics have been associated with influencing time to 
diagnosis149,406. I used a sampling grid (Figure 7.2) to assist with participant selection, limiting 
each category to a maximum of three participants to ensure diversity. Health literacy ability 
(based on the health literacy scores from the questionnaire) was initially considered as part of 
the sampling strategy. However, on review of the data following the first couple of months of 
recruitment, it was found to be an ineffective strategy as the questionnaire scores were not 
sufficiently varied for sampling participants.  
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I contacted potential participants within two weeks of receiving their questionnaire in order to 
introduce myself, to confirm their willingness to participate in the research and to arrange the 
interview, with the participant choosing a preferred time and location. I conducted the 
interviews as soon as possible, and within 10 weeks of diagnosis where possible. Recruitment 
for interviews continued until the analysis team was satisfied that the information power of the 
sample was sufficient to address the aim of the study. 
 
Figure 7.2. Template sampling grid for interviews 
 
 
7.1.3. Ethical considerations 
Ethical considerations, as described in Chapter 6, were applicable to this interview study. It 
was also important to consider the sensitive nature of the interviews as it was possible that 
people could become upset when talking about their symptoms and steps leading to their 
cancer diagnosis. However, similar studies have identified that people benefit from relating 
their story and ‘being listened to'144,145,430. In order to ensure the wellbeing of participants, 
guidelines on participant distress were followed when distress was observed within the 
interviews (Appendix 17). 
 
Researcher safety 
As interviews were primarily arranged at the participant’s home, the University’s lone worker 
guidelines were followed to ensure safety when conducting the interviews. Prior to the interview 
I provided travel and interview details to a colleague so they were aware of interview timings, 
location and the procedures to follow if I could not be contacted following the expected time of 
completion. On the day of the interview, I contacted my colleague to confirm safe arrival at the 
location, and following the interview to confirm my departure.  
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7.1.4. Consent 
Having met the participant at the specified time and location, I re-introduced myself and gave 
an explanation of the study and what the participant could expect from our conversation. This 
included details as to why I would be recording the conversation, and confirmation that the 
participant would not be identifiable, with everything remaining confidential. I also explained 
that the audio files and subsequent transcript would be kept in accordance with data protection 
guidelines. Following any questions from the participant, I asked them to complete a study 
specific interview consent form (Appendix 18). Where a friend or family member was present, 
I also asked them to complete a consent form to permit their data to be used if they contributed 
to the interview.  
 
As with the questionnaire consent form, the interview consent form followed the standard 
template as recommended by the HRA and included: 
1. Confirmation of reading the study information sheet; 
2. Understanding of the voluntary nature of the study and the option to withdraw; 
3. Acknowledgment that they would not be identifiable and personal data would remain 
confidential; 
4. Confirmation that anonymised quotes from the interview may be published; 
5. Acceptance of the interview length (approximately 60 minutes) and permission to audio 
record the conversation; 
6. Agreement for participation in the study.  
 
Participants initialled each statement and included their name and signature on the form along 
with the date. As the person taking consent, I also completed my name, signature and date on 
the form, gave a copy to the participant and kept the original document for study records.  
 
7.1.5. Interview format 
The interviews were semi-structured and were therefore conducted using an interview topic 
guide (Appendix 18). The key areas covered in the interviews are summarised in Box 8. The 
structure of the topic guide was based on a previous qualitative study exploring symptom 
appraisal and help seeking in people recently diagnosed with melanoma407. I updated it to 
include questions relevant for patients presenting through emergency routes, as these patients 
may not have sought help in primary care before their diagnosis420. I also included prompts to 
explore health literacy, reflecting on the framework of the HLQ266 and the recent definition 
proposed by Public Health England in 2015, as described in Chapter 2 (Section 2.7.1)183.  
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The patient representatives for the study reviewed and suggested edits to the topic guide prior 
to submission for ethical approval, and I piloted the interview with one of the representatives, 
drawing on his experience of oesophageal cancer.     
 
Box 8: Key areas of the interview topic guide 
1. Introduction - study overview, data protection/confidentiality, consent, any questions 
2. Opening question - encourage participants to talk about themselves, explore daily life 
prior to the symptoms/diagnosis, familiarise with participant’s social network 
3. Symptom experience - exploration of bodily changes/symptoms and experiences, 
timeline of events, appraisal of symptoms, prior knowledge, information seeking, 
symptom management, social influence 
4. Healthcare experience - help-seeking, exploration of first consultation, subsequent 
consultations, timeline of events, relationship with healthcare provider, opinions about 
the consultation(s), thoughts and feelings about the diagnosis  
5. Interview close - confirmation of data protection/confidentiality, any questions, thanks 
 
Based on previous similar studies144,145,407,430, I expected each interview to last approximately 
60 minutes. The topic guide contained key questions that I wanted to cover in the interview as 
well as prompts to encourage participants to talk about their experiences. I started each 
interview with a general question to understand the participant’s daily life prior to the cancer 
diagnosis, and then used an open question inviting the participant to talk about their experience 
prior to diagnosis. Reflecting on the participant’s narrative I adapted how I worked through the 
topic guide, incorporating their language throughout the discussion. Using the framework of 
the MoPT140,141 I explored the participant’s perspective of the pathways to diagnosis and their 
movement between the intervals. I particularly focused on how symptoms were noticed, 
described and experienced, and also explored self-management behaviours, the role of the 
participant’s social network and their healthcare experience in both primary and secondary 
care. Throughout the interview I considered the definition of health literacy and used the 
framework of the HLQ266 to explore how health literacy may influence the pathways to 
diagnosis. Where possible I confirmed the timings of symptoms and events using a calendar 
landmarking technique. For this I produced a calendar including all days and months of 2015 
to 2017, with details of key dates, such as public holidays and school term dates to assist 
participants with recalling symptoms or events based on other significant dates throughout the 
period (Appendix 18). The calendar landmarking technique was originally applied to sociology 
and health behaviour/treatment studies as described by Glasner & van der Vaart431. It is 
intended to improve recall by prompting participants to think about particular dates within the 
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period under consideration, such as birthdays or holidays, and to relate their experiences to 
the timeline of these events. The SYMPTOM studies used the calendar landmarking technique 
in accordance with the recommendation by the Aarhus Statement for assisting recall in 
qualitative research142,144,145,430. In addition, an evaluation of the technique based on a 
secondary analysis of the SYMPTOM interviews and others conducted with patients diagnosed 
with cancer, concluded that using the technique could assist with refinement of dates along 
the pathways to diagnosis432.  
 
On completion of the interview, I thanked the participant and reconfirmed that they were 
comfortable with the topics discussed and were still happy for their data to be used in the study. 
I reiterated that all data would be kept confidential and they would not be identifiable. Following 
each interview, and once I was in a private space, I wrote notes (memos) in a journal to capture 
my thoughts and feelings, such as: 
 Rapport with the participant and how this affected the interview; 
 My role in the interview and how this may have influenced the narrative; 
 Reflecting on the impact of having a family member present in the interview; 
 Observations about the participant’s focus, as some participants were naturally 
concerned with the diagnosis and treatment options and returned to this topic 
frequently; 
 How participants responded to the questions from the topic guide, which was useful to 
inform future interviews; 
 New areas that arose in the interview and could be interesting to explore further; 
 Any difficulties that I experienced with the interview. 
These memos were useful to reflect on throughout the interview period and during the analysis.  
 
7.1.6. Data management 
All interviews were audio-taped using an encrypted recorder. I transferred consent forms to 
the study office as soon as possible following the interviews and entered the details in to the 
participant identifiable data (PID) database.  
 
Transcription 
I downloaded the audio files from the audio recorder using the software associated with the 
recorder. Having pseudonymised the files with the participant study ID, I securely uploaded 
the audio files to TypeOut, an external professional transcription service, for verbatim 
transcription.  
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On receiving the transcripts from TypeOut, I reviewed the text whilst listening to the audio to 
correct any errors and to remove references to names and places. I added non-identifiable 
participant details to the first page of each transcript to contextualise the interview including: 
region, gender, age range, cancer type, living status (living alone, with family etc.), education, 
ethnic group, health literacy scores from the questionnaire, employment status (if known), 
family history of cancer (if known), date of diagnosis and date of interview.  
 
Data storage 
Interview consent forms were stored in a secure filing cabinet in the study team office, which 
was locked overnight. The filing cabinet keys were kept in a locked and secure location, 
available only to the study team.  
 
The PID database was located on the SDHS, as described in Chapter 6. Encrypted audio files 
were labelled with the participant’s study ID and stored on the SDHS. Following this, the 
original files were deleted from the recorder. Having received and reviewed the transcripts from 
TypeOut, I imported anonymised transcripts in to NVivo 11, a data management software 
package, in preparation for the analysis. I then uploaded the original and anonymised 
transcripts to the SDHS for storage.  
 
7.1.7. Analysis 
I used thematic analysis to code the dataset and identify themes433. Thematic analysis provides 
a flexible yet rigorous approach to analysing interview data. It is used to identify and describe 
patterns (themes) across the data, which can be guided by models or frameworks. Any such 
models should be acknowledged and considered as to how they may influence the data 
collection and/or analysis. For the POSTCARD study interview analysis, the MoPT140,141 
provided a framework for exploring the intervals and understanding how participants move 
along the pathways to diagnosis. I also used the framework of the HLQ266 to evaluate the 
participants’ health literacy. In particular I reflected on how the authors of the HLQ defined 
each aspect of health literacy (Appendix 19). For example, ‘social support for health’ in the 
HLQ refers to those with high health literacy having a “social system [that] provides them with 
all the support they want or need for health”, whereas those with low health literacy are 
“completely alone and unsupported for health”. 
 
Thematic analysis focuses on the identification of themes to capture important aspects of the 
data relative to the research question. Braun & Clarke suggest that themes can be identified 
via an inductive approach, where the themes are driven by the data content, or a theoretical 
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approach, driven by a certain interest or research question433. They proposed a six phase 
approach for researchers conducting thematic analysis (Table 7.1), which I referred to while 
conducting my analysis. 
 
Table 7.1. Six phase approach for thematic analysis 
Phase Description 
1. Familiarising yourself 
with your data 
Transcribing data, reading and re-reading the data, noting down initial 
ideas. 
2. Generating initial 
codes 
Coding interesting features of the data in a systematic fashion across the 
entire data set, collating data relevant to each code. 
3. Searching for themes Collating codes into potential themes, gathering all data relevant to each 
potential theme. 
4. Reviewing themes Checking if the themes work in relation to the coded extracts (Level 1) and 
the entire data set (Level 2), generating a thematic ‘map’ of the analysis. 
5. Defining and naming 
themes 
Ongoing analysis to refine the specifics of each theme, and the overall 
story the analysis tells, generating clear definitions and names for each 
theme. 
6. Producing the report The final opportunity for analysis. Selection of vivid, compelling extract 
examples, final analysis of selected extracts, relating back to the analysis 
of the research question and literature, producing a scholarly report of the 
analysis. 
Table reproduced from Braun & Clarke, 2006433 
 
Audio files were transcribed following each interview; hence, I was able to read the transcripts 
and start the analytical process shortly after the beginning of data collection. I discussed initial 
ideas with my supervisors (FW and JB), and updated the interview topic guide based on initial 
findings. This helped to refine the questions relating to health literacy and to expand the 
exploration of symptom management strategies.  
 
I read and coded all transcripts as the interviews progressed, comparing participant 
experiences across the whole cohort and between age groups, gender and cancer type 
throughout the analysis process. I reflected on my interview memos to consider my role in the 
interviews and how my prior knowledge of factors influencing timely diagnosis of oesophageal 
and gastric cancer may influence the analysis. In recognising my position in the research 
process, I was able to take steps to minimise prior assumptions when reflecting on the 
participant’s voice. This included involving others in the analysis, with my supervisors (FW and 
JB) and the patient representatives reviewing and analysing a sub-set of transcripts. Between 
May 2016 and February 2018 I had regular meetings with my supervisors and other colleagues 
involved in the study to review the interview transcripts, discuss ideas and assist with refining 
the initial coding framework. I started by splitting the data across six coding groups: 
background, appraisal interval, help-seeking interval, diagnostic interval, post-diagnosis and 
other. Each group contained multiple codes, as illustrated in Figure 7.3A, which shows the  
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Figure 7.3. Initial and final coding frameworks 
 
NVivo coding frameworks 
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initial structure of the ‘appraisal interval’ group. As the analysis progressed, I identified, 
reviewed and refined potential codes with the study research team, including the patient 
representatives. This involved grouping similar codes together, creating new codes, and 
excluding others that did not reflect the focus of the analysis, thereby providing a structure for 
further analysis. The final coding framework contained four coding groups based around 
symptoms, health literacy, heartburn or indigestion, and the pathways to diagnosis, with fewer 
and more focused codes within each group (Figure 7.3B). Final themes and sub-themes were 
based on the discussions throughout the analysis and reflected the data across the interviews.  
 
7.2. Results 
From the 127 participants recruited to the study, 81 (63.8%) indicated on their consent form 
that they would be happy to participate in an interview. I contacted 27 participants, most within 
two weeks of receiving their questionnaire (median 9 days, IQR 6.5-16.5), or within three 
weeks of consent (median 14 days, IQR 10.5-23.5). I recruited 26 participants, as one 
requested to be contacted via email, yet did not respond to the invitation. The main reasons 
for excluding the remaining 54 participants were: 1) the participant was assigned to a sampling 
category where the maximum number of interviews had already been conducted; 2) the 
participant returned their questionnaire between July and October 2017 when recruitment for 
the qualitative part of the study had closed.  
 
I conducted 25 interviews in the homes of participants, and one interview in a private room at 
a public location. I interviewed 16 participants on a one-to-one basis, while 10 had a family 
member present for all or part of the interview; this was primarily male participants with their 
partner or adult child. I conducted most interviews within 10 weeks (70 days) of diagnosis as 
planned (median 46 days, IQR 35-64). The interview length ranged from 42 to 111 minutes, 
with most interviews lasting 60 minutes or more (median 77.5 minutes, IQR 66-89). 
 
Descriptive data 
Table 7.2 summarises the characteristics (age, gender, cancer type and region) of those who 
agreed to participate (participants and exclusions) in an interview, compared to those who 
declined on the questionnaire consent form. 
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Table 7.2. Characteristics of those agreeing to interview compared to declining 
 Agreed to participate (n=81)† Declined to participate (n=46)† 
Age, median (range) 71 (44-88) 70.5 (48-96) 
Gender   
Male 
Female 
67 (82.7) 
14 (17.3) 
35 (76.1) 
11 (23.9) 
Cancer type   
Oesophageal 
Gastric 
63 (77.8) 
18 (22.2) 
39 (84.8) 
7 (15.2) 
Region   
East 
North East 
52 (64.2) 
29 (35.8) 
25 (54.3) 
21 (45.7) 
†Values are n (%) unless otherwise stated. Missing data not included.  
Agreed to participate = interview participants and exclusions; Declined to participate = declined on consent form. 
 
The characteristics of the 26 interview participants, based on the questionnaire data, are 
presented in Table 7.3. In reviewing the purposive sampling criteria (age, gender, cancer type 
and region), the median age of interview participants was 69.5 years, with oesophageal cancer 
participants slightly younger than the gastric cancer participants (68 vs 76 years). Most 
participants (n=23) were in the 60-74 or ≥75 age groups, with only three participants aged less 
than 60 (all oesophageal). There were fewer females than males (n=8 vs 18) and 11 gastric 
cancer participants compared to 15 oesophageal. An equal number of participants were 
recruited from each region. Figure 7.4 displays the distribution of interview participants across 
the sampling grid. 
 
Figure 7.4. Sampling grid for interview study participants 
 
Numbers in the grid correspond to participant IDs 
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Table 7.3. Participant, healthcare and disease characteristics 
 Oesophageal (n=15)† Gastric (n=11)† Combined (n=26)† 
Age, median (range) 68 (55-83) 76 (61-88) 69.5 (55-88) 
<60 
60-74 
≥75 
3 (20.0) 
7 (46.7) 
5 (33.3) 
0 
5 (45.5) 
6 (54.5) 
3 (11.5) 
12 (46.2) 
11 (42.3) 
Gender    
Male 
Female 
11 (73.3) 
4 (26.7) 
7 (63.6) 
4 (36.4) 
18 (69.2) 
8 (30.8) 
Highest education levela    
None/Other 
A level/GCSE/O level 
PhD/Degree/Diploma 
8 (53.3) 
3 (20.0) 
3 (20.0) 
6 (54.5) 
3 (27.3) 
2 (18.2) 
14 (53.8) 
6 (23.1) 
5 (19.2) 
Ethnic group    
White 
Other 
15 (100.0) 
0 
11 (100.0) 
0 
26 (100.0) 
0 
Living alone    
No 
Yes 
13 (86.7) 
2 (13.3) 
7 (63.6) 
4 (36.4) 
20 (76.9) 
6 (23.1) 
Region    
East 
North East 
8 (53.3) 
7 (46.7) 
5 (45.5) 
6 (54.5) 
13 (50.0) 
13 (50.0) 
Deprivation (IMD)    
Least deprivation 
Mid-deprivation 
Most deprivation 
4 (26.7) 
6 (40.0) 
5 (33.3) 
3 (27.3*) 
5 (45.5) 
3 (27.3*) 
7 (26.9) 
11 (42.3) 
8 (30.8) 
HL, mean; SD (range)b    
Engagement 
Understanding 
4.18; 0.36 (3.0-5.0) 
4.05; 0.35 (2.6-5.0) 
4.29; 0.33 (2.6-5.0) 
4.18; 0.36 (2.2-5.0) 
4.23; 0.35 (2.6-5.0) 
4.11; 0.35 (2.2-5.0) 
Reported GP consultations    
None 
1-2 
≥3 
2 (13.3*) 
11 (73.3*) 
2 (13.3*) 
4 (36.4*) 
3 (27.3*) 
4 (36.4*) 
6 (23.1) 
14 (53.8) 
6 (23.1) 
Referral route    
Urgent  
Routine 
Other 
10 (66.7) 
4 (26.7) 
0 
6 (54.5) 
2 (18.2) 
2 (18.2) 
16 (61.5) 
6 (23.1) 
2 (7.7) 
Stage     
I/II 
III/IV 
5 (33.3*) 
10 (66.6*) 
7 (63.6) 
4 (36.4) 
12 (46.2) 
14 (53.8) 
Interval, median days (IQR)    
pPIc 31 (10.5-60) 17.5 (7.5-37.5) 32 (20.5-115.5) 
HSIc 28 (20.5-60) 55 (21.5-261.5) 17.5 (10.5-58.5) 
pTDId 82 (60-158) 157.5 (46.5-280.5) 82 (48-196) 
†Values are n (%) unless otherwise stated. *Percentages subject to rounding error. Missing data (n participants 
based on cancer type): a1 oesophageal, b1 oesophageal, c 3 oesophageal, 3 gastric, d 2 oesophageal, 3 gastric 
IMD = Index of Multiple Deprivation; Least deprivation = IMD quintile 1; Mid-deprivation = IMD quintiles 2 & 3; Most 
deprivation = IMD quintiles 4 & 5. HL = health literacy; IQR = inter-quartile range; pPI = POSTCARD patient interval, 
HSI = health system interval; pTDI = POSTCARD total diagnostic interval 
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When reviewing healthcare and disease characteristics, most participants (n=14) reported one 
or two GP consultations prior to referral, primarily via the urgent pathway (n=16). For 
oesophageal cancer, there were more participants with stage III/IV cancer than stage I/II (n=10 
vs 5), with the opposite for gastric cancer (n=4 vs 7). The median pTDI, as defined in Chapter 
6, was longer for gastric participants at 157.5 days compared to 82 days for oesophageal 
participants. Gastric participants also reported a longer HSI at 55 days compared to 28 days 
for oesophageal participants, while the pPI was shorter (17.5 days vs 31 days). 
 
During the interviews, I explored the pathways to diagnosis with participants, identifying the 
start of the PI as the first symptom noticed. This contrasts with the questionnaire data, where 
the pPI was based on noticing the first trigger symptom. As the qualitative data explores the 
first symptom(s) noticed, I refer to the intervals in the analysis as the PI, HSI and TDI, with the 
PI and TDI commencing when the participant noticed the first symptom, and the HSI starting 
with the first reported consultation. As some participants had multiple consultations (two or 
more) prior to diagnosis, the HSI includes any re-appraisal and subsequent consultations 
between the first appointment with a healthcare provider and the date of diagnosis. To 
determine approximate or exact dates of noticing symptoms and healthcare use prior to 
diagnosis, I used a timeline and calendar landmarking technique431,432 with the participants. 
Based on this data I converted estimated dates to estimated exact dates, as described in 
Section 6.2.2 and outlined in Appendix 14, to determine the PI, HSI and TDI (Table 7.4). I also 
determined the number of reported consultations based on participant recall within the 
interviews (Table 7.5).  
 
Table 7.4. Interval durations based on interview narratives 
Interval Oesophageal n Gastric n Combined n 
Single consultation       
PI 145 (77-307.5) 7 62.5 (38-102) 4 123 (45.5-154) 11 
HSI 23 (13.5-37) 7 30 (17-35) 6 28 (16-35) 13 
TDI 159 (121.5-337.5) 7 88 (60-128) 4 146 (86.5-175) 11 
Multiple consultations (≥2)      
PI 111 (71.5-226) 7 28 (15-61) 5 71.5 (25.5-158.5) 12 
HSI 118 (53.5-130) 7 236 (158-281) 5 130 (74-237.5) 12 
TDI 214.5 (176-329) 8 251 (246-309) 5 233 (200-309) 13 
All participants       
PI 134 (69-292) 14 60 (16-65) 9 74 (29.5-158.5) 23 
HSI 47 (23-118) 14 48 (30-197) 11 48 (28-118) 25 
TDI 191 (152.5-329) 15 219 (100-251) 9 195.5 (134-280) 24 
Values are median days (IQR) unless otherwise stated. PI = patient interval; HSI = health system interval; TDI = 
total diagnostic interval 
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Table 7.5. Reported consultations based on interview narratives 
Reported consultations Oesophageal (n=15)† Gastric (n=11)† Combined (n=26)† 
None 
1 
2 
≥3 
0 
7 (46.7) 
3 (20.0) 
5 (33.3) 
2 (18.2*) 
4 (36.4*) 
2 (18.2*) 
3 (27.3*) 
2 (7.7) 
11 (42.3) 
5 (19.2) 
8 (30.8) 
†Values are n (%) unless otherwise stated. *Percentages subject to rounding error. 
 
It was useful to explore this interview based data, rather than using the questionnaire based 
data, when discussing healthcare use and time to diagnosis in the interview analysis. Based 
on the interview narratives, those with a single consultation had a longer PI than HSI (median 
PI 123 days vs HSI 28 days), while the opposite was found for participants with multiple 
consultations (median PI 71.5 days vs HSI 130 days) (Table 7.4). In exploring differences 
between the cancers, participants with gastric cancer had a shorter PI than those with 
oesophageal cancer across both single and multiple consultations (median 60 days vs 134 
days). However, where multiple consultations were experienced, participants with gastric 
cancer had a much longer HSI than oesophageal participants (median 236 days vs 118 days). 
 
It was not possible to compare the interview and questionnaire data relating to number of 
consultations, the PI or the TDI (Tables 6.3–6.5), due to slightly different definitions. For 
example, in reference to the number of consultations prior to diagnosis, the questionnaire 
specifically asked about GP consultations for symptoms in the previous 12 months. In 
comparison, the interviews explored consultations with any primary care healthcare provider 
prior to diagnosis (not restricted to 12 months). Regarding the time to diagnosis data, the 
definitions of the PI and TDI differed between the interviews and the questionnaire, therefore 
it was only possible to compare the HSI. This was longer for oesophageal participants based 
on interview data compared to questionnaire data (median 47 days vs 28 days), while for 
gastric participants, it was similar (median 48 days vs 55 days).  
 
Themes 
Through coding and re-coding the data and refining the themes in collaboration with the 
analysis team, I identified the following three broad themes: 
1. Appraisal 
2. Healthcare experience 
3. Heartburn, reflux and indigestion 
 
The first two themes follow the journey along the pathways to diagnosis, focusing on how 
participants appraise and re-appraise their symptoms, along with their experience with 
healthcare providers and the healthcare system. In these themes I explore where factors may 
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influence the time to diagnosis. The third theme focuses on how people understand heartburn, 
reflux and indigestion. While this overlaps with the first two themes in relation to how people 
appraise and present these symptoms, I chose to explore the content independently of the 
pathways to diagnosis. This was to focus on and explore the meaning of these terms to 
participants and the symptoms they associate with the conditions. This is important in relation 
to community awareness campaigns using these terms, such as the use of ‘heartburn’ in the 
2015 National Be Clear on Cancer campaign for oesophago-gastric cancer69.  
 
I present each theme below. Where I use participant quotes, they are contextualised with the 
participant ID (P followed by the ID number), participant’s gender (M/F), age group (<60, 60-
74, ≥75) and cancer type (O/G). 
 
7.2.1. Appraisal  
This theme focuses on how people appraise their symptoms leading up to the first consultation 
with a healthcare provider, and how some people re-appraise symptoms following the initial 
appointment. Based on the framework of the MoPT140,141, the appraisal interval commences 
with the detection of bodily change(s) and continues until a person perceives a reason to 
discuss the symptom(s) with a healthcare provider. From this point, the help-seeking interval 
starts and continues until the first consultation. However, having perceived a reason to seek 
help, people may continue to appraise their symptoms prior to arranging an appointment 
and/or leading up to the consultation. Based on the outcome of the consultation, some people 
may return to the appraisal interval to re-appraise their symptoms before deciding to seek help 
again and re-presenting to a healthcare provider.  
 
While discussing symptoms with participants, many recalled bodily changes which they had 
not thought about at the time but that, in retrospect, could have been early symptoms of the 
cancer. In the initial appraisal stages these bodily changes were often seen as side effects of 
lifestyle or other factors, such as weight loss attributed to a change in daily routine or 
indigestion caused by eating too much. In these instances, changes were either not considered 
symptoms, or were symptoms of a benign condition and managed as such. As their appraisal 
continued, participants often started to become more aware of these initial bodily 
changes/symptoms or of new symptoms developing. This could be triggered by the symptom 
experience deviating from what a participant expected based on their previous knowledge, or 
where the symptom was overwhelming, so that it interrupted activities. These types of 
experiences prompted participants to (re)consider the symptom and in some participants, 
triggered help-seeking. Others continued to appraise their symptoms until they determined that 
the symptom was not going away, either on its own or with the help of medication, or it was 
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getting more frequent and difficult to manage. By this point, the symptom was usually impacting 
on the participant’s daily life, with family/friends often starting to notice the symptoms and 
encouraging participants to seek help. Aspects of health literacy were important throughout 
the appraisal, particularly in relation to how participants appraised their symptoms and acted 
on this to manage their health, along with the social support they had for their health.  
 
In this theme I discuss participants’ initial appraisal of bodily changes/symptoms, as well as re-
appraisal in those participants presenting more than once to a healthcare provider prior to 
diagnosis. I therefore focus on the types of experience they had, rather than when specific 
symptoms occur along the pathway. The analysis focuses on the following five sub-themes: 
 Alternative explanation 
 Unusual  
 Overwhelming 
 Persistent or worsening  
 Impact on daily life 
 
Alternative explanation 
Participants’ described how bodily changes or symptoms could be attributed to other causes 
in the initial appraisal stages, with explanations including factors such as age, work, lifestyle 
changes or other health issues. 
 
Many participants talked about weight loss, with some seemingly unconcerned despite quite a 
substantial loss of weight; for instance, one participant said, “I’d only lost a stone, I hadn’t lost 
a huge amount of weight. That’s still quite a lot, but you know, not a huge amount” (P22: M, 
60-74, G). A few participants talked about how they lost weight without trying to and only 
noticed it when they had lost a large amount. However, they often still saw the weight loss as 
a positive thing despite the fact that they were not trying to lose weight. This was particularly 
evident when it made them feel better about their appearance, as these participants described. 
 
“[Daughter] said, ‘Oh look at that lovely jumper, Mum, try it on.’ I said, ‘That won’t 
fit me, I’m about a size 18 to 20.’…Well, do you know what, I couldn’t believe it, I 
looked at myself in the mirror and it didn’t look like me, I was so slim, and this 12 
to 14 jumper fit me absolutely perfect. So that shows you how much weight I’ve 
been losing without my even realising I was losing it. And altogether I think now I 
must have lost about two stone without even realising.” (P02: F, ≥75, O) 
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“So, I had lost, effectively, nearly a stone. I still didn’t think nowt of it, because 11 
stone for my height and age, if you like, is well in the BMI level and everything else.  
So, I never thought nowt of it. I just thought, ‘Oh yes, that’s good.’  I wanted to lose 
a bit of excess tummy.” (P25: M, 60-74, G) 
 
Other participants did notice and consider their weight loss but viewed it as a natural outcome 
to a change in lifestyle, such as this male participant whose daily routine altered following 
retirement: “I wasn’t eating as much and I was exercising more, it seemed a perfectly natural 
outcome” (P17: M, 60-74, O). Tiredness was another symptom that participants often found 
alternative explanations for, such as these participants who thought it related to their age 
and/or work.  
 
“Yeah, I was, again, you’re sort of over 60 and you’re doing a job like that, and 
you’re thinking, ‘Well, I’m getting older now, so I’m bound to be feeling a bit more 
tired.’ But, yes, thinking back, I did used to fall asleep perhaps, in the evenings 
more, if I had been working in the morning.” (P22: M, 60-74, G) 
 
“It was just the tiredness really and even that I thought I was just putting down to 
normal working.” (P07: M, 60-74, O) 
 
While participants were able to find alternative explanations for weight loss and tiredness, they 
also used prior knowledge and experience to explain other symptoms. This reflected on their 
health literacy skills in relation to their ability to appraise health information and feel confident 
in making decisions based on their knowledge. A couple of participants attributed their 
symptoms to side effects of medicinal products they were taking. One male participant, 
diagnosed with gastric cancer, had a persistent cough over the winter when many other people 
also had similar symptoms. He therefore thought he had a winter cough like everyone else; 
hence, he took cough sweets to alleviate his symptoms. When he subsequently noticed that 
his stools were dark, he assumed that it was an effect of the liquorice in the cough sweets. 
However, it was later found that he had a GI bleed. 
 
“My stools were dark, but I’ve been taking Jakemans cough sweets for a month, 
which are liquorice. So I thought nothing of it because when you have beetroot and 
you go to the toilet, you think, ‘Oh my god, I’m bleeding,’ and it goes away. Well, I 
thought the same with the sweets. I thought, ‘I’m eating black cough sweets, so, 
naturally, my stools are going to be dark.’” (P19: M, 60-74, G) 
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Another participant was trying newly prescribed pain medication for a different condition and 
he thought that his swallowing difficulties might have been a side effect from the tablets. This 
was based on previously experiencing various side effects from other medication.  
 
“I did wonder if it was the pain tablets I was trying before and whether they’d 
affected that and I did have a little trouble taking some of those tablets and I was 
getting side effects and I did wonder if it was them.” (P09: M, 60-74, O) 
 
Many other participants experienced difficulty swallowing, with some initially attributing it to 
their eating habits. One participant was experimenting with a new diet; therefore, when he 
started to notice his difficulties, he thought it was connected with the change in his diet. 
 
“I just noticed that I was having trouble getting food to go down my oesophagus 
basically; I hadn’t really noticed that before and I noticed that initially for the first 
couple of weeks I kind of put it aside as being slightly odd; I was doing the 5 + 2 
dieting so I thought maybe it was some peculiar effect of 5 + 2 dieting.”  
(P06: M, <60, O) 
 
This participant was not concerned by the difficulty and later said, “I hadn’t actually bothered 
to think, ‘Why can’t I swallow food?’ I just kind of accepted it”. Another male participant initially 
attributed his difficulty swallowing to the way he was eating. “It felt as though, not it was coming 
back on me but it just wouldn’t go down. I would probably have a lot of wind and burping and 
stuff like that and I thought it probably is me the way I’m eating” (P20: M, 60-74, O). He also 
described how the experience was infrequent, and although he considered the possibility of 
seeking advice for the symptom, the intermittent nature of the symptom meant there were 
times when it was not at the forefront of his mind: “It’s alright yesterday, alright today, I won’t 
bother now, forget about it and then the next time you get it you think, ‘I should really do 
something about it.’ And you just kept going off the boil sort of thing.”  
 
Other participants described a similar appraisal of other intermittent symptoms including one 
female participant who talked about her loss of appetite and a male participant referring to the 
stomach pain he experienced occasionally. For these participants, the occasional nature of the 
symptoms meant it was not something to cause concern.  
 
“I said, ‘Oh I’ll be fine, it’s just one of them things, it comes and goes’ which it did, 
it wasn’t all the time, you know, sometimes I found some days I could eat more 
than I could another day.” (P03: F, 60-74, O) 
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“The stomach pain never bothered me really, it was never constant.”  
(P15: M, ≥75, G) 
 
Likewise, indigestion was often occasional in nature, with a few participants describing how 
they did not consider it anything to be concerned about. This perspective was usually based 
on participants believing it to be something that everyone experiences at some point. 
 
“Yeah, just that, a bit of indigestion, if you will, nothing drastic, more indigestion 
than anything, and I didn’t bother about it – no reason.” (P11: M, 60-74, O) 
 
“Bother doesn’t come into it, it didn’t bother me – everybody has indigestion so why 
should me having indigestion cause a bother? It’s just me having indigestion just 
like everybody else has indigestion.” (P17: M, 60-74, O) 
 
Where participants were either not concerned by symptoms or had evaluated them and 
assigned a benign cause, help-seeking was not considered, as the participant did not perceive 
a reason to seek help. The appraisal interval was therefore lengthened, as participants were 
subsequently required to either re-consider their symptoms or evaluate new ones as they 
occurred. In this situation, the participant(s) may continue to find alternative explanations, or 
the bodily change/symptom(s) may prompt them to consider the possibility of seeking help. 
This occurred for some participants where their symptom experience was unusual; hence, I 
turn to consider this in the next sub-theme.  
 
Unusual 
Participants would sometimes describe their experiences in relation to their unusual nature, 
where there was a deviation from what the participant classed as normal. The perception of 
normal was either focused on what the participant considered normal for themselves or based 
on a general understanding of how certain symptoms should be experienced. I discuss these 
perceptions below.  
 
Participants varied in what they considered ‘normal’. For example, while some participants 
were not concerned by their weight loss, or had an explanation for it (as described previously), 
others did find their weight loss unusual. One female participant compared her experience with 
that of her sister following a family holiday together, saying: “When we came back from 
[holiday] my sister had put on 3lb and I had lost 2” (P14: F, 60-74, O). She felt it odd for them 
to be on the same holiday, undertaking the same activities and yet she lost weight while her 
sister had gained weight. Another participant, with gastric cancer, noticed his weight loss  
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because it affected his perception of his physique. In this way, the weight loss was unusual 
because he was losing muscle, which he did not want to lose. 
 
“I noticed it off my muscles. Again, because I’ve always been, I’ve always had quite 
strong legs, because I’ve always exercised…I started to notice that my legs were 
getting thinner, and I just thought, ‘That’s strange.’ Then my arms…It was those 
areas more than anything, my arms and legs, that I noticed I was starting to lose 
muscle content.” (P22: M, 60-74, G) 
 
This type of deviation from normal physical state was also experienced by another male 
participant in relation to his bowel movements, as it had changed from his normal routine. He 
explained, “well, I used to be able to set my watch by it normally, you know, and then it was 
just all over and sometimes three or four times a day and just a different consistency and stuff 
like that” (P07: M, 60-74, O). He was very aware of what he considered to be normal; thus, 
when this changed he was able to monitor the change and consider seeking help, which he 
subsequently did.  
 
Some participants also noticed they were reducing their portions or discarding part of their 
meal due to their lack of appetite, which was unusual for them. “I also noticed that I wasn’t 
eating as much, I couldn’t eat as bigger plateful of food” (P22: M, 60-74, G). While decreased 
appetite was a symptom primarily described by gastric participants, problems with swallowing 
were mentioned more often by those with oesophageal cancer, generally in relation to difficulty 
swallowing or food getting stuck (Table 7.6). While some participants had not been concerned 
by swallowing difficulties, most did recognise this as an unusual thing to experience. However, 
only a couple of participants were prompted to seek help. One of these participants was a male 
diagnosed with oesophageal cancer who vividly described what the difficulty in swallowing felt 
like.  
 
“I just felt it go all the way down from top to bottom, if that makes any sense, it just 
felt...You don’t normally feel the food go down, it just goes down, and this time I 
felt it go all the way down quite sharpish.” (P11: M, 60-74, O) 
 
By focusing on how it made him feel, he was able to recognise that something could be wrong. 
However, other participants tended to focus on managing or overcoming the symptom to 
continue as they were, such as this participant who said, “I got a little bit of food stuck there 
so, you know, I’d just have a little cough and then I’d eat the rest” (P02: F, ≥75, O). 
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While some participants were not concerned by indigestion, seeing it as a normal thing to 
experience, a couple of participants classed it as an unusual symptom. This recognition was 
based on it being a new experience for them, such as this male participant who said, “I started 
to get indigestion which I have never had before in my life” (P16: M, 60-74, G). For these 
participants, the indigestion, combined with other symptoms, was a reason to consider help-
seeking. 
 
Table 7.6. Descriptions of swallowing problems 
Category Illustrative quotes 
Difficulty 
swallowing 
“Not all the time and it was very far and few between but I had noticed that if I was 
having something like chicken for example and it was fairly dry, so it wasn’t in a sauce, 
I had problems actually swallowing it.” (P05: F, 60-74, G) 
“I’d had a little trouble swallowing, little bit of irritation.” (P09: M, 60-74, O) 
“It just felt as though it wasn’t going down.” (P20: M, 60-74, O) 
Food 
sticking 
“I thought there was something stuck maybe, cos it felt like there was something stuck 
in your throat.” (P01: M, <60, O) 
“I think, ‘God, I can’t get this food down, it’s stuck there and I can’t get it down.’ And I 
can’t get it back up and I can’t get it down, you know.” (P02: F, ≥75, O) 
“Oh it felt like you were going to choke and you could feel it sticking and rising.”
(P03: F, 60-74, O) 
“It was just like when I was eating it was sticking, the food.” (P04: M, <60, O) 
“So, it wasn’t so much swallowing, it felt very much, I could feel food getting stuck in 
my oesophagus.” (P06: M, <60, O) 
“I had to force it down a couple of times and you think, you know, it did get quite bad 
a couple of times you know is it going to get down or is it going to get stuck.” 
(P09: M, 60-74, O)  
“I was eating my chips and I’d suddenly feel, oh blooming heck, I can't swallow this, 
trying to swallow it, you know. And I felt as if it was getting stuck down here.” 
(P24: M, ≥75, G) 
 
Many participants also experienced sickness prior to diagnosis. This was a symptom that 
participants, mainly those diagnosed with oesophageal cancer, found unusual based on how 
they experienced it, rather than the presence of the symptom in itself. Participants tended to 
describe the unusual consistency or appearance of what they brought up, often likening it to 
other bodily fluids such as spit or phlegm (Table 7.7). Many also commented on the quantity 
of fluid that came up, with one man saying that he must have “coughed up over a pint of the 
stuff” over the last few months and describing how at times it was difficult to get out of his 
throat. “I had to put my fingers in my mouth and get hold of it and drag it out…I was amazed 
by it; it could be 6 inches long sometimes” (P12: M, ≥75, O). This experience of sickness was 
unusual, because as one man said: “It weren’t a normal sick. To me, sick, its contents of your 
stomach innit? What we call a ‘pavement pizza’ but it weren’t like that” (P01: M, <60, O).  
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Based on the unusual nature of the experience, participants found it difficult to find an 
explanation for it, therefore prompting them to consider the possibility of seeking advice. A 
couple of participants acted on this, with one contacting his emergency doctor because as he 
said, “I didn’t know what the devil it was” (P18: M, ≥75, O). 
 
Table 7.7. Descriptions of sickness 
Category Illustrative quotes 
Consistency “It wasn’t so much the meat it was just like thick water, like wallpaper paste.” 
(P04: M, <60, O) 
“I mean it used to be that thick at times I couldn’t get it out of my throat, I had to put 
my fingers in my mouth and get hold of it and drag it out.” (P12: M, ≥75, O)  
“That was like all stringy stuff, you know. Clear yeah. But you know there seemed 
yards and yards of it coming out.” (P13: F, ≥75, O) 
“Very quickly turning into not being able to eat or hardly drink without quite dramatic 
vomiting which was primarily just stringy goo.” (P17: M, 60-74, O) 
“It’s this gooey phlegmy type thing that's almost elastic, it sort of stretches from my 
mouth into the toilet, if you know what I mean. It's odd stuff and it's obviously what the 
stomach produces, I think.” (P18: M, ≥75, O) 
Other bodily 
fluids 
“It was just like clear phlegm, just really weird, cos it was just clear; no food in it or 
anything.” (P01: M, <60, O) 
“It was just this froth, like an enormous amount of spit.” (P08: M, ≥75, O) 
“I’ve been getting a lot of phlegm coming in up my stomach, thick phlegm and you 
know when that happens you tend to gag a lot to try and bring it up and I think I might 
have strained my throat myself by getting shot of all that phlegm that’s coming up.” 
(P12: M, ≥75, O)  
“We sat waiting for this meal and then all of a sudden without any warning I sort of 
thought, well like spit in my mouth and I couldn’t hold it in my mouth, so I got a hankie 
and went to the toilet, my daughter come with me, and it just kept coming and that 
was sort of slimy you know. And I’d never had nothing like that before.” 
(P13: F, ≥75, O) 
“There wasn’t any food to vomit really it was just like bile.” (P17: M, 60-74, O) 
“I had a lot of, well, I call it phlegm, but it wasn’t. It was very, very white and very clear, 
and with a lot of bubbles in it.” (P25: M, 60-74, G) 
 
An experience was recognised as unusual when it deviated from what the participant(s) 
perceived as normal, based on their beliefs of what they considered ‘normal’ to be. Participants 
reacted to the experiences differently, with some prompted to seek help while others continued 
to monitor and appraise their symptoms. Where symptoms became overwhelming, were 
persistent or worsened, participants increasingly recognised them as possible ‘symptoms of 
something’ rather than side effects of lifestyle or something else. While most did not link their 
symptom(s) to cancer, the nature of the symptom(s) triggered many participants to seek help. 
I consider the impact of overwhelming or persistent/worsening symptoms below. 
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Overwhelming  
Participants would sometimes talk about intense symptoms that would cause them to stop 
what they were doing and acknowledge or manage the symptom. One female participant 
described this in terms of “that overwhelming feeling” (P05: F, 60-74, G), which reflected what 
other participants were saying about their symptoms. Pain and sickness were symptoms that 
participants found particularly overwhelming, usually because of the intensity of the pain or the 
shock of suddenly being sick. Participants’ descriptions of pain ranged from mild discomfort 
through to severe pain. Where participants talked about severe pain they had experienced, it 
was often recalled in combination with the emotional reaction that the participant had felt at the 
time. One participant remembered the pain she had felt one day whilst at her son’s home: 
“He’d made me a lovely meal and I was set to enjoy this meal and I sat down and I had three 
mouthfuls and I got such a pain” (P02: F, ≥75, O). It was the first time she had experienced 
pain when eating and the memory of it was so vivid that when she continued to describe the 
experience she said, “to tell you the truth, it made me cry, you know, made me feel so horrible 
it just made me cry”. Even though this experience had been a few months prior to the interview, 
she still recalled her reaction and feelings to the event, demonstrating the intensity of what she 
had experienced.  
 
Another participant described his painful experience in a similar way. Unlike the female 
participant, his pain had gradually been getting worse yet he said, “I was controlling that 
pain…by taking Ibuprofen and that was fine” (P17: M, 60-74, O). However, he recalled one 
particular occasion when he attempted to eat something, which resulted in a pain more intense 
than what he had been experiencing to date: “I swallowed it and it was initially fine and then it 
wasn’t fine and I was just in absolute agony for half an hour, doubled over in agony, my tears 
were pouring out of my eyes because I felt so much pain, it even feels painful just talking about 
it.” As with the previous participant, he had a strong emotional reaction to the intensity of the 
pain and could still feel and recall his reaction a few months after it happened.  
 
With both of these participants, as with others experiencing intense pain, the painful 
experience was the trigger for ultimately seeking help. Sickness could also be quite shocking 
for participants based on its uncontrollable or sudden nature, making them consider the 
possibility that something was not right.  
 
“I had this overwhelming feeling of sickness and I thought, ‘I’m gonna be sick,’ and 
I was actually sick, which shocked me cos it just came out of the blue, and that was 
the very first symptom that I had.” (P05: F, 60-74, G) 
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As described previously, many participants commented on the unusual consistency or 
appearance when they were sick; although, some participants continued to manage this 
symptom rather than seeking help. However, if the participant found themselves in a situation 
where they either could not manage it, or could not do so in a discrete manner, it became a 
problem. This situation was described by this male participant who was embarrassed when he 
was sick in a public place.  
 
“This one day I had a steak and chips and I’d had a bite of steak and I was in [Pub] 
and it all just came up….it was a bit embarrassing…just like you couldn’t stop it, it 
was just like airlock, and up it came. I grabbed a tissue and off I went to the toilet 
with it.” (P04: M, <60, O) 
 
This participant had been experiencing difficulty swallowing for many months, describing how 
the “food used to stick”. He had also heard the Be Clear on Oesophago-gastric Cancer radio 
campaign69, which he described in the interview, stating: “That’s all it says really, ‘Do you ever 
get: food is sticking, food is sticking, food is sticking, food is sticking?’ just repeated a few 
times, that was basically it.” However, it was the sickness at the pub that encouraged him to 
think about his symptoms and decide to consult a GP. “I heard the advert and I took no notice 
of it until that day when I thought, ‘Yeah, food’s sticking; I’ll have to go and see about this.’” 
Despite hearing the radio campaign, this participant did not acknowledge the cancer related 
aspect of the campaign and thus did not consider oesophageal or gastric cancer as a potential 
cause of his symptoms. Other participants also reflected on their limited knowledge of these 
cancers with one male participant saying, “I didn’t know much about stomach cancer” (P22: M, 
60-74, G), while another said “I’ve never heard of it, I’ve never heard of the oesophagus even” 
(P01: M, <60, O). 
 
Persistent or worsening 
Many participants identified that their symptoms persisted or worsened prior to their diagnosis. 
This was either in the initial appraisal stages, prior to seeking help, or when a participant was 
re-appraising symptoms following a consultation in primary or secondary care. Participants 
may have thought about the symptoms previously, recognising them as unusual, or finding an 
alternative explanation for them, either by themselves or based on the advice of a healthcare 
provider. I will discuss both scenarios in this sub-theme, focusing on how participants 
appraised and managed persistent or worsening symptoms. 
 
From the language participants used, I identified persistent symptoms as those that occurred 
over a period of time, either intermittently or consistently without getting better. Worsening  
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symptoms were those that increased in frequency and/or intensity, from when they were first 
noticed. Difficulty swallowing was one of the main symptoms that either did not improve or got 
worse. The participant mentioned previously, who described how he had not given much 
thought as to why he could not swallow, subsequently realised that the issue was not getting 
better. When he also started to experience painful indigestion at night, he felt he should see a 
GP.  
 
“Clearly it wasn’t going away and was although not getting you know rapidly worse, 
clearly wasn’t getting any better and probably was getting worse…so I had had 
some pain as well…there were a couple of nights where I woke up with really 
actually very painful indigestion. So actually what made me go to the GP was…1) 
it hadn’t gone away, and 2) I woke up with this painful indigestion one night, which 
made me think.” (P06: M, <60, O) 
 
Another participant had consulted his GP about his difficulty swallowing and was being 
investigated for potential kidney stones, but during that time his symptoms got worse to the 
point where he could no longer eat or drink. It was at this point that he went back to his GP. 
“Yeah, when things were starting to get worse, a lot worse, and then as I say, that day when I 
couldn’t drink the coffee I thought, ‘That’s it, I’ve had enough. I can’t carry on any longer really’” 
(P01: M, <60, O).  
 
Many participants described how their symptoms became more noticeable to them within their 
daily lives as the symptoms persisted or worsened. A few participants described how they got 
‘fed up’ with the symptoms, prompting them to seek help, such as this participant who said: “I 
kept getting diarrhoea and then, well, get constipated then I’d get diarrhoea and so it went on 
and so in the end I went to the doctors because I was getting fed up with it” (P10: F, ≥75, G). 
Another participant said, “I just got fed up with the pain in my stomach” (P12: M, ≥75, O). 
Others described how symptoms such as pain or sickness increased in frequency, which 
started to concern them. 
 
“So it was more, you know, what triggered the decision to go to see the GP was 
more frequency, greater frequency and a greater level of discomfort, sort of said to 
me, ‘This is something that needs to be looked at.’” (P17: M, 60-74, O) 
 
“Just the period of time between each bout [of sickness]. It was happening more 
often so...and not being able to determine why, that were a bit of a...bit worrying.” 
(P18: M, ≥75, O) 
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For one female participant diagnosed with gastric cancer, pain and sickness became almost 
permanent for her. She sought help following a holiday where she described how her stomach 
was “very, very bad, it didn’t go away, it was almost permanent, the sickness got worse and I 
was being sick quite a lot” (P05: F, 60-74, G). Another participant gradually experienced loss 
of appetite, getting to the point where she did not want to eat anything. “The last three or four 
months have been the worst…as regards eating and not wanting food and, you know, the feel, 
the really fullness feeling. That’s when I’ve noticed it more than ever” (P03: F, 60-74, O).  
 
Impact on daily life 
As symptoms increased in frequency and/or intensity, or where a symptom was overwhelming, 
participants found that their daily life was affected and people around them were able to notice 
the symptoms. A male participant diagnosed with oesophageal cancer found that throughout 
the day he would frequently and urgently needed to relieve his bowels, which could occur at 
inconvenient times such as when he was out walking his dog.  
 
“I was getting caught short having to go to the toilet for a number two, and I would 
be out walking with [dog] and all of a sudden I could feel it coming on and I would 
think, ‘Oh no,’ and I would have to dive into the woods and hedge backs and 
everywhere.” (P12: M, ≥75, O) 
 
While he was never in the presence of other people when this happened, the experience of 
not being able to control his symptoms left him feeling “ashamed”, “embarrassed” and 
“disgusted”.  
 
A few participants, mainly those with gastric cancer, described how their tiredness and lack of 
energy affected them, with two participants getting to the stage where they had great difficulty 
in general activities such climbing stairs. This lack of energy was later found to be caused by 
loss of blood, from which both participants were hospitalised. 
 
“Sunday morning, I’m sitting in here, [wife] asked me to go and do something, and 
I couldn’t do it. I couldn’t go up the stairs. I got to the top of the stairs and I couldn’t 
breathe.” (P19: M, 60-74, G) 
 
“I started to lose strength. I had no energy, I just couldn’t do anything. I just felt I 
could hardly walk upstairs, I had no energy at all.” (P24: M, ≥75, G) 
 
 
Enjoyment of food, drink and social activities was also negatively affected, usually where 
participants experienced difficulty or pain when swallowing; this participant, for instance, could 
no longer enjoy his Christmas tradition.  
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“I do have this little passion at Christmas, and only Christmas, for nuts, so I would 
have Brazils, all the nuts you get, simple as that and that was hurting, really was 
hurting like going down.” (P20: M, 60-74, O) 
 
Another described how he “couldn’t even have a good old drink of water or milk, cos I love 
milk, I can’t even drink milk…I can’t keep it down” (P01: M, <60, O). This participant also 
commented on how his symptoms affected his ability to socialise, saying: “I had to come home 
from the pub there because of the pain – that’s bad”. Other participants also started to notice 
their symptoms during social occasions, which had the effect of focusing their attention on the 
symptom. “Boxing Day we went to friends for the day and we had a large lunch and I was 
unable to finish that” (P16: M, 60-74, G).  
 
Social impact 
Where symptoms had become noticeable to participants in social situations, most described 
how friends, family or colleagues also started to notice and comment on their symptoms. This 
included symptoms such as pain or belching, along with physical and behavioural differences 
including weight loss and changes to eating habits (Table 7.8).  
 
Where symptoms were noticed, people often expressed concern or encouraged participants 
to seek help or re-present to their GP following their previous consultation(s). 
 
“My wife said, ‘Don’t you think you should go and see your doctor just to get things 
checked out?’ I said, ‘Yeah it’s probably a good idea,’ and I slept on it. In the 
morning she said, ‘Are you going to or not?’ I went, ‘No, no, I don’t think it’s that 
important.’ And she said, ‘Are you sure?’ I said, ‘Actually, yeah, probably not a bad 
idea,’ so I made an appointment, it was like that.” (P17: M, 60-74, O) 
 
“Of course my family were sort of saying, ‘Please go back and see the GP.’”  
(P05: F, 60-74, G) 
 
While some participants acknowledged and acted on the advice of family or friends, a few were 
deterred by their concern or fear of finding out what was wrong. These participants had 
considered the possibility of cancer, whereas many said this was not something they had 
considered.  
 
“Yeah, and my son; they were all having a go at me about it. My friends over the 
pub, ‘You need to go and get it sorted out don’t you? You need to know what it is.’ 
I’m thinking, ‘Do I? Do I really?’ In the back of my head I weren’t sure whether it 
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was something sinister or not but I had half an inkling that it weren’t something 
good.” (P01: M, <60, O) 
 
Table 7.8. Noticeable symptoms or changes 
Category Illustrative quotes 
Symptoms “I’d get my food stuck and then I used to have a little cough. My son noticed it, ‘There 
she goes again with that little cough.’” (P02: F, ≥75, O) 
 
“So [son] had a big concern because obviously he could see me in pain and he was 
seeing how sick I was and by this time I was being sick quite a lot.”  
(P05: F, 60-74, G) 
 
“My wife used to say, ‘I noticed your face was exhibiting a degree of discomfort when 
you’re swallowing.’ I said, ‘Yeah, just now and then.’” (P17: M, 60-74, O) 
 
“I tell you what I noticed, it wasn’t the belching, I noticed that my mam kept going ‘I 
can’t clear my throat’, and I’d read about that somewhere, that the stomach acid when 
you’re lying flat on the night, some people had said that there was their 
symptoms…they couldn’t clear it, because I thought that’s getting on my nerves, my 
mam kept doing that.” (Daughter of P23: F, ≥75, G) 
 
Physical 
changes 
“Must have been about June/July time because I went on the river with [sister] and her 
husband on a long boat, she said, ‘Oh you’re looking well, you’ve lost a bit weight.’ 
And then we met up again in the October for my brother’s birthday, a couple of days 
in London she said, ‘You’re losing weight.’” (P17: M, 60-74, O) 
 
“My daughter knew I wasn’t well from Christmas when she was home, but I said, ‘It’s 
probably nothing,’ but she was a bit wary, because I didn’t look right, because I’m 
normally rosy cheeked and bubbly and fat and happy, and I wasn’t feeling that at all.”  
(P19: M, 60-74, G) 
 
“Apart from as I said when I first started feeling dead weak obviously she noticed that.”  
(P24: M, ≥75, G) 
 
“On Boxing Day of last year, we went to see our granddaughter who hadn’t seen us 
for quite a while…and she said to me, ‘You seem to have lost some weight, grandad.’” 
(P25: M, 60-74, G) 
 
Behavioural 
changes 
“They were noticing that things weren’t right with me, the daughters, you know, ‘I can’t 
eat that, I can’t eat that’ whereas before I could eat anything.” (P02: F, ≥75, O) 
 
“People at work said that they noticed when I came back from my holiday in June that 
I wasn’t my normal self they put it, and my daughter kept asking me if there was 
something wrong. She kept saying that I wasn’t my normal self, but then I was getting 
cross with her because I was saying, ‘Well you’re making me grumpy because you’re 
asking me what’s wrong.’” (P14: F, 60-74, O) 
 
“I did have one of the regurgitation issues while [daughter] was here, she didn’t see 
me, but she could see that I hadn’t eaten my … she actually mentioned it to my wife 
that I hadn’t eaten the full meal.” (P25: M, 60-74, G) 
 
One participant told her husband to “stop worrying” when he told her to go to the doctors. 
However, throughout the interview she expressed regret at not going sooner but attributed it 
to her fear of having cancer confirmed: “As I say, a lot of it was my own fault. I should have 
gone sooner than I did but like I say, you know, it’s fear isn’t it, it’s just fear because I had a 
good idea what they were going to tell me before I even had the camera down” (P03: F, 60-
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74, O). She was finally prompted to see a doctor on the insistence of a nurse at the clinic she 
regularly attended for monitoring her diabetes.  
 
“I mean really it’s thanks to [Nurse], her insistence that I went to the doctors or like 
I say I would have just have carried on and I wouldn’t have gone…She said, ‘I won’t 
rest if you don’t go see the doctor’ and I thought, ‘Well, I’d better do it.’”  
(P03: F, 60-74, O) 
 
Another participant also described how she did not want to worry her family with her own 
concerns, saying, “I just tried to push it to the back of my mind I suppose and think I was being 
silly” (P14: F, 60-74, O). She therefore tried to dismiss their concerns when her family voiced 
them, and only went back to see her GP when a colleague encouraged her to. 
 
“If it hadn’t been for [colleague]…saying to me, ‘you know your own body, you know 
there’s something wrong, you’ve got to fight for it’, I probably would have just come 
away and next thing…maybe it would have been too late.” (P14: F, 60-74, O) 
 
A few participants, mainly those aged 75 and above, mentioned having limited social support 
within their community or from family, where they lived further away. 
 
“I went by myself, you know, [family] didn’t tell me to go again, I mean, I just make 
my own decisions and I go and if I think I need to I’ll tell them afterwards but I don’t 
always tell them beforehand.” (P10: F, ≥75, G) 
 
“When I first moved here I sort of knew nearly everybody in the village, but now…I 
don’t know anybody; perhaps I’ll have 20 people walk by here in the day and I don’t 
know any of them.” (P13: F, ≥75, O) 
 
These two participants had multiple consultations and an appraisal/re-appraisal interval of 
approximately eight months. Where support was available, participants talked about the 
involvement of others in their health and care, such as children accompanying them to their 
appointments. One participant described how her daughter “goes everywhere I go and she 
writes everything down...and she reads it when she gets home, she knows exactly what they’ve 
said” (P23: F, ≥75, G). The participant’s daughter also assisted her in symptom appraisal, as 
she had read a magazine article in relation to pancreatic cancer, which concerned her because 
the symptoms were similar to those of her mother: “I’d only read this lady’s letter, and she had 
pancreatic cancer, and she had this belching” (Daughter of P23: F, ≥75, G). Another participant 
described how her daughters were concerned about her symptoms and therefore booked an 
appointment for her to see the GP: “My daughter said, ‘Look, Mum, I’ve made you an 
appointment, you’re going in the morning and that’s it.’ So I had to go” (P02: F, ≥75, O). The 
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appraisal/re-appraisal intervals for these participants was shorter (between four to six months) 
than those without social support.  
 
According to the definitions within the HLQ266, social support is an important aspect of health 
literacy. Those with high health literacy tend to have a supportive social network, while those 
with lower health literacy do not. In reflecting on the experiences of participants in the 
interviews, social support did encourage some participants to consider their symptoms and 
assisted with prompting help-seeking. It is possible that social support could reduce the 
appraisal/re-appraisal interval, particularly in older people where they have assistance in 
monitoring their symptoms and attending healthcare appointments. However, others did not 
seek help following concern from friends or family, usually based on fear of the outcome. This 
suggests that social health literacy could be more complex than the HLQ proposes. 
 
Summary 
When considering participants’ experiences with bodily changes or symptoms, and how these 
were appraised and re-appraised, it was often possible for participants to use their knowledge 
to find alternative explanations for bodily changes, or to assign symptoms to a benign cause. 
Where this occurred, participants did not perceive a reason to seek help, therefore lengthening 
the appraisal interval. Unusual symptoms sometimes prompted help-seeking, although this 
was more likely where participants experienced an overwhelming symptom or recognised 
when the symptom persisted, worsened and/or impacted on their daily life. The participant’s 
social network had an important role in assisting with appraisal and prompting help-seeking, 
although advice from family and friends to seek help sometimes conflicted with the participant’s 
fear of the diagnosis if they were to consult with a healthcare provider.  
 
I now turn to explore the participants’ experience of healthcare, including their relationship and 
interactions with healthcare providers and the healthcare system prior to their diagnosis.  
 
7.2.2. Healthcare experience 
Participants’ healthcare experiences focused on exploring and understanding their perceptions 
of primary care, the support received when seeking help and their communication with 
healthcare providers both in primary and secondary care. I reflect on the help-seeking interval 
of the MoPT140,141, along with the HSI (or diagnostic interval) to understand the pathways to 
diagnosis and how the interval lengths may be influenced. Based on the interview narratives, 
half of the participants were referred and subsequently diagnosed following the first 
consultation with a primary care healthcare professional. This first consultation was usually 
with a GP, although a few participants saw a nurse. The other half of the participants all had 
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more than one consultation in the two years prior to diagnosis, for symptoms that may have 
been related to their cancer diagnosis. I limited the analysis to two years prior to diagnosis for 
the same reasons as described in Chapter 6. I identified four sub-themes: 
 Help-seeking 
 Support 
 Alternative diagnosis 
 Assertiveness 
 
As this theme explores experiences in relation to the number of consultations, I updated the 
participant identifier to include the number of primary care consultations prior to diagnosis. The 
updated format is as follows: (participant ID: gender, age group, cancer type, number of 
consultations). 
 
Help-seeking 
Most participants decided to seek help for their symptoms, with the exception of two 
participants who were found to be anaemic following a routine blood test and were referred for 
an endoscopy. Some participants initially sought help through pharmacies, or similar, trying 
OTC medication to alleviate their symptoms. This was usually when participants associated 
their symptoms with heartburn, reflux or indigestion.  
 
“I thought, ‘Oh I’ll buy some of them Rennies, spearmint Rennies, and I’ll try them.’ 
And they did alleviate it, you know, they did help."  
(P02: F, ≥75, O, 1 consultation) 
 
“You would see an advert on the television and think, ‘Gaviscon will sort it.’”  
(P17: M, 60-74, O, ≥3 consultations) 
 
However, when the medication either did not work, or stopped working, they recognised that 
they may need additional help, such as this male participant, "I was trying to cure it myself like 
with Gaviscon and other patent medicines which didn’t work” (P08: M, ≥75, O, 1 consultation). 
 
Where participants sought help from primary care, half described having an established 
relationship with a particular GP, with this often incorporating both personal and professional 
aspects. Some healthcare providers were part of small communities so participants were able 
to connect with them on a personal level, as this participant described: “I know most of them…I 
do work for them…so I suppose they’re like friends as well” (P04: M, <60, O, 1 consultation). 
Others talked about the personal aspect of their interaction with GPs or nurses at their practice. 
This was often based on regular attendance for monitoring of other medical conditions. 
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“I’ve been seeing her for years…you get a half hour appointment, you know, so it 
doesn’t take her half an hour to do what she does, so we spend the rest of the time 
talking. I get on quite well with her.” (P24: M, ≥75, G, 1 consultation) 
 
One female participant expressed how she preferred to consult with her own GP as he was 
aware of and understood her medical history: “I’ve seen the same GP, so at the practice that 
I’m at obviously there are a number of GP’s but I make sure I go to my GP so it’s the same 
GP, so I just make sure that I can get to see him every time – he knows me, he knows what 
the issues have been” (P05: F, 60-74, G, ≥3 consultations). Participants without a specific GP 
also recognised how it could be beneficial to consult with the same GP for an ongoing issue. 
 
“I think there’s something to be said for having somebody perhaps that you do 
follow a kind of path of working through something if you’ve got a problem.”  
(P06: M, <60, O, 1 consultation) 
 
“You do have to keep repeating yourself a bit which is slightly irritating but that’s 
how it is. Obviously preference is always to see the same one because there’s 
more consistency.” (P17: M, 60-74, O, ≥3 consultations) 
 
However, where the participant did not have a specific GP, this did not deter them from seeking 
help, with most describing how they were happy to consult with any doctor. “No, they were 
different GPs…which is fine, I don’t care, I’m not bothered about which GP I see, it doesn’t 
bother me” (P22: M, 60-74, G, 2 consultations). Some participants also felt that it was no longer 
practical, within the current healthcare system, to expect to see the same GP. 
 
“Years ago I had a doctor…and he was excellent, and today you see anybody and 
I don’t know whose books I’m on…I don’t know which is my doctor, you know, we 
don’t have that type of system these days – you go and see a doctor.”  
(P20: M, 60-74, O, 1 consultation) 
 
“So talking to a GP is probably lucky without necessarily expecting to talk to the 
same GP every time, I know some people think they ought to speak to the same 
GP every time, well GPs aren’t personal and there aren’t enough of them. More of 
us than there are of them.” (P17: M, 60-74, O, ≥3 consultations) 
 
A few participants did mention potential barriers to help-seeking, both with their own GP or 
with seeking help in general. Some participants had difficulty understanding their GP, “he has 
got this accent you see which is hard to follow and of course I can’t hear so I have got to work 
out what he says” (P21: M, ≥75, G, 0 consultations). However, where participants had social  
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support available, they were generally able to work around this difficulty. “I just find him difficult 
to understand, so if I go normally and see him I take the wife and the wife listens to what he 
says and goes from then on” (P11: M, 60-74, O, ≥3 consultations). Other participants were 
unfamiliar with GPs and so either did not like to go, “I don’t like going to the doctor’s, I never 
went for anything” (P23: F, ≥75, G, ≥3 consultations), or did not want to be a burden. 
 
“But the GP, he just doesn’t have the time to take a minute with everybody, 
because there’s God knows how many they’re seeing in a day.”  
(P01: M, <60, O, ≥3 consultations) 
 
“You don’t really want to go down there and make other people late and that. So 
no I don’t go.” (P13: F, ≥75, O, 2 consultations) 
 
“There are more important people than me need the doctor.”  
(P21: M, ≥75, G, 0 consultations) 
 
Support 
When deciding to seek help, participants recognised that they needed additional support for 
managing their symptoms. “That was when I thought I can’t deal with it the way I am dealing 
with it so I need some help, so that was when I went to the doctors” (P16: M, 60-74, G, 1 
consultation). Feeling understood and supported by healthcare providers is an important 
aspect of health literacy, as is the ability to engage in consultations. When I explored the 
consultations in more depth in the interviews, some participants described how they relied on 
the healthcare professional to tell them what needed to be done.  
 
“Leave it to the doctors they know what they’re doing, let them get on with it.” 
(P04: M, <60, O, 1 consultation) 
 
“I don’t know, probably wave a magic wand or something and say like, ‘Take this 
and it will get rid of it.’ I don’t know really what I expected from the doctor, I expected 
something and I got something which was like, ‘I’m going to refer you to [Hospital] 
for an endoscopy.’” (P20: M, 60-74, O, 1 consultation) 
 
This suggests low health engagement skills for these participants, which was apparent even 
where participants were highly educated or demonstrated the ability to engage in information 
through other aspects in their lives. This was particularly illustrated by one participant who said 
“I’m used to dealing with scientific information, which is not the same as medical information 
but nevertheless, but there’s a vast amount of it”, yet expressed low health engagement. 
“When I go to the GP I don’t actually go generally with a view of what I expect to get out of it, I 
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kind of go in a very unthoughtful way and just kind of go and turn up and expect them to sort 
me out really, and throw my trust completely to them” (P06: M, <60, O, 1 consultation).  
 
Other participants talked about how they sought advice from their GP, based on the view that 
they would be able to control their symptoms with medical guidance. 
 
“I was getting a bit desperate with this diarrhoea so I rang up to see what I should 
take to stop it and I saw this [doctor].” (P10: F, ≥75, G, ≥3 consultations) 
 
“In the end I did speak to my GP over the phone to say, ‘I need some advice around 
pain relief because this is getting a bit more frequent and much more intense.’ He 
indicated that Ibuprofen was probably not the best thing to be taking.”  
(P17: M, 60-74, O, ≥3 consultations) 
 
Despite these different approaches for seeking support, most participants based their 
perception of the consultation around the ability of the healthcare provider to offer a solution 
that reassured them. I have explored this for those with a single consultation compared to 
those with multiple consultations. 
 
Single consultation 
Of the participants with a single consultation prior to diagnosis, most were positive about their 
healthcare experience. This appeared to be based on the speed of the referral to hospital 
rather than other aspects of the consultation, such as engaging with the healthcare provider to 
understand information.  
 
“From there it just took off and the doctor got me into the hospital for the cameras 
the week after.” (P03: F, 60-74, O, 1 consultation) 
 
“I mean, I’ve got to be honest and say, for all we hear about the NHS, we, as a 
family, can only say good things about it. I mean, I went to the doctor. I was in the 
hospital within two days.” (P25: M, 60-74, G, 1 consultation) 
 
One man commented that he did not understand the investigations he had been referred for, 
“[Doctor] just said, ’I think you could do with an endoscopy.’ And then I come home saying, 
‘What’s an endoscopy?’” (P20: M, 60-74, O, 1 consultation). However, he was still happy with 
his consultation based on the outcome of it, saying, “good of his like prognosis to get us sent 
over there as early as he did”. Other participants also had similar experiences, “oh they’re 
pretty good doctors, they do listen to what you’re saying; obviously I haven’t got an idea of 
what they’re on about” (P04: M, <60, O, 1 consultation), with few participants aware of the 
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possibility of a cancer outcome from the diagnostic tests. This was apparent even when they 
were referred on the two-week suspected cancer pathway. “[Doctor] didn’t use the word 
cancer, I must admit. She did not use the word, no” (P25: M, 60-74, G, 1 consultation). While 
many participants felt that the GP did not necessarily need to tell them of this possibility, one 
participant thought that in hindsight, he would have preferred a bit more information from his 
GP in regard to the potential diagnosis and the diagnostic procedures.  
 
“I was very ill-prepared for the gastroscopy actually, because I hadn’t really thought 
about it, my GP hadn’t said, ‘This could be oesophageal cancer,’ which I 
understand what she was doing, she was being positive and upbeat and not trying 
to scare the living daylights out of me and that was fine, so that meant I was actually 
very ill-prepared for the gastroscopy in a number of ways.”  
(P06: M, <60, O, 1 consultation) 
 
Multiple consultations 
For participants with multiple consultations prior to diagnosis, many participants reflected the 
opinions of those with single consultations. This related to positive views of healthcare, “the 
GP, I can’t fault them, they were very good” (P22: M, 60-74, G, 2 consultations), or their 
experience in regard to engagement and communication around medical issues or awareness 
of cancer as an outcome of investigations.  
 
“I…don’t always quite understand things but on the whole yes, not being a medical 
person at all.” (P10: F, ≥75, G, ≥3 consultations) 
 
“I mean, some doctors are quite blunt apparently...but I mean my doctor sort of 
hinted but there was no scaremongering basically I would say, you know. ‘Oh we’re 
looking for cancer’ or anything like that, you know, she just said, ‘We’ll have a look 
and see what’s causing the problem if anything’ and went about it that way rather 
than straight in with the sledgehammer, you know, so I thought her way of putting 
it was better.” (P07: M, 60-74, O, 2 consultations) 
 
However, for a few participants, difficulties with engaging and communication were more 
apparent, with one participant describing how he did not feel part of the conversation when 
talking to his GP. “He’s very difficult to talk to, he’s very old-school and quick if you understand 
what I mean, when you ask him a question, it’s boom and the answer’s there; there’s no talking 
about it – it is or it isn’t, with him” (P01: M, <60, O, ≥3 consultations). While some participants 
accepted this type of approach, as previously described, others felt like they were not being 
listened to. 
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“I knew then that there was something that was really wrong, so I went to the 
doctors and told them this, ‘oh, you’ve got a stomach bug.’ I said, ‘I don’t think it’s 
a stomach bug, it’s been going on too long now and it comes on blooming quick.’ 
‘Well, we think it’s a stomach bug.’” (P12: M, ≥75, O, ≥3 consultations) 
  
“I told her that I wasn’t happy with [Doctor], the way he hadn’t listened to me, hadn’t 
listened to what I had to say.” (P14: F, 60-74, O, ≥3 consultations) 
 
Within the following sub-themes I have focused on participants with multiple consultations. 
These participants had different experiences to those with a single consultation as they were 
not diagnosed following their first consultation. They therefore had additional experiences in 
relation to healthcare, which were important to explore in relation to their influence on time to 
diagnosis.  
 
Alternative diagnosis 
Most participants with multiple consultations received an alternative diagnosis prior to their 
cancer diagnosis. This was either within primary care, or from secondary care having been 
referred for other investigations. I have explored the participants’ experiences within each of 
these healthcare settings. 
 
Primary care 
In primary care, GPs occasionally took a ‘watch and wait’ approach at the first consultation. 
One participant described being advised to return if symptoms continued. “She said, ‘If you 
have it any more come back and see me’” (P13: F, ≥75, O, 2 consultations). Others were 
prescribed medication, such as PPIs, and told to return following a certain length of time. “He 
wanted us to take them for six weeks and then go back after six weeks” (P23: F, ≥75, G, ≥3 
consultations). Where medication was prescribed, this was sometimes based on the suspicion 
of an underlying condition, “‘I went to see the doctor and he said, ‘Yeah, you could have some 
ulcer or something,’ and he gave me some pills” (P11: M, 60-74, O, ≥3 consultations). Other 
times it was to alleviate symptoms and often followed the attempts of participants to manage 
their symptoms with OTC medication (Table 7.9). 
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Table 7.9. Managing symptoms with OTC or prescribed medication 
Participant Illustrative quotes 
OTC medication Prescribed medication 
P15: M, ≥75, G,  
2 consultations 
"I couldn’t fix it with the Gaviscon. 
Usually that sort of thing I can calm it 
down with anything like that, but I 
couldn’t." 
"Then [the nurse] put me onto this 
stuff for my stomach; gastro-resistant 
capsules [Omeprazole]. In the 
summertime."  
P17: M, 60-74, O, 
≥3 consultations 
"I knew Gaviscon wouldn’t work 
because I had tried it; eventually I 
found the liquid form did help, the 
tablet form wasn’t doing anything 
whatsoever, but the liquid form did 
actually make a slight difference." 
"When I went for my initial GP 
consultation, just ‘Take these tablets 
[Omeprazole], see you in 6 weeks.’"  
P18: M, ≥75, O,  
2 consultations 
“I actually went to a chemist where we 
were staying…and they gave me 
some medicine to supposedly help it.”
"He gave me some pills, gastric type 
pills, never did anything particularly. 
This Gaviscon he gave us round 
about that time…it’s like a jelly type 
thing and it feels as though it soothes, 
you know." 
P23: F, ≥75, G,  
≥3 consultations 
"When I was going down the road for 
a walk I used to shove a couple 
[Gaviscon] in my pocket just in case 
indigestion came on, and I used to 
shove one in my mouth."  
“Anyway the doctor gave her the 
Omeprazole, to stop the belching and 
everything.” (Daughter of P23) 
 
 
OTC = over-the-counter 
 
While some participants were reassured by the outcome of their consultation, others were not. 
This was particularly evident for the participants who described communication difficulties with 
healthcare providers. While this could be based on retrospective recall of the pathways to 
diagnosis, these participants may have been dissatisfied at the time and some did talk about 
their reasons for not feeling reassured. For the male participant who was diagnosed with a 
stomach bug, he held the opinion that the GP was misinforming him based on being unable to 
diagnose what was actually wrong.    
 
“I personally think doctors are a waste of space, because they go on the 
assumption of what you’re telling them all the time, and unless you’re telling them 
something that they can pick up on straight away they just fob you off, which has 
happened to me….but what can you do? You’ve got to take a doctor’s word and 
hope that they’ll treat you the best that they can.”  
(P12: M, ≥75, O, ≥3 consultations) 
 
The other participants all received a diagnosis based on their symptoms being attributed to 
another underlying condition. One participant was concerned about oesophageal cancer as 
her father had passed away with it when he was her current age. However, when she went to 
the GP he arranged an electrocardiogram (ECG) and diagnosed a heart condition. “I wasn’t 
convinced at all. I came out of there thinking, ‘It’s not my heart, I don’t care what you say it’s 
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not my heart’” (P14: F, 60-74, O, ≥3 consultations). Her reasons for not being reassured were 
linked both to her father’s cancer and to her own, and her sister’s, prior experience with the 
heart condition.  
 
“The thing that I’ve got with my heart I’ve probably had all my life, my sister has 
also got it, it’s probably just one of them things. I don’t really know what it is, but 
I’ve had ECGs before and I’ve had operations before and it’s never been called 
upon so obviously it’s probably something I’ve always had. So he should have 
taken notice of what I was telling him.” (P14: F, 60-74, O, ≥3 consultations) 
 
Knowledge gained from prior experience also influenced another participant, who did not feel 
that that his diagnosis reflected the symptoms he was experiencing. “Well, I didn’t really think 
it was kidney stones because that’s not what I had when I had the kidney stones before” (P01: 
M, <60, O, ≥3 consultations).  
 
Secondary care 
Some participants with multiple primary care consultations had initially been referred to 
secondary care for investigations. For example, following their initial consultation with a GP, 
two participants were referred for a colonoscopy or other tests via a two-week wait referral.   
 
“I went to my GP at the beginning of March and she thought I should have a bit 
further investigation so I went for a colonoscopy at the end of March. The results 
of that seemed to be nothing to be worried about.”  
(P07: M, 60-74, O, 2 consultations) 
 
“I saw one of the doctors there, I think she was a registrar or something, a young 
girl and she thought I’d got bowel cancer. So she sent me to hospital and had PET 
scan, CT scan and whatnot and it all come back clear.”  
(P10: F, ≥75, G, ≥3 consultations) 
 
Both of these participants were reassured by the outcome of the hospital investigations. 
Subsequently, the male participant was contacted by his GP for a second appointment and 
routine referral for an endoscopy, based on blood test results indicating anaemia. The female 
participant re-presented in primary care seven months later, where she received a two-week 
wait referral for the endoscopy that lead to her cancer diagnosis.  
 
Other participants had similar experiences, with one male participant referred for a 
colonoscopy and endoscopy where he was diagnosed with benign conditions, given 
medication and discharged following a three month follow-up. 
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“They discovered that I had a little bit of diverticulitis…They also…prescribed me with 
Omeprazole to heal the lining of my stomach because it was showing something. But 
they did biopsies as well, and sent them off, and they came back with no diagnosis of 
anything suspicious, of any cancer or anything. So they said take the Omeprazole…‘but 
we’d like you go come back…to see if the Omeprazole has healed the problem.’…So I 
went back…and the consultant said he’d sign me off. So I thought, ‘Great.’”  
(P22: M, 60-74, G, 2 consultations) 
 
Although this participant was reassured by the investigations, his symptoms persisted, leading 
him to re-present in primary care a few months later. Another participant was referred and 
diagnosed with gallstones. Following removal of her gallbladder, her symptoms continued, 
which the consultant attributed to her recovery from the operation.   
 
“I had my gallbladder out and when I went back for my 6 week check-up I 
mentioned that the symptoms had not dissipated at all, they were still there, so I 
was still having all of these symptoms. And [consultant’s] response to that would 
be, ‘Well, okay you’ve just had your gallbladder out, let’s wait for 3 months and see 
if that settles down.’” (P05: F, 60-74, G, ≥3 consultations)  
 
Assertiveness  
Following the initial consultation, the pathways to diagnosis for those with multiple 
consultations could be quite challenging. Subsequent interactions with the healthcare system 
often required the participants to be proactive or assertive in their approach to obtain their 
diagnosis, which often contrasted with the participant’s perception of the doctor-patient 
relationship. As one participant said, following her initial consultation in primary care, “Who am 
I to argue with a doctor?” (P14: F, 60-74, O, ≥3 consultations). Other participants also reflected 
this sentiment and how they felt powerless at times, “you can only take notice of what they tell 
you and you can’t demand that you have this done or that done” (P12: M, ≥75, O, ≥3 
consultations). Many participants therefore had to demonstrate a high health literacy ability to 
obtain the support they needed to navigate their way through primary and secondary care.  
 
Primary care 
Participants described re-presenting to the GP with the same or additional symptoms from a 
few weeks to eight months after their initial consultation. The male participant diagnosed with 
the stomach bug consulted for a second time a month after his initial consultation, where he 
was given the same diagnosis. This left him unsure of what to do next. “When this other doctor 
did exactly the same thing I thought, ‘Oh. Where do you go from here?’” (P12: M, ≥75, O, ≥3  
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consultations). When I explored the timeline of events with him, he estimated that it was 
another six months until he decided to go back to the GP, having experienced additional 
symptoms. “I thought, ‘I’ll go for one last time, see what they have to say’”. It was at this point 
he was referred for an endoscopy. Other participants also described how they had to be 
proactive or assertive in their subsequent interactions with healthcare providers, from 
requesting a specific course of action to finding an alternative route to diagnosis.  
 
The female participant with the heart condition described how she remained concerned 
following her initial appointment and consulted a few weeks later, where she had blood tests 
and another ECG. Following the second ECG, she consulted the GP and was told again that 
everything was fine. It was at this point that she felt she had to be assertive and push for further 
investigations.  
 
“Well, I lost my temper then and said, ‘No, I won’t go away; I’m really, really worried. 
I see signs of myself with what my father had.’ And he got a little bit stroppy with 
me and said, ‘So you want me to send you for…?’ And I said, ‘Yes, I do want you 
to send me for something,’ so he did it.” (P14: F, 60-74, O, ≥3 consultations) 
 
This experience was similar for other participants, with one requesting further investigations 
following a negative blood test. 
 
“I rang up and the receptionist said, ‘No, the blood test is fine, no further 
treatment’…I said, ‘I’m sorry, I’m not happy with that, can I have an appointment?’ 
And she said, ‘Yeah, of course you can.’ Had the appointment with [GP] and that’s 
what he done, organised... ‘Being as you’re not happy I’ll organise the endoscopy.’ 
So it was the endoscopy that discovered it.” (P11: M, 60-74, O, ≥3 consultations) 
 
A couple of participants found alternative routes to diagnosis where they felt it was not possible 
to obtain the support they required along their original path. The daughter of one participant 
described consulting with a nurse to ask for the endoscopy referral, having previously not been 
referred by the GP. “[Doctor] insisted on my mam waiting the six weeks…but the nurse, she 
looked at the internet and she said…from what you’ve brought in and what you’ve told 
me…they got her in within two weeks, the same nurse” (Daughter of P23: F, ≥75, G, ≥3 
consultations). The participant diagnosed with kidney stones also found an alternative route to 
diagnosis when he could not get an appointment with his GP. “After I had that [consultation] 
the receptionist wouldn’t let me have an appointment for 2 weeks. I said, ‘2 weeks? He wants 
to see me in 3 days.’ I said, ‘nah, nah, I’m not waiting that long,’ so I went over to [Hospital]” 
(P01: M, <60, O, ≥3 consultations). This participant described seeing a doctor at the hospital 
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and being told to go back to his GP for an urgent referral. His GP subsequently arranged an 
emergency admission to hospital, where the participant was diagnosed.  
 
Secondary care 
Participants described similar experiences in secondary care. One female participant 
respected the opinions of the consultants she saw as they were specialists in their field, 
describing how she tried “to work with the consultants the best way that I possibly could. But 
coming away sort of feeling a little bit frustrated and a little bit downhearted” (P05: F, 60-74, G, 
≥3 consultations). While she had asked the consultants if it could be “something sinister”, which 
they thought was unlikely, in hindsight she felt that she could have been more assertive in 
requesting further investigations. “Knowing what I know now I probably would have been a 
little bit more assertive and said, ‘This is what I feel. I feel maybe you should put the camera 
down and have a look, I would feel more comfortable if you did that.’” (P05: F, 60-74, G, ≥3 
consultations). In comparison, another participant did request further investigations following 
negative test results and found he was supported by the consultant managing his care. 
 
“I said to [consultant], ‘Look, I’ve still got this feeling in my stomach of indigestion 
and that.’ I said, ‘Should I not have another endoscopy?’ She agreed with me and 
said, you know, all the other scans and ultrasounds and everything weren’t 
showing anything.” (P22: M, 60-74, G, 2 consultations) 
 
Summary 
Participant experiences of healthcare differed based on the perceived support provided by the 
healthcare provider and the number of consultations prior to diagnosis. Health literacy ability 
was important when engaging with healthcare providers and navigating the healthcare system, 
particularly for those with multiple consultations. These participants often had a longer time to 
diagnosis than participants with a single consultation as their pathway included periods of re-
appraisal sometimes following initial negative diagnostic tests, along with additional help-
seeking and consultations in primary and/or secondary care. 
 
I now move on to explore participants understanding of heartburn, reflux and indigestion which 
I chose to explore as an independent theme, focusing on the meanings of the terms and the 
symptoms participants associate with the conditions. This approach was taken in order to 
better understand how people use these terms to describe their symptoms, and how they may 
relate to them in the context of healthcare consultations or community awareness campaigns. 
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7.2.3. Heartburn, reflux and indigestion 
As outlined in Chapter 2, literature describes indigestion as a collection of symptoms including 
heartburn, regurgitation, nausea, vomiting, upper abdominal pain, bloating and 
fullness57,66,72,87-89, while descriptions of reflux often refer to heartburn, regurgitation and ‘reflux-
like’ symptoms21,65,66,76,79. “Heartburn most days for three weeks or more” was the main 
message of the National Be Clear on Cancer campaign for oesophago-gastric cancer in 
201569, yet previous research has suggested that people may not understand the term 
‘heartburn’14.  
 
In the interviews, as participants talked about indigestion, heartburn and reflux, I took time to 
explore what they meant and understood by these terms. This included discussing previous 
and/or current experience, along with the symptoms they associated with these conditions. If 
the participant did not mention indigestion, heartburn or reflux in the interview, I would 
introduce the topic by referring to other people describing these terms and explore the 
participant’s understanding and experience of symptoms. From the participants’ narratives, 
there was overlap in the symptoms associated with these conditions. This was apparent 
between heartburn/reflux, heartburn/indigestion and reflux/indigestion. Many participants 
referred to ‘acid reflux’ with a few also using ‘acid’ to describe feelings associated with 
heartburn or indigestion, therefore ’acid’ was the only descriptor that crossed between all three 
conditions (Figure 7.5). I describe participants’ experience of these conditions in the following 
three sub-themes: 
 Context 
 Associated symptoms 
 Other experience 
Quotes are contextualised with the participant ID, gender, age group and cancer type. 
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Figure 7.5. Symptoms associated with heartburn, reflux and/or indigestion 
 
 
Context 
Prior to exploring symptoms and meanings associated with heartburn, reflux and indigestion, 
it is useful to understand the participants’ views of the conditions in the context of daily life. As 
mentioned previously, many participants saw heartburn, indigestion and reflux as an expected 
part of everyday life. "I wasn’t suffering from heartburn or indigestion, no more than normal 
people" (P19: M, 60-74, G), rather than a cause for concern: “I never saw heartburn as being 
anything other than just one of those things. I didn’t think of it having any serious medical 
implications, cos I’d never heard of any” (P17: M, 60-74, O). When such symptoms were 
experienced, there was usually an explanation, for example, the amount or type of food or 
drink consumed.  
 
"There was always a kind of obvious cause to that, I’d drunk a lot or I’d eaten a lot 
of hot food; it wasn’t a surprise to me that I had acid reflux that day because of 
what I had been doing the day before or whatever." (P06: M, <60, O) 
 
A few participants had never experienced indigestion before but attributed their symptoms to 
indigestion based on knowledge gained through advertisements for antacids such as those 
used for Gaviscon434.  
 
“I: So what made you think it might be indigestion? 
P: Because the adverts on the television (laughter) I suppose, the Gaviscon where 
he’s holding his chest, I was holding mine" (P08: M, ≥75, O) 
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In these advertisements, a man is seen holding his hand to his chest with “heartburn?” written 
above him and an image of flames used to illustrate a burning sensation in that area434. In a 
similar picture, the man is holding his hand over his stomach with a circular ‘fireball’ image and 
“indigestion?” written next to him. These adverts seemed to reinforce the idea that heartburn 
and indigestion are a normal part of life, with one participant commenting that the advert 
showed brothers having a shared experience of the symptoms. “Indigestion and 
heartburn...You see the advert on telly for, what is it? Gaviscon, isn’t it? One brother has one 
and one has the other." (P25: M, 60-74, G). The conditions were therefore seen as 
manageable, either with OTC medication or prescribed medication, with many participants, 
particularly those with oesophageal cancer, describing previous or long-term use of 
prescription medication (Table 7.10). 
 
“You see the adverts on the television for Gaviscon and Rennies…you get the 
people with the brushes swishing out the inside of the stomach and all the rest of 
it and that very satisfied look on a person’s face, and that’s what you think 
heartburn is all about really.” (P17: M, 60-74, O) 
 
Table 7.10. Participants with previous or long-term prescription medication   
Medication Illustrative quotes 
Previous 
use 
"My GP prescribed me a packet of Omeprazole, I don’t know, three-four years ago or 
something like that." (P06: M, <60, O) 
 
“I was always getting silly things; these tablets you suck on, and all that, Gaviscon; 
they were always pumping Gaviscon into me…it could well have been permanent for 
me if I hadn’t had that gallbladder taken out.” (P12: M, ≥75, O) 
 
Long-term 
use 
"I take something for reflux and I’ve been taking it because I’ve had reflux to do with 
the diabetes." (P01: M, <60, O) 
 
"I’ve been on Lansoprazole tablets for oh X amount of years because I used to get a 
lot of acid reflux, really, really bad.” (P03: F, 60-74, O) 
 
“I was on a high dose of Omeprazole for quite a long time, and my GP would just sort 
of repeat the prescription, so I think it was about two years that I was on that."  
(P05: F, 60-74, G) 
 
"I have been taking Omeprazole for years which was for the acid reflux that I was 
suffering from and it kept that, I had absolutely no problems with that once I started 
taking Omeprazole." (P07: M, 60-74, O) 
 
"I was on Naproxen, 500mg for my arthritis, and then a few years ago I got a phone 
call to say that they thought that Naproxen could cause a hole in your stomach, so they 
then said I had to start taking these [Omeprazole]." (P14: F, 60-74, O) 
 
"There’s one there which is for indigestion [Lansoprazole]...two or three years I’ve been 
on that." (P20: M, 60-74, O) 
 
"The doctor prescribed some Gaviscon for me before he put me on Pantoprazole.”  
(P26: F, ≥75, G) 
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Having contextualised participants’ views of heartburn, reflux and indigestion in daily life, I now 
explore and describe the symptoms that participants associate with these conditions.  
 
Associated symptoms 
Most participants mentioned heartburn, reflux and/or indigestion in their interview, recalling 
previous or current experience of the conditions and the symptoms associated with them. A 
third of participants referred to one of the conditions within their interview, while half mentioned 
a couple, or referenced all three at various points. Where a participant referred to more than 
one condition, a complex picture of symptoms and associations emerged, as I now describe. 
 
‘Acid’ was the only word used in reference to all three conditions. Many participants used it as 
a descriptor of reflux, such as this participant, “I have been taking Omeprazole for years, which 
was for the acid reflux that I was suffering from”, subsequently describing how it presented. “At 
first it was just sort of the acid catching my throat you know as if you swallowed something a 
bit bitter, you know, it just sort of caught your throat” (P07: M, 60-74, O). However, it was 
occasionally seen as a symptom associated with indigestion “so the acid was just a bit of more 
indigestion than anything” (P11: M, 60-74, O), or heartburn, “it’s acid. But how do you describe 
it? Like a burning taste that’s all I can describe it as” (P26: F, ≥75, G). 
 
While ‘acid’ was associated with all three conditions, ‘burning’ was only described in relation 
to heartburn and/or reflux, rather than indigestion, such as the female participant above 
describing the “burning taste” associated with heartburn. Another participant described the 
burning associated with her acid reflux, “just lately if like I say with the tomato just a little bit of 
burning” (P03: F, 60-74, O), while a male participant used heartburn and reflux 
interchangeably. "It kind of burns and you get that heartburn, it really does have that kind of 
burning feel about it when I had reflux” (P06: M, <60, O). These descriptions demonstrate a 
crossover between the symptoms associated with these two conditions. However, other 
participants viewed heartburn and reflux differently, associated with separate symptoms. Mild 
pain was occasionally used to describe heartburn, “mild pain to the right of my chest, which is 
traditionally the heartburn area, as I understand it” (P17: M, 60-74, O). In contrast, regurgitation 
and burping were associated with reflux.  
 
“I felt as if I was drowning and sometimes I had a regurgitation problem”… 
"So, that’s how my reflux presented itself, it just sort of felt, I could feel my food 
sort of coming back up…I could feel it coming back up into this pipe here, up into 
my throat…that’s when they said to me, ‘You have a hernia, and that’s probably 
why you’ve got reflux.’” (P05: F, 60-74, G) 
 235 
One participant explained that he had never experienced heartburn; however he had 
experienced reflux, which he described as: "The reflux to me is that burping…that's what I think 
as being reflux" (P18: M, ≥75, O).  
 
As seen in Figure 7.5 and described above, a burning sensation was associated with both 
heartburn and reflux, while other symptoms such as mild pain, burping and regurgitation were 
associated with one or the other. However, these latter symptoms could also be associated by 
some participants with indigestion, indicating the additional overlap between 
heartburn/indigestion and reflux/indigestion. One participant said “I was starting to get 
indigestion type of thing” and when I asked her what that felt like she described it in terms of 
regurgitating food or liquid.  
 
"I: You said you were having more indigestion, so what was that feeling like? 
P: Well, you know, you get your food so far down and then it just comes back up, 
you know, it’s like... what do they call it, regurgitating or something, you know, the 
food just...  And when I drink, you know, it gets so far down and then it comes back 
in my throat again.” (P02: F, ≥75, O) 
 
This was similar to the previous participant describing her reflux in relation to regurgitation. 
Another participant described his indigestion as “sort of burping and slight pain, and a bit of 
wind but nothing fantastic" (P15: M, ≥75, G), with others also referring to wind and mild pain. 
 
"I’ve been treated with in the past, when you have wind and stuff like that, that 
Gaviscon type stuff, well I’ve been treated with tablets from the doctors for years 
over stomach like indigestion problems." (P20: M, 60-74, O) 
 
"I get discomfort, like I said before, with the indigestion, and heartburn, and my 
tummy sometimes used to feel, well still does, feel a bit sore. You know, if you 
touch it or press it in, but I don’t get sharp pains or severe pain" (P22: M, 60-74, G) 
 
The narratives indicate the symptoms participants associate with heartburn, reflux and 
indigestion, with overlap apparent between conditions. There was only one symptom that 
participants exclusively associated with one condition: severe pain as a symptom of 
indigestion. Many participants referred to the serious pain they experienced with indigestion, 
often using vivid language to indicate the intensity, such as this male participant: "A real severe 
pain in my chest…it was just a horrible pain. I thought I was having a heart attack. A real vice 
like pain in my chest" (P16: M, 60-74, G). Others commented on how the pain appeared to 
radiate out and spread. 
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"I was starting to get indigestion type of thing…I was set to enjoy this meal and I 
sat down and I had three mouthfuls and I got such a pain went through from here 
right through to my back." (P02: F, ≥75, O) 
 
“Quite painful and seemed to spread…it was actually causing some pain in my 
head as well…it was in my chest but also quite painful, not for a very long period 
of time but for a short period of time." (P06: M, <60, O) 
 
When reflecting on participants’ symptom descriptions, I explored the interview transcripts to 
identify where participants described similar symptoms yet did not link them to heartburn, reflux 
or indigestion. I describe these below.  
 
Other experience 
Burping, regurgitation and severe pain were symptoms that participants also described 
independently of heartburn, reflux and indigestion. One participant described her belching, “I 
was having the belching…that belching was - the noise” (P23: F, ≥75, G), yet did not relate it 
to the indigestion she was experiencing. Others also described burping or regurgitation without 
linking these symptoms to reflux or indigestion as others had. 
 
"As soon as I tried to eat something I would start burping immediately and I would 
get the hiccups.” (P01: M, <60, O) 
 
“The worst one [regurgitation]…when it did come back up and I got some food back 
up.” (P25: M, 60-74, G) 
 
Pain was also described in similar vivid language to those who associated the pain with 
indigestion, such as referring to how the pain would spread. "The pain because it was pulsating 
pain, it was emanating and out through and at the back that was emanating all up through the 
back" (P01: M, <60, O). Participants sometimes indicated the severity of the pain through their 
use of medication, even though they described experiencing mild pain, such as this participant. 
 
“I wouldn’t call it pain, I can’t say I was in actual agony pain but there was definitely 
discomfort, definitely a lot of discomfort there but then as I say, I used to take a 
Paracetamol and it went" (P03: F, 60-74, O).  
 
While it is not possible to determine whether these symptoms indicated heartburn, reflux or 
indigestion, the narratives identify how there are multiple ways to describe symptoms, for 
example, belching could be described as belching, burping, reflux or indigestion.  
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Summary  
It was apparent from the interviews that heartburn, reflux and indigestion had various meanings 
for participants, with some describing similar symptoms yet not associating them with these 
conditions. This demonstrates how these terms may not resonate with people when they 
appraise their symptoms. When communicating about symptoms, both in symptom awareness 
campaigns and between healthcare providers and patients, it would seem more appropriate to 
describe sensations and experiences, rather than using terms which may have different 
meanings to people.  
 
7.3. Discussion 
This is the first study in the UK to use qualitative approaches to explore and compare pathways 
to diagnosis for patients recently diagnosed with either oesophageal or gastric cancer. In public 
and primary care settings, these cancers are often referred to in combination, as oesophago-
gastric or gastroesophageal cancers. An important aspect of the study was to therefore explore 
and understand similarities and differences between the symptoms, experiences and 
behaviours of patients prior to diagnosis with these cancers.  
 
Interview participants were purposively sampled from the questionnaire responders, with 26 
participating (15 oesophageal, 11 gastric). While the pathways between those with each 
cancer were broadly similar, there were some, albeit subtle, differences in symptom 
experience. Gastric participants were more likely than oesophageal participants to describe 
their decreased appetite, commenting on the unusual nature of this in comparison to their usual 
eating habits. In contrast, participants with oesophageal cancer were more likely to describe 
difficulty swallowing and the unusual consistency of the sickness they experienced, likening it 
to other bodily fluids in attempting to understand the symptom. Long-term use of prescription 
PPIs was also more often described by those with oesophageal cancer, usually based on a 
previous experience of heartburn, reflux or indigestion. I identified descriptions of symptoms 
associated with these conditions and was therefore able to explore where the terms did not 
resonate with participants, suggesting a complex picture of understanding and use for 
communicating underlying symptoms.  
 
When appraising and re-appraising symptoms, the nature of the symptom was important for 
prompting help-seeking. Where a symptom was non-specific or intermittent, participants were 
able to find alternative explanations, often attributing the symptoms to benign conditions and 
managing them as such. An unusual experience often prompted participants to reconsider 
their symptoms, while symptoms that were overwhelming, persistent, worsening or impacted 
on daily life tended to prompt participants to seek help. Family, friends and colleagues were 
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also important in prompting help-seeking for some participants, while for others their fear of 
the diagnosis counteracted this concern. Social support has been described as an important 
aspect of health literacy, with older participants in the study benefitting from having a social 
network around them to assist with managing their health.  
 
Most participants sought help in primary care, with half of the participants referred and 
diagnosed following their first consultation. Many participants felt supported by their healthcare 
provider; however, some (with multiple consultations prior to diagnosis) reflected on their 
feelings of not being listened to. Compared to those with a single consultation, participants 
with multiple consultations often had to engage and be assertive with healthcare providers. 
This required high levels of health literacy around communication with healthcare providers, 
and an ability to navigate through primary and secondary care to get the support and services 
they needed. 
 
7.3.1. Strengths 
Recruitment 
Response to this interview study was positive, with 81 (63.8%) participants willing to be 
contacted. From the 27 participants approached, 26 agreed, and most were interviewed within 
10 weeks of diagnosis as planned. I recruited a broad range of participants, including 15 
oesophageal and 11 gastric participants, allowing for comparison of experiences across 
cancers. There were more males than females (n=18 vs 8) participating in the interviews. 
However, this reflects the recruitment within the questionnaire study and is similar to the UK 
male:female ratio of approximately 2:1 for oesophageal and gastric cancers38,117. The study 
was also able to recruit 14 participants with advanced stage disease (stage III/IV cancer), 
which demonstrates the willingness of participants to assist with research even following a 
difficult diagnosis.  
 
Definitions and frameworks 
Data collection and analysis, in relation to time to diagnosis, were guided by the intervals as 
defined by the MoPT140,141. In the interviews I used a timeline and calendar landmarking 
technique to explore the experiences and events prior to diagnosis, which assisted with 
participant recall of dates and understanding of the pathway. The use of these techniques, 
both a framework for interval definitions and calendar landmarking, were recommended by the 
Aarhus Statement142 to assist with improving the design and reporting of early diagnosis 
research. The importance of clearly defining time points along the pathway was highlighted in 
the systematic review that I conducted (Chapter 3), as was clearly identifying the definition and 
assessment of health literacy in a study. In my research I reflected on the 1998 definition by 
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the World Health Organisation180, as well as the updated definition by Public Health England, 
2015183 (Chapter 2), and I used the HLQ266 to provide a framework for collection and analysis 
of the qualitative data. 
 
Health literacy 
Assessing health literacy through interviews allowed an understanding of the changing nature 
of health literacy along the pathways to diagnosis, from actively managing health and 
appraising symptoms, through to utilising social support, engaging with healthcare providers 
and navigating the healthcare system. Unlike previous health literacy in cancer, assessing a 
specific time point around screening or treatment decisions, health literacy in timely diagnosis 
incorporates the period from first noticing a bodily change through to entering the health system 
for help-seeking and diagnosis, which can be many months. It could therefore be more 
appropriate to explore health literacy via interviews, as the HLQ was found to have limitations 
in questionnaire format, as discussed in Section 6.4.2. 
 
Interview dynamics 
When conducting interviews it is important to consider the potential of the interviewer to 
influence the research or introduce bias, such as through recruitment, interaction during the 
interview or framing of the interview questions. To address this, I used a pre-defined sampling 
grid for participant recruitment, to ensure a wide range of participants took part in the 
interviews. I also used memo writing throughout the interviews to reflect on how I, as a 
researcher, may influence the data collection and analysis. I considered how a researcher from 
the University of Cambridge may be perceived, and while I noticed some difficulties with 
rapport in a couple of interviews, most participants appeared comfortable. This was reflected 
both in the length of the interviews and the feedback received from participants themselves 
and from my supervisors when reading the transcripts.  
 
During the analysis, I frequently reflected on my memos and thoughts of the interviews to 
understand each participant’s pathway, as well as exploring how they combined or diverged 
across the coding framework. Throughout the study, I regularly discussed the interviews and 
analysis with my supervisors (FW and JB) and colleagues in the Primary Care Unit, to gain a 
broad range of methodological and clinical expertise. The two study patient representatives 
were also involved in the analysis of the data, which enriched my understanding across the 
themes. 
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7.3.2. Limitations 
Sampling 
Although the number of participants recruited for the interviews was a key strength of the study, 
participants all identified as White (ethnic group), primarily White British. The experiences of 
those identifying with other ethnic groups could be different from a White population, 
particularly in relation to health literacy and aspects of communication or engagement. It would 
be useful to conduct further research specifically targeting other ethnic groups to explore timely 
diagnosis of oesophageal and gastric cancer. It was also not possible to recruit participants 
within every category in the sampling grid. The following categories could not be recruited to:  
 Females aged 60 or less with oesophageal cancer; 
 Males/females aged 60 or less with gastric cancer; 
 Females aged 60-74 with gastric cancer and living in the East of England; 
 Males aged 75 or over with gastric cancer and living in the East of England. 
I attributed this to the non-availability of participants in these categories, based on 
questionnaire responders willing to be interviewed within the interview recruitment period. 
However, despite the limited sampling in some categories, the interviews reflected a wide 
range of narratives and provided a rich dataset for exploring the pathways to diagnosis.  
 
Retrospective data collection 
As the study recruited participants following their diagnosis (retrospectively), narratives may 
have been subject to post-hoc rationalisation, for example, where participants may place more 
emphasis on experiences and events prior to the diagnosis than was apparent at the time. The 
narratives therefore reflect reported participant experiences rather than exact descriptions of 
the pathways to diagnosis. These rationalisations can potentially be influenced by post-
diagnosis events and thoughts. While this is unavoidable with retrospective interview studies, 
I tried to minimise this by conducting the interviews as soon as possible following the diagnosis, 
with most participants interviewed within 10 weeks of diagnosis.  
 
The participant narratives may also have been influenced by the interview itself, as the 
participants were aware that I had come to talk to them about what happened prior to 
diagnosis. It was apparent from a couple of the interviews that the participants had extensively 
considered their pathway prior to the interview, which may have influenced my ability to 
understand the symptoms and experiences leading to diagnosis. However, the interviews still 
provided important insights in to how people process their experiences, and acknowledge their 
role along the pathway. 
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7.4. Summary 
The main findings from the interview study relate to the pathways to diagnosis, and 
understanding of heartburn, reflux and indigestion. The nature of the symptoms experienced 
was important for appraisal and re-appraisal, while the health literacy demands on participants 
for engaging with healthcare providers and navigating the healthcare system were an 
important influence on the length of the health system interval. In exploring heartburn, reflux 
and indigestion, it was apparent that the symptoms associated with these conditions differed 
between participants, suggesting that the use of these terms may introduce uncertainty in 
relation to symptom experience.  
 
In the following chapter I integrate and discuss the findings across the thesis, highlighting 
strengths and limitations of the research approach, as well as comparing the findings with 
existing literature and discussing the implications of the work. 
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Chapter 8: Discussion 
 
 
The aim of my research was to understand the pathways to diagnosis of oesophageal and 
gastric cancer from a patient's perspective, and to explore the factors that influence the 
pathway. To achieve this I had the following objectives: 
 To explore current research investigating the factors that influence the pathways to 
diagnosis for oesophageal and gastric cancer; 
 To systematically identify and review literature exploring the role of health literacy in 
timely diagnosis of symptomatic cancer; 
 To identify and appraise health literacy instruments and to evaluate those available for 
research, designed to be self-administered and used to assess the multi-dimensional 
concept of health literacy; 
 To conduct a study exploring the perspective of newly diagnosed patients on the 
pathways to diagnosis for oesophageal and gastric cancer.   
 
In this chapter I discuss and combine the findings from each of these stages, to provide an 
integrated understanding of the results. I consider the strengths and limitations of the work, 
and reflect upon existing literature around timely diagnosis and health literacy to contextualise 
the research. In conclusion I discuss the implications for the research, both at a primary care 
and policy level, along with the possibilities for future research.  
 
8.1. Principal findings  
When exploring factors influencing the timely diagnosis of oesophageal and gastric cancer, I 
found that participants often had multiple symptoms prior to diagnosis, with subtle differences 
noticeable between the cancers. While previous research relating timely diagnosis with health 
literacy was limited, I identified that high health literacy skills were required for those with 
multiple consultations when engaging with healthcare providers and navigating the healthcare 
system to obtain a diagnosis. These findings could have implications for recognising symptoms 
of these cancers earlier and for finding ways of limiting the health literacy burden on 
participants during the HSI. I describe these principal findings in more detail below, and the 
research implications in Section 8.4. 
 
Through my background literature review on the timely diagnosis of oesophageal and gastric 
cancer, I identified a lack of qualitative research and an absence of studies exploring the 
influence of health literacy on the pathways to diagnosis. I set out to address this through the 
systematic review that I conducted, and the POSTCARD study, which used a multi-methods 
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approach to evaluate the pathways to diagnosis, and to explore health literacy within this 
patient population. 
 
The systematic review that I conducted on health literacy in the timely diagnosis of 
symptomatic cancer, identified very limited research in this field. The three included studies 
were methodologically poor and therefore, from this available evidence, it was not possible to 
evaluate the influence of health literacy on time to diagnosis. Following a further review and 
critical appraisal of health literacy instruments, I chose to evaluate aspects of health literacy in 
the POSTCARD study using the HLQ266. I chose the HLQ as it was the only instrument to fulfil 
all of my criteria for an assessment tool, including: evaluating health literacy as a multi-
dimensional concept, designed for independent completion, available for use, good 
psychometric properties, ability to briefly assess aspects of health literacy, and appropriate for 
the context of the study. Despite this careful consideration of the instrument requirements and 
its domains, the mean scores for both domains used in the POSTCARD study (engagement 
and understanding) were high. This limited the health literacy assessment possible through 
the questionnaire data, although the analysis suggested that ‘understanding’ was lower in 
participants reporting fatigue/tiredness or heartburn than participants not reporting these 
symptoms. The HLQ also provided a useful framework for evaluating health literacy in the 
interviews. 
 
Participants experienced a number of symptoms prior to diagnosis. However, they presented 
very few to their GP at the initial consultation. There were subtle differences in symptom 
experience between the cancer types: while gastric cancer participants discussed changes to 
appetite and reported fatigue/tiredness or weight loss, participants with oesophageal cancer 
reported difficulty swallowing and, in the interviews, referred to the unusual nature of their 
sickness. Only 11 (8.7%) participants (7 oesophageal, 4 gastric) reported experiencing 
heartburn all or most of the time, and when I explored understanding of ‘heartburn’, ‘reflux’ and 
‘indigestion’ in the interviews, it was apparent that numerous meanings and experiences were 
attributed to these descriptions. When exploring the appraisal of other symptoms prior to 
diagnosis, symptoms were often attributed to benign conditions or normalised until they 
became unusual, or increased in frequency or severity to the point of interfering with daily life. 
Social support was important for encouraging help-seeking, particularly for older participants, 
while a high health literacy ability was required for engaging with the healthcare system where 
multiple consultations occurred prior to diagnosis.  
 
Participants experiencing nausea or using prescription PPI medication had a longer pTDI than 
those without nausea or prescription medication, although the effect size was small and 
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caution is required in interpreting these isolated statistically significant findings. For interview 
participants describing multiple consultations, the HSI was longer than the PI, although this is 
subject to the interpretation of interval start dates, which I discuss in further detail in Section 
8.4.1.  
 
8.2. Strengths and limitations 
In this section I outline the strengths and limitations of my research based on the entire 
programme of work.   
 
8.2.1. Strengths 
Design and development 
A key strength of my research is the rigorous design and development, as outlined in Figure 
1.1 (Chapter 1). I integrated a variety of approaches, including two literature reviews, a 
systematic review and a multi-methods study, to explore the factors influencing the pathways 
to diagnosis of oesophageal and gastric cancer, and to understand the influence of health 
literacy on timely diagnosis. While the literature reviews informed the development of the multi-
methods study, the systematic review enhanced my understanding of health literacy in timely 
diagnosis, informing the analysis of the POSTCARD study and prompting reflection on the use 
of health literacy instruments in research (Figure 8.1). The findings of the interview study 
assisted with my understanding of the questionnaire data and prompted an evaluation of 
interval definitions (Section 8.4.1).  
 
Throughout the design and development, I reflected on previous research and incorporated 
the expertise of my supervisors, advisor, gastroenterology consultants and the advice of the 
patient representatives involved in the study. To underpin and clearly define the evaluation of 
timely diagnosis and health literacy, I used the MoPT140,141, as recommended by the Aarhus 
Statement142 and the HLQ266, both in questionnaire format and as a framework for interviews.   
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Figure 8.1. Research design and reflections 
 
Research design as outlined in Figure 1.1. Red arrows indicate reflections on the programme of work 
 
8.2.2. Limitations 
Patient population 
When reflecting on the overall findings in relation to factors influencing the pathways to 
diagnosis, a larger and more representative sample in the POSTCARD study would have been 
beneficial for the generalisability of results. Recruiting from additional hospitals and including 
areas with wider ethnic diversity may have helped with this issue. However, expanding the 
study would have been difficult due to the financial and time-based constraints of the research. 
 
The approach of my research also did not permit for a comparison between the pathways to 
diagnosis of those diagnosed with cancer and those experiencing benign conditions, which 
would have been useful for identifying differences that could have informed public and primary 
care awareness. The SYMPTOM studies took this approach, with the quantitative strands 
identifying some differences in patients diagnosed with lung, colorectal or pancreatic cancer 
compared to those found to have other conditions391-393, although differences were not 
identified based on the qualitative findings144,145,430. However, these were large studies 
recruiting over a four year period and of the 3861 participants recruited across the studies, only 
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424 (11%) were diagnosed with lung, colorectal or pancreatic cancer391-393. Reflecting on these 
studies, it would not have been practical to take this approach in my programme of work. I had 
limited time for conducting a study and based on the SYMPTOM studies recruitment figures, 
very few diagnoses of oesophageal or gastric cancers would have been identified in my time 
frame, therefore providing inadequate comparison between cancers and non-cancers.  
 
Healthcare perspective 
An additional consideration for the study design involved evaluating the factors influencing the 
HSI, which I identified as an important influence on timely diagnosis from my background 
review. I explored this interval with participants in the study, relying on their reporting and 
narratives to confirm consultation dates and symptoms discussed with healthcare providers. 
While this was useful for exploring the participant’s perspective of their pathways to diagnosis, 
I was not able to confirm dates with primary care medical records or symptoms discussed 
based on those recorded by GPs. For participants with multiple consultations prior to diagnosis, 
I was also not able to evaluate the healthcare provider’s views on symptoms presented, and 
therefore whether earlier referral may have been possible from a primary care perspective. I 
could have explored the diagnosis from a primary care perspective by asking participants to 
provide details of their GP practice and consent for reviewing their primary care medical 
records. In addition, it may have been possible to interview GPs in relation to the participant’s 
pathway to diagnosis, particularly for those with multiple consultations. However, this would 
have been complex to coordinate across two regions with the resources available for the study.  
 
Health literacy considerations 
While my work has highlighted some important considerations around health literacy in the 
timely diagnosis of cancer, the breadth and depth of my research could have been expanded 
by widening the systematic review criteria and taking further steps to encourage those with low 
health literacy to participate in the POSTCARD study. Health literacy incorporates many 
aspects relating to individual abilities, social networks and use of the health system. However, 
this reflects a recent expansion of the concept, therefore previous research, particularly using 
qualitative methods, may have explored aspects of health literacy without labelling them as 
such. These studies would have been excluded from my systematic review, yet may have 
provided a deeper understanding of health literacy in this patient population. In addition, the 
recruitment approach that I chose for the POSTCARD study potentially limited the ability to 
include participants with lower health literacy. Patients may not have been comfortable 
completing the questionnaire at home, or confident in contacting a researcher to complete it 
by phone. I acknowledged this when choosing to use a questionnaire based survey, rather 
than online, face-to-face or by phone. If it had been possible, completing the questionnaire in 
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person with participants would have addressed the potential exclusion of those with low health 
literacy. However, this would either have placed significant burden on the hospital teams, which 
was not practical when recruiting from busy clinics, or required my presence at the clinics each 
week, therefore detracting from my ability to complete the other phases of my research.  
 
When considering other ways to explore health literacy, filming consultations in primary care 
would be a useful way for evaluating how patients present symptoms and the communication 
between GPs and patients when discussing symptoms.  However, this approach would not be 
suitable for selecting patients subsequently diagnosed with oesophageal or gastric cancer. 
Instead, it could be used to explore gastrointestinal symptoms in a general population, either 
combined with additional patient and/or GP interviews, or with an assessment of health literacy 
to contextualise the consultation based on health literacy ability. 
 
8.3. Comparison with existing literature 
A recent systematic review explored presentation and survival in gastroesophageal cancer, 
identifying 12 studies published worldwide from 2000-2014435. The authors determined that the 
PI was the most important period for influencing timely diagnosis. However, they based this on 
the results of five methodologically weak studies assessing the PI, and did not account for the 
HSI, instead focusing on the TDI and pre-treatment interval for comparison. Having excluded 
the HSI, the conclusions from the review are limited. However, the findings from the 
POSTCARD interview study highlight the importance of the PI in timely diagnosis, as the PI 
was longer than the HSI based on all interview participants (median 74 days vs 48 days); 
although the questionnaire data showed the opposite (median pPI 21 days vs HSI 33.5 days). 
This could be attributed to the difference in definition of the PI from the questionnaire data.  
 
In this section I compare findings from the POSTCARD study with existing literature, describing 
the PI and HSI separately, and referring to previous studies exploring oesophageal and gastric 
cancer, as well as the wider literature around timely diagnosis of other cancers.  
 
8.3.1. Patient interval 
Many factors can affect the PI, influencing the time from first noticing a symptom to first 
consultation. My background literature review (Chapter 2), showed that factors lengthening the 
PI include: younger age50,61,83,94,99, medication use164 and non-recognition of symptom 
seriousness59,64,77,81,85,151,156, with some evidence to suggest that those with oesophageal 
cancer have a longer PI than gastric cancer patients156,165. I have considered some of these 
factors below, in relation to the POSTCARD study findings, along with other factors influencing 
the PI. 
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Cancer type 
A recent study exploring differences between oesophageal and gastric cancer, using data from 
the English National Audit of Cancer Diagnosis in Primary Care, identified a median PI of 21.5 
days for oesophageal patients compared to 9 days for gastric patients396. This is reflected in 
the POSTCARD interview findings where the PI was longer for oesophageal cancer than 
gastric cancer participants (median 134 days vs 60 days), although these intervals are much 
longer than the audit data mentioned above. In comparison, the questionnaire results showed 
that the length of the pPI was similar for oesophageal and gastric cancer participants (median 
21 days vs 24.5 days), although this could be attributed to the difference in definition of the PI 
and pPI. 
 
Knowledge 
While some participants were aware of oesophageal or gastric cancer through the experiences 
of family members, most had limited knowledge of these cancers prior to diagnosis. This 
resonates with the findings of a recent qualitative study, published in January 2018, exploring 
the PI with 14 participants diagnosed with oesophageal cancer in Scotland between 2012 and 
2015436. Interviews were conducted within nine-months of diagnosis, with the authors finding 
participants had limited knowledge of oesophageal cancer. In a study exploring healthcare 
providers’ opinions of main problems and solutions relating to timely diagnosis, patients’ lack 
of awareness of alarm symptoms was a key issue identified in contributing to increasing the 
time to diagnosis437.   
 
Symptom experience 
I identified subtle differences between symptoms reported by oesophageal and gastric cancer 
participants. Difficulty swallowing was reported as the trigger symptom (first symptom 
presented to the GP) by 44 (34.6%) participants, although this was mainly attributable to 
oesophageal participants (n=43), who mentioned this symptom more often than gastric 
participants. Irving et al., 2002, reported similar findings from their study of 65 oesophageal 
and 25 gastric cancer patients in one English hospital47. The most common symptom reported 
at presentation was difficulty swallowing (n=58, 64%); however, when cancer type was taken 
in to account, this symptom was more prevalent in those with oesophageal cancer compared 
to gastric (77% vs 32%). In comparison, the POSTCARD study found that gastric cancer 
participants were more likely to discuss or report decreased appetite, fatigue/tiredness or 
weight loss, although it was not possible to identify a specific trigger symptom for help-seeking 
in this group. In studies exploring the predictive values of symptoms, both difficulty swallowing 
and weight loss have been associated with oesophago-gastric cancers65,66,73-79; however, it is 
unclear whether the associations are different when considering the cancers individually.  
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Guidelines and awareness campaigns 
Differences in symptom experience could be important when considering referral guidelines 
and campaigns to raise awareness and knowledge of oesophageal and gastric cancer. 
According to the 2015 NICE referral guidelines for suspected cancer41, difficulty swallowing 
should prompt urgent referral from primary care, while non-urgent referral is recommended for 
weight loss if combined with upper abdominal pain, reflux or dyspepsia in patients aged 55 or 
over. Decreased appetite and fatigue/tiredness are not included in the guidelines. The 2015 
National Be Clear on Cancer oesophago-gastric cancer campaign69 focused on recurrent 
heartburn in the primary television and leaflet campaign, and ‘food sticking’ in their secondary 
radio campaign. The latter message may not resonate with patients experiencing symptoms 
of gastric cancer, as they rarely mentioned swallowing difficulties. Only one participant, 
diagnosed with oesophageal cancer, mentioned the campaign in the POSTCARD study 
interviews, having heard the radio advert. However, he did not act on the advice of the advert, 
to see a doctor, until he experienced additional symptoms. This differs from studies with 
patients experiencing symptoms suggestive of lung or colorectal cancer, where the Be Clear 
on Cancer campaigns for lung and colorectal symptoms were found to prompt help-
seeking145,438.  
 
I also identified a disconnect between the main message of the Be Clear on Cancer campaign 
for oesophago-gastric cancer and the experiences of participants in relation to heartburn. The 
campaign’s message was “heartburn most days for three weeks or more? Tell your doctor”69. 
Although a third of participants reported experiencing heartburn ‘some of the time’, very few 
reported it as a symptom they experienced ‘all or most of the time’, therefore the message may 
not resonate with people as intended. It is also possible that the term ‘heartburn’ is not widely 
understood, as Spechler et al. found in their study of patients diagnosed with GORD14. I found 
that heartburn was mentioned infrequently in the interviews with participants more likely to 
refer to reflux, or describe indigestion, which often prompted help-seeking due to the painful 
nature of the symptom.  
 
Two studies have recently evaluated the impact of the National Be Clear on Cancer campaign 
in South Durham and the West Midlands. The former study compared 283 patients referred at 
the time of the campaign (February-March 2015) with 123 patients referred June-July 2015439. 
The latter study focused on two-week wait referrals and compared 1266 patients referred 
during the campaign period, with 777 patients referred during the same months in 2014440. 
Both studies identified a significant increase in referrals during the campaign period, yet did 
not identify a significant increase in diagnosis of oesophageal or gastric cancer.  
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Nature of symptoms 
Many participants discussed the nature of their symptom experience and how this influenced 
their pathway to diagnosis. A novel finding from my study interviews, which has not been 
identified in previous research, is the unusual nature of the sickness participants’ experienced. 
While patient-based57,69-72,86 and published literature62,66 has associated vomiting with 
oesophageal and gastric cancer, interview participants often described how their sickness was 
not like normal vomit, and was often more like ‘stringy goo’. The unusual nature of symptoms 
often prompted participants to consider help-seeking. In contrast, participants could often find 
alternative explanations for non-specific or intermittent symptoms. This was also identified in 
the recent qualitative study by Lewis et al., exploring symptom appraisal in participants 
diagnosed with oesophageal cancer in Scotland, with participants initially appraising symptoms 
in the context of normal bodily functions436. Research across other cancer types, or exploring 
symptoms suggestive of cancer, has also emphasized the importance of symptom experience 
on influencing appraisal and re-appraisal. Many studies have found that the PI is lengthened 
where subtle or intermittent symptoms are not considered serious144,145,406,429,430,441 or when 
initial bodily changes are attributed to benign causes390,406,438,442,443. The latter was identified 
by all studies included in my systematic review, with Nakagami & Akashi proposing that health 
literacy skills are used to form a ‘disease hypothesis’ based on prior knowledge and 
experience251, while McEwan et al. considered risk factor knowledge in relation to health 
literacy.  A study published after the completion of my systematic review, explored the influence 
of health literacy on help-seeking based on interviews with 16 women diagnosed with 
endometrial cancer441. Similar to the studies in my systematic reviews, the authors related 
health literacy to how women attributed their symptoms to benign causes, knowledge of risk 
factors and understanding in relation to cervical screening, which often gave women a false 
sense of security.  
 
Lewis et al., identified the importance of changing, unexpected, or worsening symptoms for 
the oesophageal cancer patients in their study436, while I found that overwhelming, persistent 
or worsening symptoms, and those impacting on daily life, generally prompted participants to 
seek help. The changing nature of symptoms has also been found to prompt help-seeking in 
other cancers144,145,406,430,438,442,443, and persistent or worsening symptoms were factors 
identified in my systematic review for prompting participants to obtain further information and 
re-evaluate their symptoms.  
 
8.3.2. Health system interval 
The HSI can be further divided into the primary care interval (from presentation to referral) and 
secondary care interval (from referral to diagnosis), an approach taken by recent studies 
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investigating time to diagnosis across cancers42,396. I identified various factors associated with 
lengthening the HSI for patients with oesophageal or gastric cancer (Chapter 2), including: 
younger age64,74,94,147,163, female gender93,147,153, presenting without alarm symptoms63,147, use 
of medication51,59,64,73,77,90,91,157,159,164, investigations or an alternative diagnosis in primary 
care44,52,64,75,77,81,85,94,152,164 and negative investigations in secondary care61,93,155. There was 
mixed evidence regarding cancer type, as one study identified a longer primary care interval 
for oesophageal cancer patients compared to gastric cancer154, while most studies identified 
the opposite44,51,146,164. A more recent study, published in 2018 and based on data from the 
2014 National Audit of Cancer Diagnosis in England, also identified a longer HSI for patients 
with gastric cancer (n=260, median 42 days, IQR 17-89.2) compared to oesophageal cancer 
(n=383, median 28 days, IQR 12-65.5)444. My findings did not identify any differences in HSI 
length between oesophageal and gastric cancer when considering the total cohort of 
questionnaire or interview participants.  
 
Multiple consultations 
A study by Lyratzopoulos et al., published in 2013, using data from the English National Audit 
of Cancer Diagnosis in Primary Care, found a strong correlation between the number of pre-
referral consultations and length of the primary care interval42. I also found this association in 
the POSTCARD study questionnaire data, where participants reporting one or two 
consultations had a shorter HSI compared to those reporting three or more (median 28 vs 
106.5 days). This was also apparent in the interview data when exploring single consultations 
in comparison to those with more than one consultation (median 28 vs 130 days).  
 
There could be many reasons for requiring multiple consultations, including primary care-led 
investigations, or an initial alternative diagnosis with use of prescription medication. I found 
that the use of prescription PPIs lengthened the HSI and pTDI, although the effect size was 
small. In the interviews some participants with multiple consultations talked about help-seeking 
and being prescribed PPIs as an initial course of action. While some recalled being advised to 
return after a six-week period, others appeared to view the medication as a long-term solution 
to their symptoms.  
 
In an interview study of patients with symptoms suggestive of lung cancer, the authors found 
that patients re-consulted more promptly when given guidance by the GP on when to re-consult 
if symptoms persisted (safety-netting)145. In another study interviewing 155 patients in England, 
Denmark and Sweden within six months of their diagnosis of lung or bowel cancer, participants 
without clear guidance felt confused and unsure of when to re-consult, particularly if re-
consulting for the same symptom having been previously reassured442. These participants 
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often felt frustrated or dissatisfied with their experience; a feeling that was also voiced by 
participants with multiple consultations in the POSTCARD study. Participants described how 
they were not listened to, or not taken seriously, a view that Parsonage et al., 2017, also 
identified in their qualitative analysis of free-text responses to a survey of patients newly 
diagnosed with breast, ovarian, colorectal, or lung cancer in Wales, UK445. A discrete choice 
experiment in the UK identified that a key preference of patients when consulting is to see a 
GP with good listening skills446. In this study, 601 participants were presented with various 
scenarios to explore their preferences when consulting for possible cancer symptoms. Based 
on the participants’ choices, it was possible to explore consultation preferences, such as 
willingness to wait longer to obtain an appointment if they could see a GP with good listening 
skills compared to being seen quicker by a GP with poor listening skills446.  
 
Engagement with healthcare providers 
I aimed to explore interactions with healthcare providers through the inclusion of the HLQ 
‘engagement’ domain in the study questionnaire; however, the mean score was high, showing 
little variation between participants. While it is possible that participants did feel confident in 
engaging with healthcare providers, a recent qualitative study exploring patient-clinician 
agreement on HLQ scores found the highest disagreement to be the patient’s ability to actively 
engage with healthcare providers447. In this Australian study, 16 participants with complex or 
chronic conditions completed the HLQ as did their clinician, based on their view of the patient’s 
abilities. When exploring the HLQ responses in interviews with the clinicians, they felt that 
while patients could often chat with them in a social way, they were less likely to ask questions 
or understand their health issues. I also observed this in the interviews I conducted, with 
participants often speaking of the good relationship they had with their GP or a nurse, yet not 
engaging with them on a medical level. Most participants therefore accepted the outcome of 
the consultation on the basis of the GP ‘knowing best’, even when they were not reassured by 
the advice or the alternative diagnosis given. Andersen et al., 2011, explored help-seeking in 
relation to the structure of the Danish healthcare system and described this as the 
“asymmetrical relationship between the patient and the GP”, where the GP has the medical 
knowledge and the patients feel they should accept their judgement448. It was at this stage in 
the POSTCARD study that health literacy ability seemed particularly important, with some 
participants feeling the need to be assertive in their relationship with their GP or in finding 
alternative ways through the healthcare system to obtain their diagnosis. This was also 
highlighted in two of the studies in my systematic review, through the importance of the GP-
patient relationship250 and in navigating the healthcare system251 for prompting timely diagnosis 
of cancer.   
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8.4. Implications 
I now discuss the implications of my work in relation to both timely diagnosis and health literacy 
research, how my findings may impact awareness campaigns, considerations for primary care 
and suggestions for future research.  
 
8.4.1. Timely diagnosis  
I chose to use the MoPT140,141 as a framework for my research; however, I observed some 
difficulties in defining the intervals based on patient reported data, as the format of the model 
made it difficult to observe the interaction between patients and healthcare providers along the 
pathway. I have addressed these points below.  
 
Interval definitions 
Based on the definitions of the MoPT and supported by the Aarhus Statement, the HSI 
commences at the time of first presentation, defined as “the time point at which, given the 
presenting signs, symptoms, history and other risk factors, it would be at least possible for the 
clinician seeing the patient to have started investigation or referral for possible important 
pathology, including cancer”142. Most participants reported their first consultation as the start 
of their cancer pathway; therefore, based on the patient’s narrative this time point represents 
the end of the PI and the beginning of the HSI, which continued until diagnosis. While this 
definition is appropriate for those with a single consultation, when participants recall multiple 
consultations it is difficult to identify whether it would have been possible for the healthcare 
provider to start investigations at the first consultation.  
 
The period between first consultation (as perceived by the patient) and the last consultation 
(associated with the referral leading to the diagnosis) is therefore a grey area. Based on current 
definitions, this period can either be assigned to the PI while the patient re-appraises their 
symptoms and decides to seek help again, or to the HSI based on a missed opportunity for 
diagnosis. However, rather than assigning this period either to the patient or healthcare 
system, it should be seen as a time of re-appraisal influenced by both. During this period it is 
essential for the patient to monitor and re-appraise their symptoms, although, this can be 
guided by healthcare providers based on the advice given at the first consultation. This 
engagement between the patient and healthcare provider could be important for reducing the 
period of re-appraisal, which I discuss below.   
 
Format 
The current format of the MoPT represents the pathway from first thing noticed, to initiation of 
treatment, with patients moving forwards and backwards through the pathway until they reach 
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their diagnosis and treatment. In this context, the pathway can feel like a game of Snakes and 
Ladders, rather than the progression towards a diagnosis. Based on this and my observation 
of the period of re-appraisal, I have adapted the model to focus on the period leading up to 
diagnosis and to account for the interaction between patients and healthcare providers (Figure 
8.2). Unlike the original model, I have not considered the time between diagnosis and initiation 
of treatment (pre-treatment interval). 
 
The adapted model illustrates the cyclical pathway through the appraisal, help-seeking and 
diagnostic intervals. The pathway can begin at any time point; for example, some may enter 
at the diagnostic interval based on an incidental finding (related to another condition), 
prompting investigations. The patients may also cycle through the intervals multiple times 
before exiting at the point of diagnosis. In considering the processes within each interval, I 
adapted the wording relating to the appraisal and diagnostic intervals. For the appraisal interval 
I changed the wording from ‘patient appraisal and self-management’ to ‘(re)appraisal and 
management’. This was to symbolise that the appraisal interval can represent either initial 
appraisal or subsequent re-appraisal, with the latter influenced by healthcare provider advice. 
The original diagnostic interval wording was ‘HCP appraisal, investigations, referrals and 
appointments’, which I updated by removing ‘HCP’. I made this change to represent that the 
diagnostic interval is a period of interaction between patients and healthcare providers, rather 
than one dominated by the healthcare provider.  
 
This new perspective is particularly relevant for qualitative research where the cyclical nature 
of the pathway can be explored with participants to determine the movement between stages 
and therefore the periods of appraisal and re-appraisal in relation to the diagnostic interval(s). 
It may be possible to explore appraisal and re-appraisal via surveys based on patient reporting 
of the number of consultations prior to diagnosis and dates of consultations, which could be 
supported by a review of medical records. These approaches would provide insights in to the 
length of the appraisal interval as well as the re-appraisal interval, which are unique periods 
when considering interventions to improve timely diagnosis. While the focus for the appraisal 
interval could be to target symptom awareness, it may be more appropriate to address GP-
patient communication and safety-netting in primary care to shorten the re-appraisal interval.  
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Figure 8.2. Pathways to diagnosis 
 
Based on the appraisal, help-seeking and diagnostic intervals of the MoPT140,141 
 
8.4.2. Health literacy  
Over the past two decades, health literacy research has expanded from a focus on numeracy 
and comprehension skills in health, to a multi-dimensional construct encompassing 
behaviours, knowledge, social relationships and healthcare structure. With such a wide reach, 
I found it challenging to explore health literacy as an entire concept in my research, with further 
complexity added in attempting to assess health literacy across the period covered from 
symptom appraisal to diagnosis. As discussed, the assessment of health literacy in the study 
questionnaire could have been affected by the timing of recruitment. Health literacy abilities 
may change over time, even when considering the relatively short period leading up to and 
immediately following diagnosis. In this period patients engage with many healthcare providers 
and are exposed to a large amount of information, which may increase their health literacy 
abilities in comparison to the period leading up to help-seeking and referral to specialist care. 
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This makes it difficult to assess health literacy using a survey instrument, as the response is a 
reflection of one point in time.  
 
As health literacy in timely diagnosis of symptomatic cancer is a new field, findings from 
exploratory studies are important for narrowing the focus as to which aspects of health literacy 
are particularly important along the patient’s pathway. The findings of the POSTCARD study 
interviews would suggest that engagement with healthcare providers and ability to navigate 
the healthcare system are important for those with multiple consultations, and it may be 
beneficial to explore this further. 
 
8.4.3. Awareness campaigns  
An important consideration for future awareness campaigns is to reflect on the wording used 
to relate messages to the public. I identified problems with the main campaign message in the 
Be Clear on Cancer campaign for oesophago-gastric cancer, particularly around using the term 
‘heartburn’, and quantifying it as ‘most days’. My interview data showed that ‘heartburn’ was 
used infrequently, with participants instead referring to ‘reflux’, ‘acid’ or ‘burning’. Participants 
also seemed to relate more to ‘indigestion’ than heartburn. Furthermore, very few participants 
considered themselves to have heartburn all or most of the time, with most experiencing it 
occasionally, if at all. For patients who do experience heartburn occasionally yet over a long 
period, they may not feel that the campaign message in its current format prompts them to 
consult their GP.  
 
The radio campaign message focused on ‘food sticking’, yet many POSTCARD participants 
also referred to ‘difficulty swallowing’. While these may appear to reference the same issue, 
the descriptions could have different connotations for people. A bit of difficulty swallowing may 
be easier to dismiss or attribute to other things than a feeling that food is getting stuck in the 
oesophagus. Where there are different ways of referring to a symptom, as seen with ‘heartburn’ 
and ‘food sticking’, it may be beneficial for future campaigns to incorporate a wider range of 
words or small word clouds. This could reduce any barriers that come with understanding 
specific terms, and could therefore relate to a wider audience. 
 
Furthermore, I suggest that awareness campaigns should consider referring to oesophageal 
and gastric cancer separately to increase public knowledge. While both have some similar 
symptoms, there are also subtle differences such as the association of difficulty swallowing 
primarily with oesophageal cancer. With this in mind, the 2015 Be Clear on Cancer campaign 
focused more on awareness of oesophageal cancer than gastric. While the incidence of gastric 
cancer is decreasing, there are still almost 7000 people diagnosed with the cancer in the UK 
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each year3, so campaigns should aim to raise awareness of it too. Participants taking part in 
my interviews were familiar with the function of the stomach, yet the oesophagus was more 
obscure; something the participants had never thought of, and certainly never considered as 
a place for cancer. While raising awareness and understanding of symptoms is important, a 
key factor of awareness campaigns should also be to increase knowledge and understanding 
about the workings of the human body. This may assist the public to recognise illness based 
on the nature of symptoms and the connection between them, rather than focusing on 
individual symptoms that are unlikely to be experienced in isolation.    
 
8.4.4. Primary care 
Although my research did not directly involve primary care, the findings have implications for 
improving the pathways to diagnosis in this setting. Participants had many symptoms prior to 
diagnosis, yet, according to the questionnaire responses, they presented very few at their first 
consultation. If this does accurately reflect GP-patient communication during the consultation, 
the data highlights that in-depth exploration for additional symptoms should be encouraged, 
particularly those that the participant may not recognise as important, such as weight loss or 
tiredness. As discussed, patients’ language for describing experiences differs and this should 
be in mind when primary care clinicians are exploring symptoms with patients, and interpreting 
patient responses. Brindle et al.’s qualitative study of symptoms and help-seeking for 
symptoms suggestive of lung cancer, identified that patients did not present symptoms that 
they had normalised389. They also found that when health changes were explored, questions 
using non-disease related terminology, such as ‘discomfort’, prompted fuller accounts of 
symptom experience in comparison to disease related questions, for example, those referring 
to ‘pain’. I also observed this in the POSTCARD study interviews, with participants seemingly 
reluctant to refer to pain, instead preferring to describe their ‘discomfort’.  
 
While I found health literacy ability to be particularly important in the health system interval, it 
should not be viewed as the sole responsibility of the patient. Healthcare providers have an 
essential role to play in enhancing the health literacy of their patients, particularly in 
empowering them to re-consult and to access the specialist care required. Where patients are 
given medication or reassured in a consultation (either at the first consultation or following 
investigations), they should be made aware that (other) investigations are available if the 
symptoms persist, change or worsen. This strategy for safety-netting could encourage some 
patients to re-present sooner. 
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8.4.5. Further research 
I successfully applied for nine months of funding (April 2018-December 2018) to the National 
Institute for Health Research’s School for Primary Care Research to conduct a secondary 
analysis of the data from the POSTCARD study interviews along with the SYMPTOM pancreas 
study interview data430. This secondary analysis aims to explore patients’ personal and social 
relationship with food in relation to appraisal and management of symptoms suggestive of 
upper gastrointestinal cancer, and how this affects presentation of these symptoms in primary 
care. Combining the interview data from the two studies will provide a rich dataset (52 
interviews) for exploring adaptations to eating, leading to a more robust analysis than I could 
have achieved if I had explored this topic within my thesis. This will be an important piece of 
research, continuing the exploration of how participants experience and manage their 
symptoms. It could underpin further applications to develop interventions to alter behaviours 
around symptom management and potentially lead to a new focus for messages in cancer 
awareness campaigns. 
 
Timely diagnosis 
Based on the study findings it is possible that patients experience more symptoms than they 
present to primary care, which could influence the GP assessment of symptoms and therefore 
the decision to refer. A CPRD based study would provide a large sample to evaluate the 
number and types of symptoms presented in primary care leading up to a diagnosis of 
oesophageal or gastric cancer, and to identify any differences between the cancers. This could 
inform a larger patient-GP dyad interview study to explore symptom understanding and 
presentation, particularly in relation to unusual symptoms, such as the sickness that 
participants reported in the POSTCARD study.  
 
Exploring and understanding the re-appraisal interval for patients with multiple consultations 
may also provide insights into effective strategies for safety-netting patients in primary care 
and minimising missed opportunities for timely diagnosis of cancer. Qualitative interview 
studies are essential for understanding the patient perspective of the re-appraisal interval, 
while combining this method with a review of the patient’s primary care medical records or 
interviews with GPs would allow for exploration of the primary care perspective. When 
publishing findings, it would be useful to report the length of the re-appraisal interval, in addition 
to the PI and HSI, and to compare the patient and primary care perspective at time points 
along the pathway to identify any mismatch in understanding of this period.  
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Health literacy 
Engagement with healthcare providers and ability to navigate the healthcare system could be 
important aspects of health literacy for timely diagnosis of cancer; however, to determine the 
influence of health literacy, it would be beneficial to recruit patients prior to their diagnosis. A 
large primary care based survey study could use the HLQ to explore and compare health 
literacy ability in patients presenting with symptoms suggestive of cancer where they are: 1) 
not referred, 2) referred and either discharged or diagnosed with a benign condition, or 3) 
referred and diagnosed with cancer. Recruitment for this study would be similar to the 
approach taken for the SYMPTOM studies391-393, with a sample of patients interviewed to 
explore participants’ responses to the HLQ and to compare health literacy between the patient 
groups. This approach would allow for a more robust assessment of the usefulness of the HLQ 
as a research tool in this patient population.  
 
It would also be useful to further explore the individual domains of health literacy in previous 
timely diagnosis research. My systematic review was aimed at identifying research that 
specifically referenced health literacy (or literacy in relation to health). However, in exploring 
research related to each of the domains of health literacy, yet not classifying it as such, it could 
be possible to identify the more nuanced health literacy issues relevant for influencing timely 
cancer diagnosis.  
 
8.5. Summary 
In this thesis I have reflected on previous research in relation to oesophageal and gastric 
cancers, and integrated knowledge gained from other cancers with the new perspective of 
health literacy to guide my research aimed at exploring the timely diagnosis of oesophageal 
and gastric cancers. Throughout my research I took a rigorous, evidence-based and 
systematic approach in exploring, understanding and developing each stage to ensure the 
overall quality of the research. I have found parallels between my research and existing cancer 
literature, whilst also generating novel insights around symptom experience and the influence 
of health literacy on patient’s symptom appraisal and encounters with the healthcare system. 
In adapting the MoPT, I have introduced a new perspective for considering the interval 
definitions, which may be particularly relevant for qualitative research where the cyclical nature 
of the pathway can be explored. I hope that my research may lead others to consider the 
influence of health literacy in the healthcare system, and to explore oesophageal and gastric 
cancers with the goal of improving outcomes for people diagnosed with these cancers. 
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Appendices 
Appendix 1: Gastro-oesophageal Reflux Disease Questionnaire (GerdQ)
 
 
Respondents enter the frequency scores after reflecting on their symptoms over the previous 
week 
Question 
Frequency score (points) for symptom 
0 day 1 day 2-3 days 4-7 days 
1. How often did you have a burning feeling behind 
your breastbone (heartburn)? 
0 1 2 3 
2. How often did you have stomach contents (liquid or 
food) moving upwards to your throat or mouth 
(regurgitation)? 
0 1 2 3 
3. How often did you have a pain in the centre of the 
upper stomach? 
3 2 1 0 
4. How often did you have nausea? 
 
3 2 1 0 
5. How often did you have difficulty getting a good 
night’s sleep because of your heartburn and/or 
regurgitation? 
0 1 2 3 
6. How often did you take additional medication for your 
heartburn and/or regurgitation, other than what the 
physician told you to take? (such as Tums, Rolaids, 
Maalox?) 
0 1 2 3 
 
The GerdQ comprises four positive predictors and two negative predictors of GORD. 
 Positive: heartburn, regurgitation, sleep disturbance and use of over the counter 
medication in addition to that prescribed.  
 Negative: abdominal pain and nausea. 
 
Replicated from Jones et al., 200911 
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Appendix 2: NICE guidelines for suspected cancer, 201541 
 
Oesophageal cancer, page 13-14 
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Gastric (stomach) cancer, page 15-16 
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Appendix 3: National Be Clear on Cancer campaign69 
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Appendix 5: Search strategies adapted from MEDLINE/Embase 
 
Scopus 
Search Query 
1 “Cancer*”  TITLE-ABS-KEY 
2 “Tumour*” TITLE-ABS-KEY 
3 “Tumor*” TITLE-ABS-KEY 
4 “Malignan*” TITLE-ABS-KEY 
5 “Neoplasm*” TITLE-ABS-KEY 
6 Or/1-5  
7 “Health Literacy” TITLE-ABS-KEY 
8 “Health Literate” TITLE-ABS-KEY 
9 “Health Literacies”  TITLE-ABS-KEY 
10 “Literacy” TITLE-ABS-KEY 
11 “Literate” TITLE-ABS-KEY 
12 “Literacies”  TITLE-ABS-KEY 
13 “Cancer literacy”  TITLE-ABS-KEY 
14 “Cancer literate” TITLE-ABS-KEY 
15 “Numeracy” TITLE-ABS-KEY 
16 “Numerate” TITLE-ABS-KEY 
17 Or/7-16  
18 6 AND 17  
19 “Systematic review” TITLE 
20 18 NOT 19  
21 Limit 20 to yr="1990 -Current"  
 
CINAHL 
Search Query 
1 “Cancer*”.mp 
2 “Tumour*”.mp 
3 “Tumor*”.mp 
4 “Malignan*”.mp 
5 “Neoplasm*”.mp 
6 Or/1-5 
7 exp Health Literacy/ 
8 “Health Literacy”.mp 
9 “Health Literate”.mp 
10 “Health Literacies”.mp  
11 “Literacy”.mp 
12 “Literate”.mp 
13 “Literacies”.mp  
14 “Cancer literacy”.mp  
15 “Cancer literate”.mp 
16 “Numeracy”.mp 
17 “Numerate”.mp 
18 Or/7-17 
19 6 AND 18 
20 “Systematic review”.m_titl 
21 19 NOT 20 
22 Limit 21 to yr="1990 -Current" 
  
Current = May 2017 
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ASSIA 
Search Query 
1 “Cancer*”.mp 
2 “Tumour*”.mp 
3 “Tumor*”.mp 
4 “Malignan*”.mp 
5 “Neoplasm*”.mp 
6 Or/1-5 
7 “Health Literacy” 
8 “Health Literate” 
9 “Health Literacies”  
10 “Literacy” 
11 “Literate” 
12 “Literacies”  
13 “Cancer literacy”  
14 “Cancer literate” 
15 “Numeracy” 
16 “Numerate” 
17 Or/7-16 
18 6 AND 17 
19 ti(“Systematic review”) 
20 18 NOT 19 
21 Limit 20 to yr="1990 -Current" 
 
PsycINFO 
Search Query 
1 “Cancer*” 
2 “Tumour*” 
3 “Tumor*” 
4 “Malignan*” 
5 “Neoplasm*” 
6 DE "Neoplasms" OR DE "Benign Neoplasms" OR DE "Breast Neoplasms" OR DE 
"Endocrine Neoplasms" OR DE "Leukemias" OR DE "Melanoma" OR DE "Metastasis" OR 
DE "Nervous System Neoplasms" OR DE "Terminal Cancer" 
7 Or/1-6 
8 DE “Health Literacy” 
9 “Health Literacy” 
10 “Health Literate” 
11 “Health Literacies”  
12 “Literacy” 
13 “Literate” 
14 “Literacies”  
15 “Cancer literacy”  
16 “Cancer literate” 
17 “Numeracy” 
18 “Numerate” 
19 Or/8-18 
20 7 AND 19 
21 TI “Systematic review” 
22 20 NOT 21 
23 Limit 22 to yr="1990 -Current" 
Current = May 2017 
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Appendix 6: Data extraction form 
 
Template data extraction form 
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Completed data extraction form: Nakagami & Akashi 2010251 
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Completed data extraction form: Tecu & Potter 2012256 
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Completed data extraction form: McEwan et al. 2014250 
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Appendix 7: Joanna Briggs Institute Critical Appraisal Tools230 
 
Template Qualitative Research checklist 
 
 329 
 
Template Analytical Cross Sectional Studies checklist 
 
 
 330 
 
Completed JBI checklist: Nakagami & Akashi 2010251 
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Completed JBI checklist: Tecu & Potter 2012256 
 
 
 332 
 
Completed JBI checklist: McEwan et al. 2014250 
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Appendix 8: Health literacy instrument search strategies 
 
 
PsycINFO and CINAHL search strategies are included in this appendix. Refer to Table 4.1 for 
the Ovid Medline/Embase search strategy. 
 
PsycINFO  
No Search 
1 DE “Health literacy” 
2 “Health Literacy” 
3 1 OR 2 
4 Instrument 
5 Tool 
6 Assessment 
7 Measure* 
8 Indices 
9 Screening 
10 Or/4-9 
11 3 AND 10 
12 Limit 11 to yr=”2014-current” 
Current = September 2015 
 
 
CINAHL  
No Search 
1 MH “Health literacy” 
2 “Health Literacy” 
3 1 OR 2 
4 Instrument 
5 Tool 
6 Assessment 
7 Measure* 
8 Indices 
9 Screening 
10 Or/4-9 
11 3 AND 10 
12 Limit 11 to yr=”2014-current” 
Current = September 2015 
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Appendix 9: Critically appraised health literacy instruments 
 
This appendix includes the following health literacy instruments: 
 
 Health Literacy Questionnaire (HLQ)  
The HLQ is protected by copyright and requires a licence for use. Distribution of the 
questionnaire is therefore restricted and the full version cannot be published. The 
version included in this appendix was published by Osborne et al. in 2013 when 
describing the development and validation of the questionnaire266. 
 
 European Health Literacy Questionnaire (HLS-EU-Q)  
The HLS-EU-Q47 included in this appendix is the additional file published by Sorensen 
et al. in 2013 when describing the design and development of the questionnaire321. 
 
 Cancer Health Literacy Test (CHLT-30 & CHLT-6)  
The CHLT-30 and CHLT-6 included in this appendix are direct copies of the versions 
published by Dumenci et al. in their 2014 paper describing the development of the 
instruments378. 
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Health Literacy Questionnaire (HLQ)  
HLQ domains and items 
1. Feeling understood and supported by healthcare providers 
1 I have at least one healthcare provider who… 
2 I have at least one healthcare provider I can… 
3 I have the healthcare providers I need… 
4 I can rely on at least one… 
2. Having sufficient information to manage my health 
1 I feel I have good information about health 
2 I have enough information to help me deal… 
3 I am sure I have all the information I… 
4 I have all the information I need to… 
3. Actively managing my health 
1 I spend quite a lot of time actively managing… 
2 I make plans for what I need to do to be… 
3 Despite other things in my life, I make time… 
4 I set my own goals about health and fitness 
5 There are things that I do regularly… 
4. Social support for health 
1 I can get access to several people who… 
2 When I feel ill, the people around me really… 
3 If I need help, I have plenty of people I… 
4 I have at least one person… 
5 I have strong support from… 
5. Appraisal of health information 
1 I compare health information from different… 
2 When I see new information about health, I… 
3 I always compare health information from… 
4 I know how to find out if the health… 
5 I ask healthcare providers about the quality… 
6. Ability to actively engage with healthcare providers 
1 Make sure that healthcare providers understand… 
2 Feel able to discuss your health concerns with a… 
3 Have good discussions about your health… 
4 Discuss things with healthcare providers… 
5 Ask healthcare providers questions to get… 
 
Modified from Table 4, Osborne et al., 2013266
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HLQ domains and items (continued) 
7. Navigating the healthcare system 
1 Find the right healthcare 
2 Get to see the healthcare providers I need to 
3 Decide which healthcare provider you need… 
4 Make sure you find the right place to get… 
5 Find out what healthcare services you are… 
6 Work out what is the best care for you 
8. Ability to find good health information 
1 Find information about health problems 
2 Find health information from several… 
3 Get information about health so you are… 
4 Get health information in words you… 
5 Get health information by yourself 
9. Understanding health information well enough to know what to do 
1 Confidently fill medical forms in the correct… 
2 Accurately follow the instructions from… 
3 Read and understand written health… 
4 Read and understand all the information on… 
5 Understand what healthcare providers are… 
Domains 1-5 scored on a disagree/agree Likert scale; domains 6-9 scored on a difficulty Likert scale 
Items are truncated due to licence restrictions 
 
Modified from Table 4, Osborne et al., 2013266 
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European Health Literacy Questionnaire (HLS-EU-Q)  
 
Additional file 1 from Sorensen et al., 2013321
 338 
 
Additional file 1 from Sorensen et al., 2013321 
 339 
Cancer Health Literacy Test (CHLT-30) 
 
Correct responses in bold. Appendix from Dumenci et al., 2014378 
 340 
 
Correct responses in bold. Appendix from Dumenci et al., 2014378
 341 
 
Correct responses in bold. Appendix from Dumenci et al., 2014378
 342 
 
 
 
 
 
 
 
 
 
 
 
 
Correct responses in bold. Appendix from Dumenci et al., 2014378
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Cancer Health Literacy Test (CHLT-6) 
Correct responses in bold. Table 8 from Dumenci et al., 2014378 
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Appendix 10: SYMPTOM study questionnaires 
 
This appendix includes the following: 
 Outline of the SYMPTOM study questionnaire content; 
 Full version of the colorectal and pancreas questionnaire392,393; 
 Full version of the respiratory (lung) questionnaire391. 
 
 
Summary of SYMPTOM study questionnaire content 
Pagea Question(s) Contents 
1 - Detachable consent form 
Part 1: About your symptoms 
2 - 
1 
Example question 
Question to determine: 
 The first ‘thing or symptom’ noticed (free text) 
 The date it was noticed 
 If/when this was presented to a GP or nurse 
3-5 2-10 Questions relating to specific symptoms e.g. change in bowel habit for the 
colorectal/pancreas cancer questionnaire, and asking the participant: 
 If they had the symptom (Yes/No) 
If yes, 
 The date it was noticed 
 If/when this was presented to a GP or nurse 
6 11 
12 
Free text question to describe any additional symptoms experienced 
Question to determine if the GP requested any tests e.g. blood tests 
Part 2: About you 
7 13-15 Multiple choice questions to determine: 
 Employment status 
 Highest level of qualification 
 Ethnic group 
8 16-19 Questions to determine: 
 Living status (Yes/No and free text) 
 Comorbidities (List) 
 Smoking status (Multiple choice) 
 Perceived risk of diabetes, cancer, heart disease or other due to family 
history (Yes/No/Don’t know and free text) 
9 20 Spielberger State-Trait Anxiety Inventory (short-form)416 to determine how the 
participant felt whilst completing the questionnaire 
a 12 sided A4 booklet including front/back cover with patient barcode (Study ID), and one blank page 
(p.10) 
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Colorectal and Pancreas Questionnaire 
 
 
 
 
 
 
 
 
 346 
 
 
 
 
 
 
 
 
 
 
 347 
 
 
 
 
 
 
 
 
 
 
 348 
 
 
 
 
 
 
 
 
 
 
 349 
 
 
 
 
 
 
 
 
 
 
 350 
 
Respiratory (Lung) Questionnaire 
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 352 
 
 
 
 
 
 
 
 
 
 
 353 
 
 
 
 
 
 
 
 
 
 
 354 
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Appendix 11: The POSTCARD study questionnaire 
 
 
 
 356 
 
 
 357 
 
 
 358 
 
 
 359 
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Appendix 12: Think aloud study example questionnaire 
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Appendix 13: POSTCARD study participant information sheet 
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Appendix 14: Analysis codes for interval dates 
 
The following table contains the SYMPTOM study analysis codes (version 4, 03 December 
2012) for converting estimated dates to estimated exact dates391-393. 
 
Analysis codes 
Text for estimated date Rule  Example text Example recode 
‘x days/weeks/months/ 
years ago’ 
 ‘4 months ago’ Count back 4 months 
from completion date 
Few /about/approx./range etc. 
‘Range of months or 
years ago’ 
Take midpoint of 
range 
‘2-3 years ago’  
 
Count back 2.5 years 
from completion date 
‘about (or approx.) x 
days/weeks/months/ 
years ago’ 
Ignore ‘about’ or 
‘approx.’ 
‘About 4 months ago’ Count back 4 months 
from completion date 
‘Two days’ Take first date ‘3/4 Feb 2008’ 03.02.2008 
‘Early Feb/Late Jan 09’ 
(or similar) 
Take 1st Feb 09 ‘Early Feb/Late Jan 09’ 01.02.09 
‘shortly after’; 
‘first opportunity’;  
‘as soon as I could’ 
Take as recent = 7 
days 
‘told GP shortly after 
noticing symptom’ 
Count 7 days after 
symptom date 
Few/some 
weeks/months etc. ago 
Few/some = 3 ‘Few months ago’ Count back 3 months 
from completion dates 
‘weeks ago’ or ‘months 
ago’ 
Take as 3 ‘Months ago’ Count back 3 months 
from completion dates 
many weeks/months/ 
years 
Take as 6 ‘Many weeks ago’ Count back 6 weeks 
from completion date 
‘years ago’ or ‘over 
many years’ or ‘always’ 
Longstanding, so 
999 days 
 Enter as “999 days” 
Incomplete month/year 
‘Year’ (only) 01.07.xxxx ‘2008’ 01.07.2008 
‘Date/Month but no year’ 
 
Take first one ‘15th July’ The first 15.07 prior to 
completion date 
‘Month’ (no date) 
 
Take 15th of the 
month 
January 2007 15.01.2007 
Early/late/mid etc. 
‘Early year’  15.02.xxxx ‘Early 2008’ 15.02.2008 
‘Late year’ 15.11.xxxx ‘Late 2007’ 15.11.2007 
‘End of year’ Take last date in year ‘End of 2009’ 31.12.2009 
‘Early month’ Take 8th of month ‘Early March 2008’ 08.03.2008 
‘Mid-month’ Take 15th of month ‘Mid-January 2007’ 15.01.2007 
‘Late month’ Take 23rd of month ‘Late-January 2007’ 23.01.2007 
‘End of month’ 
 
Take last date of the 
month 
‘End Jan 09’ 31.01.2009 
‘2nd week in the month’ Take 10th month ‘2nd week in Jan 07’ 10.01.2009 
‘Beginning of month’  1st date of the given 
month 
Beg Feb 08 01.02.2008 
‘Beginning of month’ (no 
year given) 
 
1st date of the given 
month 
Beg Feb The first 01.02 counting 
back from completion 
date 
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Analysis codes continued 
Text for estimated date Rule  Example text Example recode 
Seasons and holidays 
‘Spring’ 15.04.xxxx ‘Spring 2007’ 15.04.2007 
‘Early Spring’ 15.03.xxxx ‘Early Spring 2007’ 15.03.2007 
‘Late spring’ 15.05.xxxx ‘Late spring 2007’ 15.05.2007 
‘Summer’ 15.07.xxxx ‘Summer 2007’ 15.07.2007 
‘Early Summer’ 15.06.xxxx ‘Early Summer 2007’ 15.06.2007 
‘Late Summer’ 15.08.xxxx ‘Late Summer 2007’ 15.08.2007 
‘Autumn’ 15.10.xxxx ‘Autumn 2007’ 15.10.2007 
‘Early Autumn’ 15.09.xxxx ‘Early Autumn 2007’ 15.09.2007 
‘Late Autumn’ 15.11.xxxx ‘Late Autumn 2007’ 15.11.2007 
‘Winter’ 15.01.xxxx ‘Winter 2007’ 15.01.2007 
‘Early Winter’ 15.12.xxxx ‘Early Winter 2007’ 15.12.2007 
‘Late Winter’ 15.02.xxxx ‘Late Winter 2007’ 15.02.2007 
‘Good Friday’ Recode to exact date ‘Good Friday 2009’ 10.04.2009 
Easter  Recode to exact date 
of Easter Sunday 
‘Easter 2009’ 12.04.2009 
Xmas Recode to exact date ‘Xmas 2009’ 25.12.2009 
Before Xmas 15.12.xxxx Before Xmas 2009 15.12.2009 
After Xmas 31.12.xxxx After Xmas 2009 31.12.2009 
Other 
‘Week beginning…’ 
 
Code as that date ‘Week beginning 
15.02.07’ 
15.02.2007 
‘Unclassified’ e.g. illegible, 
nonsense or missing 
e.g. 1910 99/99/9999 
A/A Means ‘as above’ 
use same date as 
previously entered. 
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Appendix 15: Interval durations for all variables 
 
 pPI (days) HSI (days) pTDI (days) 
Median (IQR) n Median (IQR) n Median (IQR) n 
All participants 21 (2.5-59.5) 103 33.5 (16-89) 106 81 (45-137.5) 107
Region       
East 20.5 (4.5-58) 68 36.5 (19-114) 70 82 (47-138) 69
North East 25 (0-61.5) 35 28.5 (13.5-62.5) 36 68.5 (44-137) 38
Cancer type        
Oesophageal 21 (2-60) 85 33 (17.5-86) 87 77 (43.5-135) 88
Gastric 24.5 (5-45) 18 34 (14-101.5) 19 94 (47-267.5) 19
Age range       
<60 17 (0-40.5) 11 27 (11.5-107.5) 12 62 (49.5-124) 11
60-74 26 (3.5-59.5) 64 28 (15-74.5) 67 70.5 (44-133) 66
≥75 17.5 (0-82) 28 52 (27.5-117.5) 27 117.5 (48-186) 30
Gender        
Male 23 (3-59) 84 33 (15-87) 85 76 (43.5-133) 87
Female 19 (1-61.5) 19 36 (22-121) 21 104 (50.5-244.5) 20
Highest education level       
None/Other 30 (3-60.5) 47 28 (13-63) 49 78.5 (44-133) 50
A level/GCSE/O level 15.5 (0-31) 30 41.5 (21-121) 30 65.5 (40-133) 30
PhD/Degree/Diploma 38.5 (8-62) 22 23 (14-85) 22 80 (60-155) 22
Living alone       
No 27 (4-60) 85 28 (13.5-80) 87 74.5 (44-137) 86
Yes 14 (0-32) 17 60 (42-114) 18 92.5 (52-175.5) 20
Deprivation (IMD)       
Least deprivation 18 (2.5-53) 24 27.5 (15-103) 24 76.5 (42-135) 24
Mid-deprivation 30 (4.5-52) 43 37 (17.5-91.5) 44 82.5 (49-150.5) 44
Most deprivation 15.5 (0-71) 22 34 (26-84) 23 56 (38-135) 23
Comorbidities       
Arthritis 16 (4-60) 29 32 (15.5-90.5) 30 70 (40.5-172) 32
Cancer (other than OG) 16 (6.5-68) 15 37 (21-82.5) 16 81 (44-186) 17
Heart disease 10 (0-60) 14 48 (16-85) 13 73 (36-121) 15
Anxiety or depression 15 (2-59) 10 196 (14.5-290.5) 11 192 (26-379) 10
Prescription medication       
None 30.5 (5-63) 50 22.5 (13-42) 50 64 (38-121) 53
PPI/similar 16 (0-49) 39 46.5 (20-133) 42 82 (54-159.5) 40
Other 13.5 (0-51) 10 88 (63-265) 10 126 (89-284) 10
OTC medication       
None 19 (1.5-59.5) 63 28.5 (13-117.5) 64 82 (43.5-135) 67
Antacid/similar 31 (11.5-92) 27 30 (17-60) 28 73 (46-201) 27
Other 13.5 (3.5-40.5) 8 58 (33.5-86) 8 86 (67-127) 8 
IMD = Index of Multiple Deprivation. Least deprivation = IMD quintile 1; Mid-deprivation = IMD quintiles 2 & 3; Most 
deprivation = IMD quintiles 4 & 5. HL = health literacy; OG = oesophago-gastric; PPI = proton pump inhibitor; OTC 
= over-the-counter; pPI = POSTCARD patient interval; HSI = Health system interval; pTDI = POSTCARD total 
diagnostic interval 
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Interval durations, continued 
 pPI (days) HSI (days) pTDI (days) 
Median (IQR) n Median (IQR) n Median (IQR) n 
Reported GP consultations       
1-2 30 (4-60) 85 28 (14.5-63.5) 88 69 (44-128) 85
≥3 13 (0-52) 16 106.5 (62-270) 16 133 (90-280.5) 19
Referral route       
Urgent (2WW) 27.5 (2-60) 74 28 (15-62.5) 76 71.5 (42-133) 78
Routine 16 (4.5-65.5) 15 41 (16-139.5) 16 84 (54.5-159.5) 15
Other       
Symptom       
Difficulty swallowing 30.5 (0-60) 62 39 (17.5-106.5) 64 83 (56-143) 65
Fatigue or tiredness 16 (0-59) 58 37 (19-89) 61 81.5 (46-140) 60
Regurgitation 31 (4-60.5) 48 38 (20-88) 51 85 (52-147) 51
Weight loss 16 (0-51) 53 38.5 (19-89) 54 82 (47-138) 54
Pain swallowing 26 (3-60) 50 40.5 (20.5-93) 52 93 (48-151) 53
Decreased appetite 23 (1-60) 46 46 (17.5-90.5) 47 84 (55.5-159.5) 47
Heartburn 18.5 (0-57) 42 42.5 (20.5-99.5) 44 82 (47.5-149) 43
Fullness or bloating 30 (5-59) 41 34 (15.5-105) 43 81 (44.5-178.5) 43
Upper abdominal pain 30 (8-60) 37 49 (15.5-141) 40 88 (57-178.5) 39
Nausea 16 (0-60) 25 52.5 (22-123) 26 122 (62-196) 26
Vomiting 42 (4.5-95) 20 34 (20-68) 21 108.5 (62-140) 20
Histology       
Adenocarcinoma 30 (4-60) 76 36 (15.5-89) 79 84 (47-140.5) 79
Squamous cell carcinoma 15 (0-31) 22 35 (21-121) 22 60 (41-122) 23
Stage (pre-treatment)       
I/II 
III/IV 
27.5 (2-61) 
19 (2.5-59) 
46
58
30 (13-62) 
41 (20-124) 
46 
58 
73 (44-127) 
82 (53.5-159.5) 
49
56
2WW = two week wait suspected cancer pathway; pPI = POSTCARD patient interval; HSI = Health system interval; 
pTDI = POSTCARD total diagnostic interval 
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Appendix 16: SPSS outputs for Mann-Whitney U Test analysis 
 
Health literacy understanding: fatigue or tiredness 
HL = health literacy 
 
 
H
L 
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de
rs
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g
6.00
4.00
2.00
0.00
Frequency
25.0 20.0 15.0 10.0 5.0 0.0
H
L understanding
6.00
4.00
2.00
0.00
Frequency
25.020.015.010.05.0
Fatigue or tiredness
YesNo
N = 68 
Mean Rank = 50.51
N = 43 
Mean Rank = 64.67
Independent-Samples Mann-Whitney U Test
Total N
Mann-Whitney U
Wilcoxon W
Test Statistic
Standard Error
Standardized Test Statistic
Asymptotic Sig. (2-sided test) .022
-2.293
162.667
1,089.000
3,435.000
1,089.000
111
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Health literacy understanding: heartburn 
HL = health literacy
H
L 
un
de
rs
ta
nd
in
g
6.00
4.00
2.00
0.00
Frequency
25.0 20.0 15.0 10.0 5.0 0.0
H
L understanding
6.00
4.00
2.00
0.00
Frequency
25.020.015.010.05.0
Heartburn
YesNo
N = 49 
Mean Rank = 46.87
N = 59 
Mean Rank = 60.84
Independent-Samples Mann-Whitney U Test
Total N
Mann-Whitney U
Wilcoxon W
Test Statistic
Standard Error
Standardized Test Statistic
Asymptotic Sig. (2-sided test) .019
-2.343
159.596
1,071.500
2,296.500
1,071.500
108
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POSTCARD total diagnostic interval: prescription medication (PPIs or similar) 
PPI = proton pump inhibitor 
PO
ST
C
AR
D
 to
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l 
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ag
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st
ic
 in
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rv
al
1,000.0
800.0
600.0
400.0
200.0
0.0
-200.0
Frequency
30.0 20.0 10.0 0.0
PO
STC
AR
D
 total 
diagnostic interval
1,000.0
800.0
600.0
400.0
200.0
0.0
-200.0
Frequency
30.020.010.0
Prescription medication
PPI/similarNone
N = 53 
Mean Rank = 42.06
N = 40 
Mean Rank = 53.55
Independent-Samples Mann-Whitney U Test
Total N
Mann-Whitney U
Wilcoxon W
Test Statistic
Standard Error
Standardized Test Statistic
Asymptotic Sig. (2-sided test) .042
2.033
128.858
1,322.000
2,142.000
1,322.000
93
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POSTCARD total diagnostic interval: nausea 
 
 
 
PO
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D
 to
ta
l 
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al
1,000.0
800.0
600.0
400.0
200.0
0.0
-200.0
Frequency
30.0 20.0 10.0 0.0
PO
STC
AR
D
 total 
diagnostic interval
1,000.0
800.0
600.0
400.0
200.0
0.0
-200.0
Frequency
30.020.010.0
Nausea
YesNo
N = 68 
Mean Rank = 43.92
N = 26 
Mean Rank = 56.87
Independent-Samples Mann-Whitney U Test
Total N
Mann-Whitney U
Wilcoxon W
Test Statistic
Standard Error
Standardized Test Statistic
Asymptotic Sig. (2-sided test) .040
2.058
118.299
1,127.500
1,478.500
1,127.500
94
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Health system interval: prescription medication (PPIs or similar) 
PPI = proton pump inhibitor 
 
 
H
ea
lth
 s
ys
te
m
 in
te
rv
al 600.0
400.0
200.0
0.0
Frequency
40.0 30.0 20.0 10.0 0.0
H
ealth system
 interval
600.0
400.0
200.0
0.0
Frequency
40.030.020.010.0
Prescription medication
PPI/similarNone
N = 50 
Mean Rank = 39.40
N = 42 
Mean Rank = 54.95
Independent-Samples Mann-Whitney U Test
Total N
Mann-Whitney U
Wilcoxon W
Test Statistic
Standard Error
Standardized Test Statistic
Asymptotic Sig. (2-sided test) .005
2.783
127.545
1,405.000
2,308.000
1,405.000
92
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Appendix 17:  
Guidelines for interviewers who observe participant distress 
 
The following guidelines are based on those used in the SYMPTOM study144,145,430 and 
were used in the POSTCARD study interviews where participant distress was observed: 
1. All interviews are to be conducted from the outset with the greatest of sensitivity and 
concern for the respondent’s welfare.   
2. The interviewer should be observant of the respondent’s level of comfort and watch 
for early signs of distress, such as breaks in speech or nervous body movements. 
Should early signs appear the interviewer should express concern about the 
respondent’s comfort and ask questions such as (gauged by respondent’s signs): 
would they like a glass of water; if a break is needed; if they would prefer to complete 
the interview another time; or if they would prefer to discontinue.   
3. If overt distress occurs, the interview should cease immediately and actions taken to 
support the respondent, such as offering tissues or water; seeking immediate 
additional support from a more familiar person, if available; and staying with the 
respondent until they are ready to express their wishes on the options available to 
them.   
4. If it becomes apparent that a distressed respondent has particular areas of need 
concerning their illness or circumstances, where appropriate, the interviewer should 
offer to assist the respondent to make contact with a relevant support, such as their 
GP surgery.   
5. Concerning the interview, the options eventually offered to a distressed respondent 
should be (in order): withdraw from the study; or complete the interview another time. 
The interview should only be continued after a break if the respondent requests this 
as their unprompted decision.   
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Appendix 18: Documents used in the POSTCARD study interviews 
 
Interview consent form 
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Interview topic guide: page 1 
 
 378 
 
Interview topic guide: page 2 
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Interview topic guide: page 3 
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Calendar landmarking tool: page 1 
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Calendar landmarking tool: page 2 
 
 
382 
 
 
Calendar landmarking tool: page 3 
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